View Filing Data

Print Document View Excel Document

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Jun. 29, 2018	Aug. 03, 2018
Document And Entity Information [Abstract]
Entity Registrant Name	Mallinckrodt plc
Entity Central Index Key	0001567892
Trading Symbol	MNK
Current Fiscal Year End Date	--12-28
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Jun. 29, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q2
Amendment Flag	false
Ordinary Shares Outstanding		83,209,486

Condensed Consolidated Statements of Income - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 29, 2018	Jun. 30, 2017	Jun. 29, 2018	Jun. 30, 2017
Net sales	$ 631.7	$ 600.1	$ 1,204.3	$ 1,160.1
Cost of sales	314.7	280.4	610.5	540.3
Gross profit	317.0	319.7	593.8	619.8
Selling, general and administrative expenses	164.3	214.6	356.7	432.2
Research and development expenses	81.3	52.3	145.4	97.3
Restructuring charges, net	58.7	0.6	81.8	10.9
Losses (gains) on divestiture	0.0	2.1	0.0	(57.0)
Operating income	12.7	50.1	9.9	136.4
Interest expense	(95.1)	(92.2)	(186.5)	(186.4)
Interest income	1.4	0.6	4.6	1.5
Other (expense) income, net	(0.5)	6.3	4.1	(73.6)
Loss from continuing operations before income taxes	(81.5)	(35.2)	(167.9)	(122.1)
Income tax benefit	(53.4)	(53.6)	(96.8)	(95.6)
Income from continuing operations	(28.1)	18.4	(71.1)	(26.5)
Income from discontinued operations, net of income taxes	43.7	44.4	68.7	488.5
Net income (loss)	$ 15.6	$ 62.8	$ (2.4)	$ 462.0
Basic earnings per share (Note 8):
Income from continuing operations, per share	$ (0.34)	$ 0.19	$ (0.84)	$ (0.26)
(Loss) income from discontinued operations, per share	0.53	0.45	0.81	4.84
Net income, per share	$ 0.19	$ 0.64	$ (0.03)	$ 4.58
Basic weighted-averaged shares outstanding (in shares)	83.2	98.5	84.7	100.9
Diluted earnings per share (Note 8):
Income from continuing operations, per share	$ (0.34)	$ 0.19	$ (0.84)	$ (0.26)
(Loss) income from discontinued operations, per share	0.53	0.45	0.81	4.84
Net income, per share	$ 0.19	$ 0.64	$ (0.03)	$ 4.58
Diluted weighted-average shares outstanding (in shares)	83.2	98.7	84.7	100.9

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 29, 2018	Jun. 30, 2017	Jun. 29, 2018	Jun. 30, 2017
Net income (loss)	$ 15.6	$ 62.8	$ (2.4)	$ 462.0
Other comprehensive (loss) income, net of tax:
Investments, net of $-, $-, $-, and $- tax	0.0	(2.8)	0.0	10.6
Currency translation adjustments	(5.0)	5.0	(7.3)	7.4
Derivatives, net of $-, ($0.2), $- and ($0.2) tax	0.1	0.4	0.5	0.6
Benefit plans, net of $-, $-, $- and ($31.4) tax	0.0	(0.7)	(0.5)	45.9
Total other comprehensive (loss) income, net of tax	(4.9)	1.9	(7.3)	64.5
Comprehensive income (loss)	$ 10.7	$ 64.7	$ (9.7)	$ 526.5

Condensed Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 29, 2018	Jun. 30, 2017	Jun. 29, 2018	Jun. 30, 2017
Unrecognized gain derivatives, tax	$ 0.0	$ (0.2)	$ 0.0	$ (0.2)
Unrecognized (loss) gain on benefit plans, tax	0.0	0.0	0.0	(31.4)
Unrecognized (loss) gain on investments, tax	$ 0.0	$ 0.0	$ 0.0	$ 0.0

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Jun. 29, 2018	Dec. 29, 2017
Current Assets:
Cash and cash equivalents	$ 235.7	$ 1,260.9
Accounts receivable, less allowance for doubtful accounts of $3.7 and $2.8	337.6	275.4
Inventories	184.4	128.7
Prepaid expenses and other current assets	135.6	74.7
Notes receivable	0.0	154.0
Current assets held for sale	1,112.5	391.5
Total current assets	2,005.8	2,285.2
Property, plant and equipment, net	430.1	413.2
Goodwill	3,676.7	3,482.7
Intangible assets, net	8,769.0	8,261.0
Disposal Group, Including Discontinued Operation, Assets, Noncurrent	0.0	742.7
Other assets	168.2	156.2
Total Assets	15,049.8	15,341.0
Current Liabilities:
Current maturities of long-term debt	22.2	313.7
Accounts payable	75.8	77.3
Accrued payroll and payroll-related costs	74.6	78.4
Accrued interest	60.4	57.0
Income taxes payable	39.9	15.5
Accrued and other current liabilities	441.0	368.5
Current liabilities held for sale	170.6	140.0
Total current liabilities	884.5	1,050.4
Long-term debt	6,335.1	6,420.9
Pension and postretirement benefits	65.3	67.1
Environmental liabilities	62.2	62.8
Deferred income taxes	809.7	749.1
Other income tax liabilities	129.2	94.1
Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent	0.0	22.6
Other liabilities	289.4	352.0
Total Liabilities	(8,575.4)	(8,819.0)
Shareholders' Equity:
Preferred shares	0.0	0.0
Ordinary shares	18.5	18.4
Ordinary shares held in treasury at cost	(1,619.1)	(1,564.7)
Additional paid-in capital	5,508.9	5,492.6
Retained earnings	2,587.8	2,588.6
Accumulated other comprehensive loss	(21.7)	(12.9)
Total Shareholders' Equity	6,474.4	6,522.0
Total Liabilities and Shareholders' Equity	15,049.8	15,341.0
Ordinary A
Shareholders' Equity:
Ordinary A shares	$ 0.0	$ 0.0

Condensed Consolidated Balance Sheets (Parenthetical) $ in Millions	Jun. 29, 2018 USD ($) $ / shares shares	Jun. 29, 2018 € / shares	Dec. 29, 2017 USD ($) $ / shares shares	Dec. 29, 2017 € / shares
Allowance for doubtful accounts \| $	$ 3.7		$ 2.8
Preferred shares, par value (in usd per share) \| $ / shares	$ 0.20		$ 0.20
Preferred shares, shares authorized (in shares)	500,000,000		500,000,000
Preferred shares, shares issued (in shares)	0		0
Preferred shares, shares outstanding (in shares)	0		0
Ordinary shares, par value (in usd per share) \| $ / shares	$ 0.20		$ 0.20
Ordinary shares, shares authorized (in shares)	500,000,000		500,000,000
Ordinary shares, shares issued (in shares)	92,548,700		92,196,662
Ordinary shares, shares outstanding (in shares)	83,097,746		86,336,232
Ordinary shares held in treasury at cost (in shares)	9,450,954		5,860,430
Ordinary A
Ordinary shares, par value (in usd per share) \| € / shares		€ 1.00		€ 1.00
Ordinary shares, shares authorized (in shares)	40,000		40,000
Ordinary shares, shares issued (in shares)	0		0
Ordinary A shares, shares outstanding (in shares)	0		0

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions	6 Months Ended
	Jun. 29, 2018	Jun. 30, 2017
Cash and Cash Equivalents, Including Restricted Cash, Period End	$ 254.1	$ 348.4
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents		348.4
Cash Flows From Operating Activities:
Net (loss) income	(2.4)	462.0
Adjustments to reconcile net cash from operating activities:
Depreciation and amortization	397.1	406.0
Share-based compensation	16.4	31.8
Deferred income taxes	(101.0)	(157.6)
Gain on divestitures	0.0	(419.1)
Other non-cash items	(19.0)	32.4
Changes in assets and liabilities, net of the effects of acquisitions:
Accounts receivable, net	(21.8)	(52.6)
Inventories	18.4	(8.5)
Accounts payable	2.1	(10.7)
Income taxes	7.4	12.5
Other	(35.4)	(73.7)
Net cash from operating activities	261.8	222.5
Cash Flows From Investing Activities:
Capital expenditures	(67.1)	(101.6)
Acquisitions, net of cash acquired	(699.9)	0.0
Proceeds from divestitures, net of cash	298.3	576.9
Other	12.4	(9.9)
Net cash from investing activities	(456.3)	465.4
Cash Flows From Financing Activities:
Issuance of external debt	657.2	40.0
Repayment of external debt and capital lease obligation	(1,392.8)	(332.8)
Debt financing costs	(12.0)	(13.0)
Proceeds from exercise of share options	0.0	3.9
Repurchase of shares	(56.8)	(380.8)
Other	(24.9)	(19.5)
Net cash from financing activities	(829.3)	(702.2)
Effect of currency rate changes on cash	(1.2)	1.6
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	(1,025.0)	(12.7)
Cash and cash equivalents	235.7	330.2
Restricted Cash and Investments, Noncurrent	$ 18.4	$ 18.2

Condensed Consolidated Statement of Changes in Shareholders' Equity Statement - 6 months ended Jun. 29, 2018 - USD ($) $ in Millions	Total	Ordinary Shares	Treasury Shares	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Loss
Beginning balance, ordinary shares (in shares) at Dec. 29, 2017	92,196,662	92,200,000
Beginning balance, treasury shares (in shares) at Dec. 29, 2017	5,860,430		5,900,000
Beginning balance at Dec. 29, 2017	$ 6,522.0	$ 18.4	$ (1,564.7)	$ 5,492.6	$ 2,588.6	$ (12.9)
Impact of accounting standard adoptions, net of tax	1.1				2.6	(1.5)
Net (loss) income	(2.4)				(2.4)
Currency translation adjustments	(7.3)					(7.3)
Change in derivatives, net of tax	0.5					0.5
Change in benefit plans, net of tax	(0.5)					(0.5)
Vesting of restricted shares (in shares)		300,000	100,000
Vesting of restricted shares (in usd)	(1.6)	$ 0.1	$ (1.6)	(0.1)
Share-based compensation	16.4			16.4
Stock Issued During Period, Shares, Treasury Stock Reissued			(100,000)
Reissuance of treasury shares	1.4		$ 2.4		(1.0)
Repurchase of shares (in shares)			3,600,000
Repurchase of shares (in usd)	$ 55.2		$ (55.2)
Ending balance, ordinary shares (in shares) at Jun. 29, 2018	92,548,700	92,500,000
Ending balance, treasury shares (in shares) at Jun. 29, 2018	9,450,954		9,500,000
Ending balance at Jun. 29, 2018	$ 6,474.4	$ 18.5	$ (1,619.1)	$ 5,508.9	$ 2,587.8	$ (21.7)

Background and Basis of Presentation

6 Months Ended

Jun. 29, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Background and Basis of Presentation



1.	Background and Basis of Presentation

Background

Mallinckrodt plc and its subsidiaries (collectively, "Mallinckrodt" or "the Company") is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies.

On February 22, 2018, the Company's Board of Directors authorized commencement of a process to dispose of (1) its Specialty Generics business comprised of the previously reported Specialty Generics segment, with the exception of BioVectra, Inc. - a wholly-owned subsidiary of the Company that operates a contract manufacturing business in Canada ("BioVectra"), (2) certain of its non-promoted brands business, which was previously reflected in the Specialty Brands segment; and (3) its ongoing, post-divestiture supply agreement with the acquirer of the contrast media and delivery systems (CMDS) business, which was previously reflected in the Other non-operating segment (referred to collectively as the "Specialty Generics Disposal Group"). The Company evaluated the criteria prescribed by United States ("U.S.") Generally Accepted Accounting Principles ("GAAP") for recording a disposal group as held for sale and discontinued operations. This criteria was met during the three months ended March 30, 2018, and as a result, prior year balances have been recast to present the financial results of the disposal group as a discontinued operation.

As the Specialty Generics Disposal Group is reported as a discontinued operation, the Company's continuing operations are limited to the results of operations from the Specialty Brands segment. The Specialty Brands segment markets branded pharmaceutical products for autoimmune and rare disease in the specialty areas of neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal respiratory critical care therapies, analgesics and gastrointestinal products. The Company's diversified, in-line portfolio of both marketed and development products is focused on patients with significant unmet medical needs.

The Company owns or has rights to use the trademarks and trade names that are used in conjunction with the operation of its business. One of the more important trademarks that the Company owns or has rights to use that appears in this Quarterly Report on Form 10-Q is "Mallinckrodt," which is a registered trademark or the subject of pending trademark applications in the U.S. and other jurisdictions. Solely for convenience, the Company only uses the ™ or ® symbols the first time any trademark or trade name is mentioned in the following notes. Such references are not intended to indicate in any way that the Company will not assert, to the fullest extent permitted under applicable law, its rights to its trademarks and trade names. Each trademark or trade name of any other company appearing in the following notes is, to the Company's knowledge, owned by such other company.

Basis of Presentation

The unaudited condensed consolidated financial statements have been prepared in U.S. dollars and in accordance with GAAP. The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses. Actual results may differ from those estimates. The unaudited condensed consolidated financial statements include the accounts of the Company, its wholly-owned subsidiaries and entities in which they own or control more than 50% of the voting shares, or have the ability to control through similar rights. All intercompany balances and transactions have been eliminated in consolidation and all normal recurring adjustments necessary for a fair presentation have been included in the results reported. The results of entities disposed of are included in the unaudited condensed consolidated financial statements up to the date of disposal, and where appropriate, these operations have been reported in discontinued operations. Divestitures of product lines and businesses not meeting the criteria for discontinued operations have been reflected in operating income. The fiscal year end balance sheet data was derived from audited consolidated financial statements, but do not include all of the annual disclosures required by GAAP; accordingly these unaudited condensed consolidated financial statements should be read in conjunction with the Company's audited annual consolidated financial statements included in its Annual Report on Form 10-K for the period ended December 29, 2017 filed with the Securities and Exchange Commission ("SEC") on February 27, 2018.

Fiscal Year

The Company reports its results based on a "52-53 week" year ending on the last Friday of December. Unless otherwise indicated, the three and six months ended June 29, 2018 refers to the thirteen and twenty-six week periods ended June 29, 2018 and the three and six months ended June 30, 2017 refers to the thirteen and twenty-six week periods ended June 30, 2017.

Recently Issued Accounting Standards

6 Months Ended

Jun. 29, 2018

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

Recently Issued Accounting Standards



2.	Recently Issued Accounting Standards

Adopted

The Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") 2018-05, "Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 (SEC Update)," in March 2018. This update adds SEC paragraphs pursuant to the SEC's Staff Accounting Bulletin ("SAB") 118, which provides guidance on accounting for the tax effects of the Tax Cuts and Jobs Act ("TCJA") that was enacted in December 2017. SAB 118 provides a measurement period that should not extend beyond one year from the TCJA enactment date for companies to complete their accounting for the tax effects of the TCJA. The amendments are effective upon addition to the FASB Accounting Standards Codification ("ASC"). The Company adopted this guidance in fiscal 2018. See Note 7 for additional details of the Company's assessment of impact of this adoption.

The FASB issued ASU 2017-09, "Compensation - Stock Compensation: Scope of Modification Accounting," in May 2017. Under the new guidance, the effects of a modification should be accounted for unless all of the following are met: (1) the fair value or calculated intrinsic value of the modified award is the same as the fair value of the original award immediately before the original award is modified; (2) the vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified; and (3) the classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. The Company adopted this standard in fiscal 2018 and will apply this standard to prospective modifications. The adoption of this guidance did not result in any material changes to the unaudited condensed consolidated financial statements.

The FASB issued ASU 2017-07, "Compensation - Retirement Benefits: Improving the Presentation of Net Periodic Pension Cost and Net Periodic Post Retirement Benefit Cost," in March 2017. This update requires that the service cost component be disaggregated from the other components of net benefit cost. Service cost should be reported in the same line item or items as other compensation costs arising from services rendered by pertinent employees during the period. The other components of net benefit cost should be presented in the income statement separately from the service cost component and outside a subtotal of income from operations, if one is presented. The Company adopted this guidance in fiscal 2018 which required retroactive application resulting in the reclassification of $72.3 million of other components of net benefit costs to other (expense) income, net for the six months ended June 30, 2017 from selling, general and administrative expenses ("SG&A") of $70.7 million, cost of sales of $1.2 million, and research and development expenses ("R&D") of $0.4 million. The adoption of this guidance did not result in any material changes to the unaudited condensed consolidated financial statements.

The FASB issued ASU 2017-01, "Business Combinations (Topic 805): Clarifying the Definition of a Business," in January 2017. This update provides a screen to determine whether or not a set of assets is a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set of assets is not a business. If the screen is not met, the amendments in this update (1) require that to be considered a business, a set of assets must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output and (2) remove the evaluation of whether a market participant could replace missing elements. The Company adopted this guidance in fiscal 2018, which did not have a material impact to the unaudited condensed consolidated financial statements.

The FASB issued ASU 2016-01, "Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities," in January 2016. This update addresses certain aspects of recognition, measurement, presentation and disclosure of financial instruments. Under the new guidance, equity investments, other than equity method investments, are to be measured at fair value with changes in fair value recognized through net income. The Company adopted this guidance in fiscal 2018, resulting in a $1.5 million increase to beginning retained earnings with an offsetting decrease to accumulated other comprehensive loss ("AOCI") relating to the unrealized gain on its investment in Mesoblast Limited ("Mesoblast"). The adoption of this standard did not result in any material changes to the unaudited condensed consolidated financial statements.

The FASB issued ASU 2014-09, "Revenue from Contracts with Customers," in May 2014. The issuance of ASU 2014-09 and International Financial Reporting Standards ("IFRS") 15, "Revenue from Contracts with Customers," completes the joint effort by the FASB and the International Accounting Standards Board to clarify the principles for recognizing revenue and develop a common revenue standard for GAAP and IFRS. Under the new guidance, an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services, applying the following steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract(s); (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract(s); and (5) recognize revenue when (or as) the entity satisfies a performance obligation. The FASB subsequently issued additional ASUs to clarify the guidance in ASU 2014-09. The additional ASUs issued include ASU 2016-08, "Revenue from Contracts with Customers;" ASU 2016-10 "Revenue from Contracts with Customers, Identifying Performance Obligations and Licensing;" and ASU 2016-12, "Narrow-Scope Improvements and Practical Expedients."

The Company adopted ASU 2014-09 and its related amendments (collectively known as "ASC 606") effective on December 30, 2017 using the modified retrospective transition approach. The adoption of ASC 606 represents a change in accounting principle that more closely aligns revenue recognition with the delivery of the Company's products and will provide financial statement readers with enhanced disclosures, which have been included in Note 3. The cumulative effect of applying the new standard to contracts not completed at December 30, 2017 was recorded as a $1.1 million increase, net of tax, to beginning retained earnings. The prior periods were not restated. The adoption of this standard did not result in any material changes to the unaudited condensed consolidated financial statements.

Not Yet Adopted

The FASB issued ASU 2018-02, "Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income," in February 2018. This update allows a reclassification from AOCI to retained earnings for the tax effects resulting from TCJA that are stranded in AOCI. This guidance is effective for the Company in the first quarter of fiscal 2019. The Company expects the impact of this guidance to be immaterial to its unaudited condensed consolidated financial statements upon adoption.

The FASB issued ASU 2017-12, "Derivatives and Hedging: Targeted Improvements to Accounting for Hedging Activities," in August 2017. This update simplifies the application of hedge accounting and enhances the economics of the entity's risk management activities in its financial statements. The update amends the guidance on designation and measurement for qualifying hedging relationships requiring the application of a modified retrospective approach on the date of adoption. This guidance is effective for the Company in the first quarter of fiscal 2019. The Company expects the impact of this guidance to be immaterial to its unaudited condensed consolidated financial statements upon adoption.

The FASB issued ASU 2016-02, "Leases," in February 2016. This update was issued to increase transparency and comparability among organizations by recognizing all lease transactions (with terms in excess of 12 months) on the balance sheet as a lease liability and a right-of-use asset (as defined under ASU 2016-02). This guidance is effective for the Company in the first quarter of fiscal 2019. The Company has identified its population of lease agreements and is currently assessing other arrangements such as supply and service agreements for embedded leases. Although the Company is in process of determining the potential impact on its consolidated financial statements, it anticipates that the most significant change will be related to the Company recording additional assets and corresponding liabilities on the balance sheet for operating leases. The ultimate impact of the new standard will depend on the total amount of the Company's lease commitments as of the adoption date.

Revenue from Contracts with Customers Revenue from Contracts with Customers (Notes)

6 Months Ended

Jun. 29, 2018

Revenue from Contract with Customer [Abstract]

Revenue from Contract with Customer [Text Block]



3.	Revenue from Contracts with Customers

Product Sales Revenue

The Company sells its products through distributors who resell the products to institutions and end user customers, while certain products are sold and distributed directly to hospitals. The Company also enters into arrangements with indirect customers, such as health care providers and payers, to establish contract pricing for certain products that provides for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of the Company's products.

Reserves for variable consideration

Product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. These reserves result from estimated chargebacks, rebates, product returns and other sales deductions that are offered within contracts between the Company and its customers, health care providers and payers relating to the Company's sales of its products. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other than a customer). Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as the Company's historical experience, estimated future trends, estimated customer inventory levels, current contracted sales terms with customers, level of utilization of the Company's products and other competitive factors. Overall, these reserves reflect the Company's best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained (reduced), and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. The Company adjusts reserves for chargebacks, rebates, product returns and other sales deductions to reflect differences between estimated and actual experience. Such adjustments impact the amount of net sales recognized in the period of adjustment.

The following table reflects activity in the Company's sales reserve accounts, on a continuing operations basis:



	Rebates and Chargebacks			Product Returns			Other Sales Deductions			Total
Balance at December 29, 2017	$	60.3		$	4.1		$	1.1		$	65.5
Provisions	147.7			4.1			4.9			156.7
Payments or credits	(119.5		)	(4.6		)	(4.7		)	(128.8		)
Balance at June 29, 2018	$	88.5		$	3.6		$	1.3		$	93.4

See Note 19 for presentation of the Company's net sales by product family.

Product sales are recognized when the customer obtains control of the Company's product. Control is transferred either at a point in time, generally upon delivery to the customer site, or in the case of certain of the Company's hospital products, over the period in which the customer has access to the product and related services. Revenue recognized over time is based upon either consumption of the product or passage of time based upon the Company's determination of the measure that best aligns with how the obligation is satisfied. The Company's considerations of why such measures provide a faithful depiction of the transfer of its products are as follows:


•	For those contracts whereby revenue is recognized over time based upon consumption of the product, the Company either has:


1)	the right to invoice the customer in an amount that directly corresponds with the value to the customer of the Company's performance to date, for which the practical expedient to recognize revenue in proportion to the amount it has the right to invoice has been applied, or


2)	the remaining goods and services to which the customer is entitled is diminished upon consumption.

•

For those contracts whereby revenue is recognized over time based upon the passage of time, the benefit that the customer receives from unlimited access to the Company's product does not vary, regardless of consumption. As a result, the Company's obligation diminishes with the passage of time; therefore, it was determined that ratable recognition of the transaction price over the contract period is the measure that best aligns with how the obligation is satisfied.

Product sales transferred to customers at a point in time and over time are as follows:



	Three Months Ended		Six Months Ended
	June 29, 2018		June 29, 2018
Product sales transferred at a point in time	79.1	%	77.3	%
Product sales transferred over time	20.9	%	22.7	%

Transaction price allocated to the remaining performance obligations

The majority of the Company's contracts (as defined under ASC 606) are less than one year; therefore, the related disclosure of the amount of transaction price allocated to the performance obligations that are unsatisfied at period end has been omitted, with the exception of those noted below. The following table includes estimated revenue from certain of the Company's hospital products that are expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied at June 29, 2018:



Remainder of Fiscal 2018	$	63.9
Fiscal 2019	119.4
Fiscal 2020	101.8
Fiscal 2021	14.2

Costs to obtain a contract

As the majority of the Company's contracts are short term in nature, sales commissions are generally expensed when incurred as the amortization period would have been less than one year. These costs are recorded within SG&A expenses. For contracts that extend beyond one year, the incremental expense recognition matches the recognition of related revenue and therefore, no costs to obtain a contract were capitalized upon adoption of ASC 606.

Costs to fulfill a contract

The Company capitalizes the costs associated with the devices used in the Company's portfolio of hospital drug-device combination products, which are used in satisfying future performance obligations. Capital expenditures for these devices represent cash outflows for the Company's cost to produce the asset, which is classified in property, plant and equipment, net on the unaudited condensed consolidated balance sheet and expensed to cost of sales over the useful life of the equipment. As of June 29, 2018, the total net book value of these devices was $27.9 million. The associated depreciation expense recognized during the six months ended June 29, 2018 was $6.8 million.

Product Royalty Revenues

In relation to the Company's acquisition of Sucampo Pharmaceuticals, Inc. on February 13, 2018, as discussed in further detail in Note 5, it acquired an arrangement under which the Company licenses certain rights to Amitiza^® (lubiprostone) ("Amitiza") to a third party in exchange for royalties on net sales of the product. The Company recognizes such royalty revenue as the related sales occur. The associated royalty revenue recognized during the three and six months ended June 29, 2018 was $21.6 million and $29.6 million, respectively.

Contract Balances

Accounts receivable are recorded when the right to consideration becomes unconditional. Payments received from customers are typically based upon payment terms of 30 days. The Company does not maintain contract asset balances aside from the accounts receivable balance presented on the unaudited condensed consolidated balance sheet as costs to obtain a contract are expensed when incurred and the amortization period would have been less than one year. These costs are recorded within SG&A expenses.

Contract liabilities are recorded when cash payments are received in advance of the Company's performance, including amounts which are refundable. Contract liabilities as of June 29, 2018 and December 29, 2017 were as follows:



	June 29, 2018		December 29, 2017
Accrued and other current liabilities	$	20.2	$	13.9
Other liabilities	5.2		6.3
Contract liabilities	$	25.4	$	20.2

Revenue recognized during the six months ended June 29, 2018 from amounts included in contract liabilities at the beginning of the period was approximately $14.6 million.

Discontinued Operations and Divestitures

6 Months Ended

Jun. 29, 2018

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations and Divestitures



4.	Discontinued Operations and Divestitures

Discontinued Operations

Specialty Generics Disposal Group: On February 22, 2018, the Specialty Generics Disposal Group met the criteria for held for sale classification and discontinued operation presentation upon commencement of a process to dispose of the group.

The following table summarizes the financial results of the Specialty Generics Disposal Group presented in the unaudited condensed consolidated statements of income:



	Three Months Ended				Six Months Ended
	June 29, 2018		June 30, 2017		June 29, 2018		June 30, 2017
Major line items constituting income from discontinued operations
Net sales	$	193.8	$	224.4	$	376.5	$	475.3
Cost of sales	116.8		128.0		228.8		259.2
Selling, general and administrative expenses	25.6		16.2		44.4		37.3
Research and development expenses	11.3		16.9		29.2		33.7
Restructuring charges, net	0.1		—		5.2		6.9
Other income, net	0.3		2.4		0.3		3.8
Income from discontinued operations	40.3		65.7		69.2		142.0
Income tax expense	9.0		13.5		15.8		16.0
Income from discontinued operations, net of income taxes	$	31.3	$	52.2	$	53.4	$	126.0

The following table summarizes the assets and liabilities of the Specialty Generics Disposal Group that are classified as held for sale on the unaudited condensed consolidated balance sheets:



	June 29, 2018		December 29, 2017
Carrying amounts of major classes of assets included as part of discontinued operations
Accounts receivable	$	164.7	$	170.4
Inventories	202.1		211.7
Property, plant and equipment, net	558.6		553.6
Intangible assets, net	112.3		114.0
Other current and non-current assets	74.8		84.5
Total assets classified as held for sale in the balance sheet	$	1,112.5	$	1,134.2

Carrying amounts of major classes of liabilities included as part of discontinued operations
Accounts payable	$	40.0	$	36.0
Other current and non-current liabilities	130.6		126.6
Total liabilities classified as held for sale in the balance sheet	$	170.6	$	162.6

The following table summarizes significant cash and non-cash transactions of the Specialty Generics Disposal Group that are included within the unaudited condensed consolidated statements of cash flows for the respective periods:



	Three Months Ended				Six Months Ended
	June 29, 2018		June 30, 2017		June 29, 2018		June 30, 2017
Depreciation, including accelerated depreciation	$	2.6	$	14.9	$	11.5	$	30.4
Amortization	—		5.4		1.7		10.7
Capital expenditures	7.1		14.3		15.8		30.6

All other notes to the unaudited condensed consolidated financial statements that were impacted by this discontinued operation have been reclassified accordingly.

Nuclear Imaging: On January 27, 2017, the Company completed the sale of its Nuclear Imaging business to IBA Molecular ("IBAM") for approximately $690.0 million before tax impacts, including up-front consideration of approximately $574.0 million, up to $77.0 million of contingent consideration and the assumption of certain liabilities. The Company recorded a pre-tax gain on the sale of the Nuclear Imaging business of $363.4 million during the six months ended June 30, 2017, which excluded any potential proceeds from the contingent consideration and reflects a charge of $5.9 million during the three months ended June 30, 2017 primarily as a result of ongoing working capital adjustments associated with the purchase agreement. During the three months ended June 29, 2018 the Company received a total of $15.0 million in contingent consideration related to the sale of the Nuclear Imaging business, consisting of a $6.0 million cash payment and the issuance of $9.0 million par value non-voting preferred equity certificates. The preferred equity certificates accrue interest at a rate of 10.0% per annum and are redeemable on the retirement date of July 27, 2025, or earlier if elected by the issuer, for cash at a price equal to the par value and any accrued but unpaid interest. The Company recorded a tax expense of $1.5 million associated with the $6.0 million contingent consideration cash payment. The $9.0 million in preferred equity certificates is presented as a non-cash investing activity on the unaudited condensed consolidated statement of cash flows. The $13.5 million of contingent consideration received, net of tax, was recorded as income from discontinued operations.

The following table summarizes the financial results of the Nuclear Imaging business presented in the unaudited condensed consolidated statements of income:



	Three months ended			Six months ended
	June 30, 2017			June 30, 2017
Major line items constituting income from discontinued operations
Net sales	$	—		$	31.6
Cost of sales	—			15.6
Selling, general and administrative expenses	—			7.8
Other	—			(0.2		)
Income from discontinued operations	—			8.4
(Loss) gain on divestiture of discontinued operations	(5.9		)	363.4
(Loss) income from discontinued operations, before income taxes	(5.9		)	371.8
Income tax (benefit) expense	(0.1		)	5.3
(Loss) income from discontinued operations, net of income taxes	$	(5.8	)	$	366.5

During the three months ended June 30, 2017, there was income tax benefit of $0.1 million associated with the $5.9 million loss recognized on divestiture. During the six months ended June 30, 2017, there was income tax expense of $1.0 million associated with the $363.4 million gain on divestiture and a $4.3 million income tax expense associated with the $8.4 million income from discontinued operations. The tax impact of the gain recognized on divestiture was favorably impacted by a benefit from permanently deductible items.

The Company incurred $0.3 million of capital expenditures related to the Nuclear Imaging business that are included within the unaudited condensed consolidated statements of cash flows for the six months ended June 30, 2017.

All other notes to the unaudited condensed consolidated financial statements that were impacted by this discontinued operation have been reclassified accordingly.

Divestitures

PreveLeak/Recothrom: On March 16, 2018, the Company completed the sale of a portion of its Hemostasis business, inclusive of its PreveLeak™ Surgical Sealant ("PreveLeak") and RECOTHROM^® Thrombin topical (Recombinant) ("Recothrom") products to Baxter International, Inc. ("Baxter") for approximately $185.0 million, with a base payment of $153.0 million, inclusive of existing inventory and subject to a closing inventory adjustment, with the remainder in potential future milestones. Baxter assumed other expenses, including contingent liabilities associated with PreveLeak. During the six months ended June 29, 2018, the Company recorded a pre-tax gain on the sale of less than $0.1 million, which excluded any potential proceeds from the attainment of future milestones and reflected a post-sale closing inventory adjustment of $14.3 million. The financial results of the PreveLeak and Recothrom operations are presented within continuing operations as this divestiture did not meet the criteria for discontinued operations presentation.

As part of the divestiture and calculation of the gain, the Company wrote off intangible assets of $49.9 million and goodwill of $51.5 million, from the Specialty Brands segment, ascribed to the PreveLeak and Recothrom operations. The remaining items included in the gain calculation are primarily attributable to inventory transferred, contingent consideration transferred and transaction costs incurred by the Company.

Intrathecal Therapy: On March 17, 2017, the Company completed the sale of its Intrathecal Therapy business to Piramal Enterprises Limited's subsidiary in the United Kingdom ("U.K."), Piramal Critical Care ("Piramal"), for approximately $203.0 million, including fixed consideration of $171.0 million and contingent consideration of up to $32.0 million. The $171.0 million of fixed consideration consisted of $17.0 million received at closing and a $154.0 million note receivable that was due one year from the transaction closing date. During the six months ended June 30, 2017, the Company recorded a pre-tax gain on the sale of the business of $57.0 million, which excluded any potential proceeds from the contingent consideration and reflects a post-sale adjustment of $2.1 million during the three months ended June 30, 2017. On February 28, 2018, the Company received $154.0 million from Piramal for the settlement of the aforementioned note receivable. The financial results of the Intrathecal Therapy business are presented within continuing operations as this divestiture did not meet the criteria for discontinued operations presentation.

As part of the divestiture and calculation of the gain, the Company wrote off intangible assets of $48.7 million and goodwill of $49.8 million, from the Specialty Brands segment, ascribed to the Intrathecal Therapy business. The Company is committed to reimburse up to $7.3 million of product development expenses incurred by Piramal, of which $3.2 million was included in accrued and other current liabilities on the unaudited condensed consolidated balance sheet as of June 29, 2018. The remaining items included in the gain calculation are attributable to inventory transferred and transaction costs incurred by the Company.

Acquisitions, License Agreements and Other Investments

6 Months Ended

Jun. 29, 2018

Business Combinations [Abstract]

Business Combination Disclosure [Text Block]



5.	Acquisitions

Sucampo Pharmaceuticals, Inc.

On February 13, 2018, the Company acquired Sucampo Pharmaceuticals, Inc. ("Sucampo") through the acquisition of all the outstanding common stock of Sucampo. Consideration for the transaction consisted of approximately $1.2 billion, including the assumption of Sucampo's third-party debt ("the Sucampo Acquisition"). The acquisition was funded through the issuance of $600.0 million aggregate principal amount of senior secured notes, a $900.0 million borrowing under the Company's revolving credit facility, as discussed further in Note 12, and cash on hand. Sucampo's commercialized products include Amitiza, a leading global product in the branded constipation market, and Rescula^® (unoprostone isopropyl ophthalmic solution) 0.15% ("Rescula"), which is indicated for ocular hypertension and open-angle glaucoma, and marketed in Japan. Through this acquisition, the Company acquired VTS-270, a Phase 3 development product for Niemann-Pick Type C, a rare, neurodegenerative and ultimately fatal disease that can present at any age. Also acquired was a collaborative agreement with Cancer Prevention Pharmaceuticals ("CPP") associated with the development of CPP-1X/sulindac, a Phase 3 development product for Familial Adenomatous Polyposis ("FAP").

Upon completion of the Sucampo Acquisition, Sucampo's 3.25% convertible senior notes due 2021 ("the Sucampo Notes") became eligible to receive increased consideration in conjunction with a make-whole fundamental change, such that each $1,000 principal face amount of Sucampo Notes could be converted into $1,221 cash. As of June 29, 2018, the issued convertible debt of $300.0 million had been converted and paid in full by the Company.

Fair value allocation

The following amounts represent the preliminary allocations of the fair value of the identifiable assets acquired and liabilities assumed for the Sucampo Acquisition, including preliminary goodwill, intangible assets and the related deferred tax balances. The Company expects to complete its valuation analysis and finalize deferred tax balances as of the acquisition date no later than twelve months from the date of the acquisition. The changes in the purchase price allocation and preliminary goodwill based on the final valuation may include, but are not limited to, finalization of working capital settlements, the impact of U.S. state tax rates in determining the deferred tax balances and changes in assumptions utilized in the preliminary valuation report.



Cash and cash equivalents	$	149.6
Accounts receivable	35.7
Inventory	153.2
Intangible assets	919.5
Goodwill	246.0
Other current and non-current assets	25.6
Total assets acquired	1,529.6
Current liabilities	108.2
Deferred tax liabilities, net (non-current)	170.8
Debt	366.3
Other noncurrent liabilities	36.7
Total liabilities assumed	682.0
Net assets acquired	$	847.6

The following is a reconciliation of the total consideration to net assets acquired:



Total consideration, net of cash	$	698.0
Plus: cash assumed in acquisition	149.6
Total consideration/net assets acquired	$	847.6

Intangible assets acquired consist of the following:



	Amount		Amortization Period	Discount Rate
Completed technology - Amitiza	$	634.0	9 years	14.0%
Completed technology - Rescula	11.0		8 years	14.0%
In-process research and development - VTS-270	274.5		Non-Amortizable	15.0%

The fair value of the completed technology and in-process research and development ("IPR&D") was determined using the income approach, which is a valuation technique that provides an estimate of fair value of the assets based on the market participant expectations of cash flows the asset would generate. The cash flows were discounted commensurate with the level of risk associated with each asset or its projected cash flows. The discount rates were developed after assigning a probability of success to achieving the projected cash flows based on the current stage of development, inherent uncertainty in the U.S. Food and Drug Administration ("FDA") approval process and risks associated with commercialization of a new product. Based on the Company's preliminary estimate, the excess of purchase price over net tangible and intangible assets acquired resulted in goodwill, which represents future product development, the assembled workforce, and the tax status of the transaction. The goodwill is not deductible for U.S. income tax purposes. All assets acquired are included within the Company's Specialty Brands segment.

Financial results - The amount of net sales and loss included in the Company's results for the periods presented were as follows:



	Three Months Ended					Six Months Ended
	June 29, 2018			June 30, 2017		June 29, 2018			June 30, 2017
Net sales	$	49.6		$	—	$	73.8		$	—
Operating loss	(37.0		)	—		(67.7		)	—

The following was included within cost of sales for the periods presented:



	Three Months Ended				Six Months Ended
	June 29, 2018		June 30, 2017		June 29, 2018		June 30, 2017
Intangible asset amortization	$	17.9	$	—	$	27.0	$	—
Inventory fair value step-up expense	31.5		—		46.5		—

Acquisition-related costs incurred for the acquisition of $2.7 million were recognized during the six months ended June 29, 2018.

Licenses

On April 5, 2018 (the "Exercise Date"), the Company exercised the option under its collaborative agreement with CPP to negotiate terms of an exclusive license to commercialize CPP-1X/sulindac in North America. In addition, the Company provided CPP with a $10.0 million upfront R&D payment for expenses related to the FAP pivotal trial incurred during the "Negotiation Period," or the period from the Exercise Date through the execution of such license agreement, which shall not exceed 120 days. CPP shall return to the Company any portion of the R&D payment that is not utilized during the Negotiation Period. Of the $10.0 million upfront payment, $6.3 million was utilized during the three months ended June 29, 2018 and recorded as R&D expense within the condensed consolidated statement of income. The remaining $3.7 million was included in prepaid expenses and other current assets on the unaudited condensed consolidated balance sheet as of June 29, 2018. See Note 21 for discussion of the license agreement entered into with CPP subsequent to the date of this report.

Restructuring and Related Charges

6 Months Ended

Jun. 29, 2018

Restructuring and Related Activities [Abstract]

Restructuring and Related Charges



6.	Restructuring and Related Charges

In July 2016, the Company's Board of Directors approved a $100.0 million to $125.0 million restructuring program ("the 2016 Mallinckrodt Program") designed to further improve the Company's cost structure as it continues to transform the business. The 2016 Mallinckrodt Program is expected to include actions across both the Specialty Brands segment and the Specialty Generics Disposal Group, as well as within corporate functions. There is no specified time period associated with the 2016 Mallinckrodt Program.

In February 2018, the Company's Board of Directors approved a $100.0 million to $125.0 million restructuring program ("the 2018 Mallinckrodt Program") that is of similar design as the 2016 Mallinckrodt Program. The utilization of the 2018 Mallinckrodt Program will commence upon completion of the 2016 Mallinckrodt Program. There is no specified time period associated with the 2018 Mallinckrodt Program.

In addition to the 2016 and 2018 Mallinckrodt Programs, the Company takes certain restructuring actions to generate synergies from its acquisitions.

Net restructuring and related charges reflected in continuing operations by segment are as follows:



	Three Months Ended					Six Months Ended
	June 29, 2018		June 30, 2017			June 29, 2018		June 30, 2017
Specialty Brands	$	53.4	$	0.3		$	70.5	$	9.5
Corporate	5.3		0.7			11.3		2.8
Restructuring and related charges, net	58.7		1.0			81.8		12.3
Less: accelerated depreciation	—		(0.4		)	—		(1.4		)
Restructuring charges, net	$	58.7	$	0.6		$	81.8	$	10.9

Net restructuring and related charges reflected in continuing operations by program are comprised of the following:



	Three Months Ended					Six Months Ended
	June 29, 2018		June 30, 2017			June 29, 2018		June 30, 2017
2016 Mallinckrodt Program	$	52.3	$	1.0		$	55.4	$	12.3
Acquisition programs	6.4		—			26.4		—
Total	58.7		1.0			81.8		12.3
Less: accelerated depreciation	—		(0.4		)	—		(1.4		)
Total charges expected to be settled in cash	$	58.7	$	0.6		$	81.8	$	10.9

The following table summarizes cash activity for restructuring reserves reflected in continuing operations, substantially all of which are related to contract termination costs and employee severance and benefits:



	2016 Mallinckrodt Program			Acquisition Programs			Total
Balance at December 29, 2017	$	14.1		$	0.8		$	14.9
Charges	56.8			26.8			83.6
Changes in estimate	(1.4		)	(0.4		)	(1.8		)
Cash payments	(8.1		)	(17.8		)	(25.9		)
Balance at June 29, 2018	$	61.4		$	9.4		$	70.8

Total Company net restructuring and related charges, including associated asset impairments, incurred cumulative-to-date related to the 2016 Mallinckrodt Program was as follows:



	2016 Mallinckrodt Program
Specialty Brands	$	80.0
Corporate	16.9
Specialty Generics Disposal Group	14.3
	$	111.2

On January 8, 2018, the Company announced that it would discontinue marketing of Raplixa^® after an evaluation of strategic options. During the three months ended June 29, 2018, the Company incurred restructuring expenses of $48.1 million under the 2016 Mallinckrodt Program, consisting primarily of contract termination costs related to the production of Raplixa. Amounts paid in the future may differ from the amount currently recorded.

All of the restructuring reserves were included in accrued and other current liabilities on the Company's unaudited condensed consolidated balance sheets.

Income Taxes

6 Months Ended

Jun. 29, 2018

Income Tax Disclosure [Abstract]

Income Taxes



7.	Income Taxes

The Company recognized an income tax benefit of $53.4 million on a loss from continuing operations before income taxes of $81.5 million for the three months ended June 29, 2018, and an income tax benefit of $53.6 million on a loss from continuing operations before income taxes of $35.2 million for the three months ended June 30, 2017. This resulted in effective tax rates of 65.5% and 152.3% for the three months ended June 29, 2018 and June 30, 2017, respectively. The income tax benefit for the three months ended June 29, 2018 is comprised of $9.5 million of current tax expense and $62.9 million of deferred tax benefit which is predominantly related to acquired intangible assets. The income tax benefit for the three months ended June 30, 2017 is comprised of $33.9 million of current tax expense and $87.5 million of deferred tax benefit which is predominantly related to acquired intangible assets.

The Company recognized an income tax benefit of $96.8 million on a loss from continuing operations before income taxes of $167.9 million for the six months ended June 29, 2018, and an income tax benefit of $95.6 million on a loss from continuing operations before income taxes of $122.1 million for the six months ended June 30, 2017. This resulted in effective tax rates of 57.7% and 78.3% for the six months ended June 29, 2018 and June 30, 2017, respectively. The income tax benefit for the six months ended June 29, 2018 is comprised of $13.1 million of current tax expense and $109.9 million of deferred tax benefit which is predominantly related to acquired intangible assets. The income tax benefit for the six months ended June 30, 2017 is comprised of $67.8 million of current tax expense and $163.4 million of deferred tax benefit. The net deferred tax benefit of $163.4 million includes $190.6 million of deferred tax benefit, which is predominantly related to acquired intangible assets offset by $27.2 million of deferred tax expense related to utilization of tax attributes.

The income tax benefit was $53.4 million for the three months ended June 29, 2018, compared with a tax benefit of $53.6 million for the three months ended June 30, 2017. The $0.2 million net decrease in the tax benefit includes a decrease of $9.8 million attributable to U.S. Tax Reform; partially offset by an increase of $6.0 million attributable to changes in the amount and jurisdictional mix of operating income and an increase of $3.6 million attributable to the impact of acquisitions occurring since June 30, 2017.

The income tax benefit was $96.8 million for the six months ended June 29, 2018, compared with a tax benefit of $95.6 million for the six months ended June 30, 2017. The $1.2 million net increase in the tax benefit includes an increase of $31.2 million attributable to the impact of dispositions, an increase of $12.8 million attributable to changes in the amount and jurisdictional mix of operating income, and an increase of $8.1 million attributable to the impact of acquisitions occurring since June 30, 2017; partially offset by a decrease of $33.4 million attributable to U.S. Tax Reform and a decrease of $17.5 million attributable to the termination of the defined benefit pension plans which occurred during the six months ended June 30, 2017.

On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the TCJA. The TCJA reduces the U.S. federal corporate statutory rate from 35% to 21%, requires companies to pay a one-time transition tax on certain undistributed earnings of the Company's foreign subsidiaries of U.S. entities and creates new taxes on certain foreign sourced earnings. The Company is applying the guidance in SAB 118 when accounting for the enactment-date effects of the TCJA. At June 29, 2018, the Company has not completed its accounting for all of the tax effects of the TCJA. As discussed below, the Company has recorded provisional estimates for certain provisions where the accounting is incomplete but a reasonable estimate can be made. In other cases, the Company continues to evaluate certain portions of the TCJA and the application of ASC 740 and no adjustments have been made in the unaudited condensed consolidated financial statements. In all cases, the Company will continue to make and refine its calculations as additional analysis is completed. These estimates may also be affected as the Company gains a more thorough understanding of the tax law.

In fiscal 2017, the Company adjusted certain U.S. deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future, which is generally 21%. A provisional decrease of $444.8 million was recognized resulting in a corresponding deferred income tax benefit in fiscal 2017. For the six months ended June 29, 2018, no adjustments related to this provisional estimate were made. While the Company is able to make a reasonable estimate of the impact of the reduction in the U.S. federal corporate statutory tax rate, it may be affected by other analyses related to the TCJA. These analyses include having a U.S. tax return year that straddles the effective date of the statutory rate change and that is different than the Company's fiscal year, the calculation of deemed repatriation of deferred foreign income, and the state tax effect of adjustments made to federal temporary differences.

The one-time transition tax under the TCJA is based upon the amount of post-1986 cumulative undistributed earnings of certain of the Company's subsidiaries which was deferred from U.S. income tax under previous U.S. law. In fiscal 2017, the Company estimated this item would not result in any current or future tax. For the six months ended June 29, 2018, no adjustments related to this provisional estimate have been made. While the Company is able to make a reasonable estimate of the impact of the one-time transition tax, additional information will continue to be gathered to finalize this conclusion.

Because of the complexity and uncertainties of the new global intangible low-taxed income rules, the Company continues to evaluate this portion of the TCJA and the application of ASC 740. Under GAAP, the Company is allowed to make an accounting policy choice of either (1) treating taxes due on future U.S. inclusions in taxable income related to global intangible low-taxed income as a current-period expense when incurred or (2) factoring such amounts into a company's measurement of its deferred taxes. The Company's selection of an accounting policy with respect to these new tax rules will depend on whether it expects to have future U.S. inclusions in taxable income related to global intangible low-taxed income and, if so, what the tax impact is expected to be. Whether the Company expects to have future U.S. inclusions in taxable income depends on not only the Company's current structure and estimated future results of global operations but also its intent and ability to modify its structure and/or business. While the Company estimates these rules will not have a material tax impact, it is not yet able to finalize the effect of this portion of the TCJA. Therefore, the Company has not made any adjustments related to this item in its unaudited condensed consolidated financial statements and has not made a policy decision regarding whether to record deferred taxes on global intangible low-taxed income.

During the six months ended June 29, 2018, and the fiscal year ended December 29, 2017, the net cash payments for income taxes were $13.7 million and $73.4 million, respectively.

During the three and six months ended June 29, 2018, the Company recognized income tax expense of $9.0 million and $15.8 million, respectively, associated with the Specialty Generics Disposal Group, as shown in Note 4.

During the three and six months ended June 29, 2018, the Company received a total of $15.0 million in contingent consideration related to the sale of the Nuclear Imaging business, consisting of a $6.0 million cash payment and the issuance of $9.0 million par value non-voting preferred equity certificates. The Company recorded a tax expense of $1.5 million associated with the $6.0 million contingent consideration cash payment. The consideration received and related tax expense were recorded net as income from discontinued operations.

The Sucampo Acquisition resulted in a net deferred tax liability increase of $170.8 million. Significant components of this increase include $180.5 million of deferred tax liabilities associated with intangible assets and a $24.1 million deferred tax liability associated with inventory step-up. The increase in deferred tax liabilities is partially offset by $28.0 million of deferred tax assets associated with U.S. net operating losses, $2.7 million of deferred tax assets associated with U.S. tax credits, and various other net deferred tax assets of $3.1 million.

The sale of a portion of the Hemostasis business, inclusive of the PreveLeak and Recothrom products, was completed on March 16, 2018. This divestiture resulted in a net deferred tax liability decrease of $3.0 million. A significant component of this decrease includes a decrease of $3.0 million of deferred tax liability associated with inventory step-up. In addition, there was a decrease of $1.5 million of deferred tax asset associated with potential future consideration, a decrease of $2.4 million of deferred tax asset associated with net operating losses, and a decrease of $4.2 million of deferred tax asset associated with intangible assets, all of which were offset by a reduction in valuation allowance of $8.1 million.

The Company's unrecognized tax benefits, excluding interest, totaled $202.9 million at June 29, 2018 and $182.5 million at December 29, 2017. The net increase of $20.4 million primarily resulted from a net increase to current year tax positions of $0.9 million, net increases from prior period tax positions predominately from acquired companies of $19.9 million, and net decreases from settlements of $0.4 million. If favorably settled, $190.2 million of unrecognized tax benefits at June 29, 2018 would benefit the effective tax rate, of which up to $20.0 million may be reported in discontinued operations. The total amount of accrued interest related to these obligations was $17.8 million at June 29, 2018 and $7.1 million at December 29, 2017.

It is reasonably possible that within the next twelve months, as a result of the resolution of various U.K. and non-U.K. examinations, appeals and litigation and the expiration of various statutes of limitation, that the unrecognized tax benefits will decrease by up to $39.8 million and the amount of related interest and penalties will decrease by up to $6.6 million.

Earnings per Share

6 Months Ended

Jun. 29, 2018

Earnings Per Share [Abstract]

Earnings per Share



8.	Earnings per Share

Basic earnings per share is computed by dividing net income (loss) by the number of weighted-average shares outstanding during the period. Diluted earnings per share is computed using the weighted-average shares outstanding and, if dilutive, potential ordinary shares outstanding during the period. Potential ordinary shares represent the incremental ordinary shares issuable for restricted share units and share option exercises. The Company calculates the dilutive effect of outstanding restricted share units and share options on earnings per share by application of the treasury stock method. Dilutive securities, including participating securities, are not included in the computation of loss per share when the Company reports a net loss from continuing operations as the impact would be anti-dilutive.

The weighted-average number of shares outstanding used in the computations of basic and diluted earnings per share were as follows (in millions):



	Three Months Ended		Six Months Ended
	June 29, 2018	June 30, 2017	June 29, 2018	June 30, 2017
Basic	83.2	98.5	84.7	100.9
Dilutive impact of restricted share units and share options	—	0.2	—	—
Diluted	83.2	98.7	84.7	100.9

The computation of diluted weighted-average shares outstanding for both the three and six months ended June 29, 2018 excludes approximately 3.6 million shares of equity awards because the effect would have been anti-dilutive. The computation of diluted weighted-average shares outstanding for the three and six months ended June 30, 2017 excludes approximately 4.0 million and 3.6 million shares of equity awards, respectively, because the effect would have been anti-dilutive.

Inventories

6 Months Ended

Jun. 29, 2018

Inventory, Net [Abstract]

Inventories



9.	Inventories

Inventories were comprised of the following at the end of each period:



	June 29, 2018		December 29, 2017
Raw materials and supplies	$	26.1	$	23.7
Work in process	118.1		61.1
Finished goods	40.2		43.9
	$	184.4	$	128.7

Property, Plant and Equipment

6 Months Ended

Jun. 29, 2018

Property, Plant and Equipment

Property, Plant and Equipment Disclosure



10.	Property, Plant and Equipment

The gross carrying amount and accumulated depreciation of property, plant and equipment at the end of each period was as follows:



	June 29, 2018			December 29, 2017
Property, plant and equipment, gross	$	599.6		$	569.7
Less: accumulated depreciation	(169.5		)	(156.5		)
Property, plant and equipment, net	$	430.1		$	413.2

Depreciation expense for property, plant and equipment was as follows:



	Three Months Ended				Six Months Ended
	June 29, 2018		June 30, 2017		June 29, 2018		June 30, 2017
Depreciation expense	$	11.6	$	12.5	$	23.3	$	25.8

Goodwill and Intangible Assets

6 Months Ended

Jun. 29, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets



11.	Goodwill and Intangible Assets

The gross carrying amount and accumulated impairment of goodwill at the end of each period were as follows:



	June 29, 2018				December 29, 2017
	Gross Carrying Amount		Accumulated Impairment		Gross Carrying Amount		Accumulated Impairment
Specialty Brands	$	3,676.7	$	—	$	3,482.7	$	—

During the six months ended June 29, 2018, the gross carrying value of goodwill within the Specialty Brands segment increased by $194.0 million. The increase was attributable to the Sucampo Acquisition, which yielded $246.0 million of goodwill, partially offset by $51.5 million of goodwill ascribed to the sale of a portion of the Company's Hemostasis business, inclusive of the PreveLeak and Recothrom products. The remaining change in goodwill was related to purchase accounting adjustments during the twelve month measurement period for previous acquisitions.

Stannsoporfin

On May 3, 2018, in a joint meeting, the FDA's Gastrointestinal Drugs Advisory Committee and Pediatric Advisory Committee (the "Advisory Committee") recommended that the risk benefit profile of the Company's stannsoporfin IPR&D product does not support approval for the treatment of newborns ≥35 weeks of gestational age with indicators of hemolysis who are at risk of developing hyperbilirubinemia (severe jaundice). While the timing of the development program is expected to shift outward, the Company continues to have conversations with the FDA to determine the best path forward. The Prescription Drug User Fee Act ("PDUFA") date for this development product is August 22, 2018. The Company will continue to assess the impact of any changes to planned revenue or earnings on the fair value of the associated IPR&D asset of $113.5 million included within intangible assets, net on the unaudited condensed consolidated balance sheets as of June 29, 2018 and December 29, 2017. Refer to Note 18 for the associated impact on the Company's contingent consideration liability related to stannsoporfin.

The Company annually tests the indefinite-lived intangible assets for impairment, or whenever events or changes in circumstances indicate that the carrying value may not be recoverable by either a qualitative or income approach. Management relies on a number of qualitative factors when considering a potential impairment such as changes to planned revenue or earnings that could affect significant inputs used to determine the fair value of the indefinite-lived intangible asset.

The gross carrying amount and accumulated amortization of intangible assets at the end of each period were as follows:



	June 29, 2018				December 29, 2017
	Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization
Amortizable:
Completed technology	$	10,278.4	$	2,473.7	$	9,693.0	$	2,126.1
Customer relationships	28.0		13.0		29.5		12.2
Trademarks	75.2		12.5		75.5		10.8
Other	8.6		8.6		8.6		8.6
Total	$	10,390.2	$	2,507.8	$	9,806.6	$	2,157.7
Non-Amortizable:
Trademarks	$	35.0			$	35.0
In-process research and development	851.6				577.1
Total	$	886.6			$	612.1

Intangible asset amortization expense was as follows:



	Three Months Ended				Six Months Ended
	June 29, 2018		June 30, 2017		June 29, 2018		June 30, 2017
Amortization expense	$	184.3	$	169.3	$	360.6	$	339.1

The estimated aggregate amortization expense on intangible assets owned by the Company is expected to be as follows:



Remainder of Fiscal 2018	$	368.4
Fiscal 2019	737.1
Fiscal 2020	736.8
Fiscal 2021	736.5
Fiscal 2022	609.6

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Debt

6 Months Ended

Jun. 29, 2018

Debt Disclosure [Abstract]

Debt



12.	Debt

Debt was comprised of the following at the end of each period:



	June 29, 2018				December 29, 2017
	Principal		Unamortized Discount and Debt Issuance Costs		Principal		Unamortized Discount and Debt Issuance Costs
Current maturities of long-term debt:
3.50% notes due April 2018	$	—	$	—	$	300.0	$	0.2
Term loan due September 2024	16.4		0.2		14.0		0.3
Term loan due February 2025	6.0		0.1		—		—
ACOA loan due December 2028	0.1		—		—		—
Capital lease obligation and vendor financing agreements	—		—		0.2		—
Total current debt	22.5		0.3		314.2		0.5
Long-term debt:
4.875% notes due April 2020	700.0		4.5		700.0		5.7
Variable-rate receivable securitization due July 2020	240.0		0.5		200.0		0.7
9.50% debentures due May 2022	10.4		—		10.4		—
5.75% notes due August 2022	884.0		8.5		884.0		9.5
8.00% debentures due March 2023	4.4		—		4.4		—
4.75% notes due April 2023	500.2		3.9		526.5		4.5
5.625% notes due October 2023	731.4		8.8		738.0		9.7
Term loan due September 2024	1,601.5		21.6		1,837.2		26.7
Term loan due February 2025	592.5		11.6		—		—
5.50% notes due April 2025	692.1		8.4		692.1		9.0
ACOA loan due December 2028	1.6		—		—		—
Revolving credit facility	450.0		5.2		900.0		5.9
Total long-term debt	6,408.1		73.0		6,492.6		71.7
Total debt	$	6,430.6	$	73.3	$	6,806.8	$	72.2

In April 2018, $300.0 million of the Company's 3.50% unsecured, fixed-rate notes matured and were repaid with cash on hand.

In March 2018, BioVectra entered into an agreement with the Atlantic Canada Opportunities Agency ("ACOA") to obtain an interest-free loan of up to $5.0 million Canadian Dollars ("CAD") in exchange for specified investments in Canada. The loan is repayable in equal monthly installments over 10 years starting in January 2019. The Company has the option of prepaying this loan without any penalties. As of June 29, 2018, the outstanding principal under this agreement was approximately $1.7 million.

In February 2018, in conjunction with the Sucampo Acquisition, Mallinckrodt International Finance S.A. ("MIFSA") and Mallinckrodt CB LLC ("MCB") issued a $600.0 million senior secured term loan. The variable-rate loan bears an interest rate of LIBOR plus 300 basis points and was issued with a discount of 25 basis points. The incremental term loan requires quarterly principal amortization payments in an amount equal to 1.00% of the original principal balance of the incremental term loan, and may be reduced by making optional prepayments. The quarterly principal amortization is payable on the last day of each calendar quarter, which will commence on June 30, 2018, with the remaining principal balance due on February 24, 2025. The incremental term loan matures on February 24, 2025 under terms generally consistent with the term loan due September 2024.

In January 2018, the Company made a $225.0 million voluntary prepayment on its term loan due September 2024. In making this payment, the Company satisfied certain obligations included within external debt agreements to reinvest proceeds from the sale of assets and businesses within one year of the respective transaction or use the proceeds to pay down debt.

As of June 29, 2018, the applicable interest rate and outstanding borrowings on the Company's variable-rate debt instruments were as follows:



	Applicable interest rate		Outstanding borrowings
Term loan due September 2024	5.20	%	$	1,617.9
Term loan due February 2025	5.52	%	598.5
Variable-rate receivable securitization	2.99	%	240.0
Revolving credit facility	4.58	%	450.0

As of June 29, 2018, the Company continues to be in full compliance with the provisions and covenants associated with its debt agreements. The Company's debt instruments are further described within the notes to the financial statements included within the Company's Annual Report filed on Form 10-K for the fiscal year ended December 29, 2017.

Retirement Plans

6 Months Ended

Jun. 29, 2018

Retirement Benefits [Abstract]

Retirement Plans



13.	Retirement Plans

The net periodic benefit cost for the Company's defined benefit pension plans was as follows:



	Three Months Ended				Six Months Ended
	June 29, 2018		June 30, 2017		June 29, 2018		June 30, 2017
Service cost	$	—	$	0.2	$	0.1	$	1.3
Interest cost	0.1		0.4		0.3		1.6
Expected return on plan assets	—		—		—		(0.8		)
Amortization of net actuarial loss	0.2		0.3		0.3		1.8
Amortization of prior service cost	0.1		0.1		0.1		0.2
Plan settlements	—		0.5		—		69.7
Net periodic benefit cost	$	0.4	$	1.5	$	0.8	$	73.8

The net periodic benefit credit for the Company's postretirement benefit plans was approximately $0.7 million and zero for the three months ended June 29, 2018 and June 30, 2017, respectively, and $1.0 million and zero for the six months ended June 29, 2018 and June 30, 2017, respectively.

Of the net periodic benefit cost for the Company's defined benefit pension plans and postretirement benefit plans, only service costs are included within other employee compensation costs recorded within cost of sales, R&D, and SG&A expenses, while all other components of the net periodic benefit costs are included within other income and expense on the unaudited condensed consolidated statements of income.

Pension Plan Termination

During the six months ended June 30, 2017, the Company completed the third-party settlement of the remaining obligations of six defined benefit pension plans that were terminated during fiscal 2016. In conjunction with this final settlement, the Company made a $61.3 million cash contribution to the terminated plans and recognized a $69.7 million charge, included within other (expense) income expense, net within the unaudited condensed consolidated statement of income.

Accumulated Other Comprehensive Income

6 Months Ended

Jun. 29, 2018

Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]

Accumulated Other Comprehensive Income



14.	Accumulated Other Comprehensive Loss

The following summarizes the change in accumulated other comprehensive loss for the six months ended June 29, 2018 and June 30, 2017:



	Currency Translation			Unrecognized Loss on Derivatives			Unrecognized Loss on Benefit Plans			Unrecognized Gain on Investment ⁽¹⁾		Accumulated Other Comprehensive Loss ⁽¹⁾
Balance at December 29, 2017	$	(8.2	)	$	(4.7	)	$	(1.5	)	$	—	$	(14.4	)
Other comprehensive (loss) income before reclassifications	(7.3		)	—			0.9			—		(6.4		)
Amounts reclassified from accumulated other comprehensive loss	—			0.5			(1.4		)	—		(0.9		)
Net current period other comprehensive (loss) income	(7.3		)	0.5			(0.5		)	—		(7.3		)
Balance at June 29, 2018	$	(15.5	)	$	(4.2	)	$	(2.0	)	$	—	$	(21.7	)


(1)	Upon adoption of ASU 2016-01, a reclassification of $1.5 million relating to the unrealized gain on investment resulted in an increase to beginning retained earnings with an offsetting decrease to accumulated other comprehensive loss. See Note 2 for additional details.



	Currency Translation			Unrecognized Loss on Derivatives			Unrecognized Loss on Benefit Plans			Unrecognized Gain on Investment		Accumulated Other Comprehensive Loss
Balance at December 30, 2016	$	(19.5	)	$	(5.7	)	$	(47.3	)	$	—	$	(72.5	)
Other comprehensive income before reclassifications	12.1			—			5.9			10.6		28.6
Amounts reclassified from accumulated other comprehensive loss	(4.7		)	0.6			40.0			—		35.9
Net current period other comprehensive income	7.4			0.6			45.9			10.6		64.5
Balance at June 30, 2017	$	(12.1	)	$	(5.1	)	$	(1.4	)	$	10.6	$	(8.0	)

The following summarizes reclassifications from accumulated other comprehensive loss for the six months ended June 29, 2018 and June 30, 2017:



	Amount Reclassified from Accumulated Other Comprehensive Loss
	Six Months Ended
	June 29, 2018			June 30, 2017			Line Item in the Unaudited Condensed Consolidated Statement of Income
Currency translation	$	—		$	(4.7	)	Income from discontinued operations, net of income taxes

Amortization and other of unrealized loss on derivatives	0.5			0.8			Interest expense
Income tax provision	—			(0.2		)	Income tax benefit
Net of income taxes	0.5			0.6

Amortization of pension and post-retirement benefit plans:
Net actuarial loss	0.3			1.8			⁽¹⁾
Prior service credit	(1.0		)	(1.0		)	⁽¹⁾
Divestiture of discontinued operations	—			(3.1		)	Income from discontinued operations, net of income taxes
Plan settlements	(0.7		)	69.7			⁽¹⁾
Total before tax	(1.4		)	67.4
Income tax provision	—			(27.4		)	Income tax benefit
Net of income taxes	(1.4		)	40.0

Total reclassifications for the period	$	(0.9	)	$	35.9


(1)	These accumulated other comprehensive loss components are included in the computation of net periodic benefit cost. See Note 13 for additional details.

Equity

6 Months Ended

Jun. 29, 2018

Equity [Abstract]

Equity



15.	Equity

Share Repurchases

On March 16, 2016, the Company's Board of Directors authorized a $350.0 million share repurchase program (the "March 2016 Program"), which was completed during the three months ended March 31, 2017. On March 1, 2017, the Company's Board of Directors authorized an additional $1.0 billion share repurchase program (the "March 2017 Program"), which commenced upon the completion of the March 2016 Program. The March 2017 Program has no expiration date, and the Company currently expects to fully utilize the program.



	March 2017 Repurchase Program			March 2016 Repurchase Program
	Number of Shares	Amount		Number of Shares	Amount
Authorized repurchase amount		$	1,000.0		$	350.0
Repurchases:
Transition Period 2016 ⁽¹⁾	—	—		1,501,676	84.0
Fiscal 2017	13,490,448	380.6		5,366,741	266.0
Fiscal 2018	3,610,968	55.2		—	—
Remaining amount available		$	564.2		$	—

⁽¹⁾ Represents the period from October 1, 2016 through December 30, 2016. The Company historically reported its results based on a "52-53 week" year ending on the last Friday in September. On May 17, 2016, the Board of Directors of the Company approved a change in the Company's fiscal year end to the last Friday in December from the last Friday in September. The change in fiscal year end became effective for the Company's 2017 fiscal year, which began on December 31, 2016 and ended on December 29, 2017. As a result of the change in fiscal year end, the Company filed a Transition Report on Form 10-Q on February 7, 2017 covering the period from October 1, 2016 through December 30, 2016.

The Company also repurchases shares from employees in order to satisfy employee tax withholding requirements in connection with the vesting of restricted shares and share option exercises.

Guarantees

6 Months Ended

Jun. 29, 2018

Guarantees [Abstract]

Guarantees



16.	Guarantees

In disposing of assets or businesses, the Company has from time to time provided representations, warranties and indemnities to cover various risks and liabilities, including unknown damage to assets, environmental risks involved in the sale of real estate, liability to investigate and remediate environmental contamination at waste disposal sites and manufacturing facilities, and unidentified tax liabilities related to periods prior to disposition. The Company assesses the probability of potential liabilities related to such representations, warranties and indemnities and adjusts potential liabilities as a result of changes in facts and circumstances. The Company believes, given the information currently available, that their ultimate resolutions will not have a material adverse effect on its financial condition, results of operations and cash flows.

In connection with the sale of the Specialty Chemicals business (formerly known as Mallinckrodt Baker) in fiscal 2010, the Company agreed to indemnify the purchaser with respect to various matters, including certain environmental, health, safety, tax and other matters. The indemnification obligations relating to certain environmental, health and safety matters have a term of 17 years from the sale, while some of the other indemnification obligations have an indefinite term. The amount of the liability relating to all of these indemnification obligations included in other liabilities on the Company's unaudited condensed consolidated balance sheets as of June 29, 2018 and December 29, 2017 was $14.5 million and $14.9 million, respectively, of which $11.7 million and $12.1 million, respectively, related to environmental, health and safety matters. The value of the environmental, health and safety indemnity was measured based on the probability-weighted present value of the costs expected to be incurred to address environmental, health and safety claims made under the indemnity. The aggregate fair value of these indemnification obligations did not differ significantly from their aggregate carrying value at June 29, 2018 and December 29, 2017. As of June 29, 2018, the maximum future payments the Company could be required to make under these indemnification obligations were $70.2 million. The Company was required to pay $30.0 million into an escrow account as collateral to the purchaser, of which $18.4 million and $18.3 million remained in restricted cash, included in long-term other assets on the unaudited condensed consolidated balance sheets at June 29, 2018 and December 29, 2017, respectively.

The Company has recorded liabilities for known indemnification obligations included as part of environmental liabilities, which are discussed in Note 17.

The Company is also liable for product performance; however, the Company believes, given the information currently available, that the ultimate resolution of any such claims will not have a material adverse effect on its financial condition, results of operations and cash flows.

As of June 29, 2018, the Company had various other letters of credit, guarantees and surety bonds totaling $23.5 million.

Commitments and Contingencies

6 Months Ended

Jun. 29, 2018

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies



17.	Commitments and Contingencies

The Company is subject to various legal proceedings and claims, including patent infringement claims, product liability matters, environmental matters, employment disputes, contractual disputes and other commercial disputes, including those described below. The Company believes that these legal proceedings and claims likely will be resolved over an extended period of time. Although it is not feasible to predict the outcome of these matters, the Company believes, unless indicated below, given the information currently available, that their ultimate resolutions are not expected to have a material adverse effect on its financial condition, results of operations and cash flows.

Governmental Proceedings

Opioid Related Matters

Multidistrict Litigation. The Company, along with other opioid manufacturers and often, distributors, has been named in lawsuits brought by various counties, cities, Native American tribes, hospitals, health care clinics, Medicaid managed care organizations, third-party payers. In general, the lawsuits assert claims of public nuisance, negligence, civil conspiracy, fraud, violations of the Racketeer Influenced and Corrupt Organizations Act ("RICO") or similar state laws, consumer fraud, deceptive trade practices, insurance fraud, unjust enrichment and other common law claims arising from defendants' manufacturing, distribution, marketing and promotion of opioids and seek restitution, damages, injunctive and other relief and attorneys' fees and costs. These lawsuits were originally filed against, or amended to include, the Company in various U.S. District Courts or in state courts with the state court lawsuits subsequently removed to U.S. District Courts. On December 5, 2017, the Judicial Panel in Multidistrict Litigation ("JPML") issued its order establishing a Multidistrict Litigation ("MDL") in the Northern District of Ohio for opioid litigation cases and transferring those cases to the MDL that were originally filed in U.S. District Courts or removed to U.S. District Courts from state court. There are currently 1,019 lawsuits naming the Company that either are in the MDL or are expected to be transferred to the MDL. The Company intends to vigorously defend itself in these matters.

State Court Lawsuits. On July 12, 2018, the Commonwealth of Kentucky, through its Attorney General, filed suit in the Madison County Circuit Court in Kentucky against the Company. The lawsuit asserts violations of the Kentucky Consumer Protection Act, Medicaid Fraud Statute and Assistance Program Fraud Statute, asserts claims of public nuisance, fraud, negligence and unjust enrichment, and seeks relief similar to that sought in other state and federal actions.

On May 15, 2018, the State of Florida, through its Attorney General, filed suit in the Circuit Court of the Sixth Judicial Circuit in and for Pasco County in Florida against certain opioid distributors and manufacturers, including the Company. The lawsuit asserts violations of the Florida Deceptive and Unfair Trade Practices and RICO, asserts claims of public nuisance and negligence and seeks relief similar to that sought in other state and federal actions.

On December 20, 2017, the State of New Mexico, through its Attorney General, amended its lawsuit pending in the First Judicial District Court in the County of Santa Fe against certain opioid distributors and manufacturers, to add the Company. The lawsuit asserts violations of public nuisance laws and the New Mexico Unfair Practices, Medicaid Fraud and Racketeering Acts and seeks relief similar to that sought in other state and federal actions.

In addition, the Company is currently named in 59 lawsuits pending in state courts in Alabama (1), Arkansas (1), Connecticut (2), Florida (1), Georgia (1), Illinois (1), Louisiana (2), Maine (1), Massachusetts (1), Missouri (1), Nevada (1), New York (1), Ohio (8), Oklahoma (6), Pennsylvania (9), Tennessee (3), Texas (11), Utah (3), Virginia (3) and West Virginia (2). These state lawsuits are brought on behalf of cities, counties, towns, villages, third party payers, Medicaid managed care organizations, Native American tribes, individuals, and corporations that provide emergency medicine, addiction treatment and recovery services. The lawsuits assert claims and seek damages similar to those sought in the cases pending before the MDL. The Company intends to vigorously defend itself in these state court matters.

Investigations. The Company has also received various subpoenas and requests for information related to the distribution, marketing and sale of the Company's opioid products. On July 26, 2017, the Company received a subpoena from the Department of Justice ("DOJ"), on August 24, 2017, the Company received a Civil Investigative Demand ("CID") from the Missouri Attorney General's Office, on September 22, 2017, the Company received a subpoena from the New Hampshire Attorney General's Office, on January 9, 2018, the Company received a subpoena and CID from the Kentucky Attorney General's Office, on January 16, 2018, the Company received a CID from the Attorney General's Office for the State of Washington, on February 5, 2018, the Company received a subpoena from the Attorney General's Office from the State of Alaska and on May 15, 2018, the Company received a CID from the Attorney General's Office for the State of South Carolina.

In addition, on January 27, 2018 the Company received a grand jury subpoena from the U.S. Attorneys' Office ("USAO") for the Southern District of Florida for documents related to the Company's distribution, marketing and sale of its oxymorphone generic products.

The Company is in the process of responding to these subpoenas and CIDs.

The Company has been contacted by the coalition of State Attorneys General investigating the role manufacturers and distributors may have had in contributing to the increased use of opioids in the U.S.

The Company intends to cooperate fully in these investigations.

Since these lawsuits and investigations are in early stages, the Company is unable to predict their outcome or estimate a range of reasonably possible losses.

Other Matters

Generic Pricing Subpoena. In March 2018, the Company received a grand jury subpoena issued by the U.S. District Court for the Eastern District of Pennsylvania pursuant to which the Antitrust Division of the Department of Justice is seeking documents regarding generic products and pricing, communications with generic competitors and other related matters. The Company is in the process of responding to this subpoena, and the Company intends to cooperate fully in the investigation.

SEC Subpoena. In January 2017, the Company received a subpoena from the SEC for documents related to the Company's public statements, filings and other disclosures regarding H.P. Acthar^® Gel sales, profits, revenue, promotion and pricing. The Company has responded to this subpoena, and in February 2018, the SEC notified the Company that it had concluded its investigation and that no enforcement action was recommended against the Company.

Boston Subpoena. In December 2016, the Company received a subpoena from the USAO for the District of Massachusetts for documents related to the Company's provision of financial and other support to patients, including through charitable foundations, and related matters. The Company is in the process of responding to this subpoena, and the Company intends to cooperate fully in the investigation.

Texas Pricing Investigation. In November 2014, the Company received a CID from the Civil Medicaid Fraud Division of the Texas Attorney General's Office. According to the CID, the Attorney General's office is investigating the possibility of false reporting of information by the Company regarding the prices of certain of its drugs used by Texas Medicaid to establish reimbursement rates for pharmacies that dispensed the Company's drugs to Texas Medicaid recipients. The Company has responded to these requests.

Mallinckrodt Inc. v. U.S. Food and Drug Administration and United States of America. In November 2014, the Company filed a Complaint ("the Complaint") in the U.S. District Court for the District of Maryland Greenbelt Division against the FDA and the United States for judicial review of what the Company believes is the FDA's inappropriate and unlawful reclassification of the Company's Methylphenidate HCl Extended-Release tablets USP (CII) ("Methylphenidate ER") in the Orange Book: Approved Drug Products with Therapeutic Equivalence ("Orange Book"). The Company also sought a temporary restraining order ("TRO") directing the FDA to reinstate the Orange Book AB rating for the Company's Methylphenidate ER products. The court denied the Company's motion for a TRO and in July 2015, the court granted the FDA's motion to dismiss with respect to three of the five counts in the Complaint and granted summary judgment in favor of the FDA with respect to the two remaining counts. The Company appealed the court's decision to the U.S. Court of Appeals for the Fourth Circuit. On October 18, 2016, the FDA initiated proceedings, proposing to withdraw approval of the Company's Abbreviated New Drug Application ("ANDA") for Methylphenidate ER. On October 21, 2016, the United States Court of Appeals for the Fourth Circuit issued an order placing that litigation in abeyance pending the outcome of the withdrawal proceedings. The Company concurrently submitted to the FDA requests for a hearing in the withdrawal proceeding and for an extension of the deadline for submitting documentation supporting the necessity of a hearing. The FDA granted the Company's initial request to extend the deadline, and on February 21, 2017, the FDA suspended the deadline in order to give the Center for Drug Evaluation and Research ("CDER") an opportunity to complete its production of documents. CDER shared an initial set of documents with the Company in June 2017 and a second set of documents in October 2017. Following the Company's receipt of the October tranche of documents from CDER, the Company presented a supplemental document request to CDER to ensure all of its initial document requests were fulfilled, and on February 13, 2018, CDER provided a final set of documents in response to the Company's requests. In April 2018, the Company filed its submission in support of its position in the withdrawal proceedings. A potential outcome of the withdrawal proceedings is that the Company's Methylphenidate ER products may lose their FDA approval, which could have a negative impact to the Company's Specialty Generics Disposal Group.

FTC Investigation. In June 2014, Questcor Pharmaceuticals, Inc. ("Questcor") received a subpoena and CID from the Federal Trade Commission ("FTC") seeking documentary materials and information regarding the FTC's investigation into whether Questcor's acquisition of certain rights to develop, market, manufacture, distribute, sell and commercialize Synacthen Depot® from Novartis AG and Novartis Pharma AG (collectively, "Novartis") violates antitrust laws. Subsequently, California, Maryland, Texas, Washington, New York and Alaska (collectively, "the Investigating States") commenced similar investigations focused on whether the transaction violates state antitrust laws. On January 17, 2017, the FTC, all Investigating States (except California) ("the Settling States") and the Company entered into an agreement to resolve this matter for a one-time cash payment of $102.0 million and an agreement to license Synacthen Depot to a third party designated by the FTC for possible development in Infantile Spasms ("IS") and Nephrotic Syndrome ("NS") in the U.S. To facilitate that settlement, a complaint was filed on January 18, 2017, in the U.S. District Court for the District of Columbia. The settlement was approved by the court on January 30, 2017. On July 16, 2017, the Company announced the completion of the U.S. license of both the Synacthen trademark and certain intellectual property associated with Synacthen Depot to West Pharmaceuticals to develop and pursue possible FDA approval of the product in IS and NS. The Company retains the right to develop MNK-1411 (the product formerly described as Synacthen Depot) for all other indications in the U.S. and retains rights to the Synacthen trademark outside the U.S.

Therakos Investigation. In March 2014, the USAO for the Eastern District of Pennsylvania requested the production of documents related to an investigation of the U.S. promotion of Therakos'^® drug/device system UVADEX/UVAR XTS and UVADEX/CELLEX (collectively, the "Therakos System"), for indications not approved by the FDA, including treatment of patients with graft versus host disease ("GvHD") and solid organ transplant patients, including pediatric patients. The investigation also includes Therakos' efforts to secure FDA approval for additional uses of, and alleged quality issues relating to, UVADEX/UVAR. In August 2015, the USAO for the Eastern District of Pennsylvania sent Therakos a subsequent request for documents related to the investigation and has since made certain related requests. The Company is in the process of responding to these requests.

DEA Investigation. In November 2011 and October 2012, the Company received subpoenas from the U.S. Drug Enforcement Administration ("DEA") requesting production of documents relating to its suspicious order monitoring program for controlled substances. The USAO for the Eastern District of Michigan investigated the possibility that the Company failed to report suspicious orders of controlled substances during the period 2006-2011 in violation of the Controlled Substances Act and its related regulations. The USAO for the Northern District of New York and Office of Chief Counsel for the U.S. DEA investigated the possibility that the Company failed to maintain appropriate records and security measures with respect to manufacturing of certain controlled substances at its Hobart, New York facility during the period 2012-2013. In July 2017, the Company entered into a final settlement with the DEA and the USAOs for the Eastern District of Michigan and the Northern District of New York to settle these investigations. As part of the agreement, the Company paid $35.0 million to resolve all potential claims.

Questcor DOJ Investigation. In September 2012, Questcor received a subpoena from the USAO for the Eastern District of Pennsylvania for information relating to its promotional practices related to H.P. Acthar Gel. Questcor has also been informed by the USAO for the Eastern District of Pennsylvania that the USAO for the Southern District of New York and the SEC were participating in the investigation to review Questcor's promotional practices and related matters related to H.P. Acthar Gel. On March 9, 2015, the Company received a "No Action" letter from the SEC regarding its review of the Company's promotional practices related to H.P. Acthar Gel. The Company intends to cooperate fully in the investigation.

Patent Litigation

Amitiza Patent Litigation: Teva Pharmaceuticals USA, Inc. In September 2017, Sucampo AG and Sucampo Pharmaceuticals, Inc., subsidiaries of the Company, and Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals USA, Inc., and Takeda Pharmaceuticals America, Inc. (collectively "Takeda," the exclusive licensee under the patents in litigation) filed suit in the U.S. District Court for the District of New Jersey against Teva Pharmaceuticals USA, Inc. ("Teva") alleging that Teva infringed U.S. Patent Nos. 6,414,016, 6,982,283, 7,795,312, 8,026,393, 8,071,613, 8,097,653, 8,338,639, 8,389,542 and 8,748,481 following receipt of an August 2017 notice from Teva concerning its submission of an ANDA containing a Paragraph IV patent certification with the FDA for a generic version of Amitiza. On June 28, 2018, the parties entered into a settlement agreement under which Teva was granted the non-exclusive right to market a competing lubiprostone product in the U.S. under its ANDA on or after January 1, 2023, or earlier under certain circumstances.

Amitiza Patent Litigation: Amneal Pharmaceuticals, LLC. In April 2017, Sucampo AG and Sucampo Pharmaceuticals, Inc., subsidiaries of the Company, and Takeda filed suit in the U.S. District Court for the District of New Jersey against Amneal Pharmaceuticals, LLC ("Amneal") alleging that Amneal infringed U.S. Patent Nos. 6,982,283, 8,026,393, 8,097,653, 8,338,639 and 8,389,542 following receipt of a March 2017 notice from Amneal concerning its submission of an ANDA containing a Paragraph IV patent certification with the FDA for a generic version of Amitiza. On June 28, 2018, the parties entered into a settlement agreement under which Amneal was granted the non-exclusive right to market a competing lubiprostone product in the U.S. under its ANDA on or after January 1, 2023, or earlier under certain circumstances.

Amitiza Patent Litigation: Par and DRL. Settlement and License Agreements were entered into with Anchen Pharmaceuticals, Inc., Par Pharmaceutical, Inc. and Par Pharmaceutical Companies, Inc. (collectively "Par") and Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd. (collectively "DRL") to settle Paragraph IV patent litigation with each of Par and DRL. Under the terms of the Par settlement dated September 30, 2014, Par was granted a non-exclusive license and right to market a competing generic of Amitiza on or after January 1, 2021, or earlier under certain circumstances. Under the terms of the DRL settlement dated September 14, 2016, DRL was granted a non-exclusive license and right to market a competing generic of Amitiza on or after January 1, 2023, or earlier under certain circumstances.

Inomax Patent Litigation: Praxair Distribution, Inc. and Praxair, Inc. (collectively "Praxair"). In February 2015, INO Therapeutics LLC and Ikaria, Inc., subsidiaries of the Company, filed suit in the U.S. District Court for the District of Delaware against Praxair following receipt of a January 2015 notice from Praxair concerning its submission of an ANDA containing a Paragraph IV patent certification with the FDA for a generic version of Inomax^®. In July 2016, the Company filed a second suit against Praxair in the U.S. District Court for the District of Delaware following receipt of a Paragraph IV notice concerning three additional patents recently added to the FDA Orange Book that was submitted by Praxair regarding its ANDA for a generic version of Inomax. The infringement claims in the second suit have been added to the original suit. In September 2016, the Company filed a third suit against Praxair in the U.S. District Court for the District of Delaware following receipt of a Paragraph IV notice concerning a fourth patent recently added to the FDA Orange Book that was submitted by Praxair regarding its ANDA for a generic version of Inomax.

The Company intends to vigorously enforce its intellectual property rights relating to Inomax in both the Inter Partes Review ("IPR") and Praxair litigation proceedings to prevent the marketing of infringing generic products prior to the expiration of the patents covering Inomax. Trial of the suit filed in February 2015 was held in March 2017 and a decision was rendered September 5, 2017 that ruled five patents invalid and six patents not infringed. The Company has appealed the decision to the Court of Appeals for the Federal Circuit. An adverse outcome in the appeal of the Praxair litigation decision ultimately could result in the launch of a generic version of Inomax before the expiration of the last of the listed patents on May 3, 2036 (November 3, 2036 including pediatric exclusivity), which could adversely affect the Company's ability to successfully maximize the value of Inomax and have an adverse effect on its financial condition, results of operations and cash flows.

Inomax Patents: IPR Proceedings. In February 2015 and March 2015, the U.S. Patent and Trademark Office ("USPTO") issued Notices of Filing Dates Accorded to Petitions for IPR petitions filed by Praxair Distribution, Inc. concerning ten patents covering Inomax (i.e., five patents expiring in 2029 and five patents expiring in 2031).

In July 2015 the USPTO Patent Trial and Appeal Board ("PTAB") issued rulings denying the institution of four of the five IPR petitions challenging the five patents expiring in 2029. The PTAB also issued a ruling in July 2015 that instituted the IPR proceeding in the fifth of this group of patents and the PTAB ruled in July 2016 that one claim of this patent survived review and is valid while the remaining claims were unpatentable. The Company believed the claim held valid by the PTAB describes and encompasses a manner in which Inomax is distributed in conjunction with its approved labeling and that Praxair infringes that claim. Praxair filed an appeal and Mallinckrodt filed a cross-appeal of this decision to the Court of Appeals for the Federal Circuit. Oral argument of that appeal occurred in January 2018. The Federal Circuit decision was issued May 16, 2018 and held all claims unpatentable (invalid).

In March 2016, Praxair Distribution, Inc. submitted additional IPR petitions for the five patents expiring in 2029. The PTAB issued non-appealable rulings in August and September 2016 denying institution of all five of these additional IPR petitions.

In September 2015 the USPTO PTAB issued rulings that instituted the IPR proceedings in each of the second set of five patents that expire in 2031. In September 2016 the PTAB ruled that all claims in the five patents expiring in 2031 are patentable.

Ofirmev Patent Litigation: Aurobindo Pharma U.S.A., Inc. In December 2017, Mallinckrodt Hospital Products Inc. and Mallinckrodt IP Unlimited Group, subsidiaries of the Company, and New Pharmatop L.P. ("Pharmatop"), the current owner of the two U.S. patents licensed exclusively by the Company, filed suit in the U.S. District Court for the District of Delaware against Aurobindo Pharma U.S.A., Inc. ("Aurobindo") alleging that Aurobindo infringed U.S. Patent No. 6,992,218 ("the '218 patent"), U.S. Patent No. 9,399,012 ("the '012 patent") and U.S. Patent No. 9,610,265 ("the '265 patent") following receipt of a November 2017 notice from Aurobindo concerning its submission of an ANDA, containing a Paragraph IV patent certification with the FDA for a competing version of Ofirmev^®. On May 7, 2018 the parties entered into a settlement agreement under which Aurobindo was granted the non-exclusive right to market a competing intravenous acetaminophen product in the U.S. under its ANDA on or after December 6, 2020, or earlier under certain circumstances.

Ofirmev Patent Litigation: B. Braun Medical Inc. In April 2017, Mallinckrodt Hospital Products Inc. and Mallinckrodt IP, subsidiaries of the Company, and Pharmatop, the then owner of the two U.S. patents licensed exclusively by the Company, filed suit in the U.S. District Court for the District of Delaware against B. Braun Medical Inc. ("B. Braun") alleging that B. Braun infringed the '218 patent and the '012 patent following receipt of a February 2017 notice from B. Braun concerning its submission of a New Drug Application ("NDA"), containing a Paragraph IV patent certification with the FDA for a competing version of Ofirmev. Following receipt of a second Paragraph IV notice letter from B. Braun on April 24, 2017 directed to the '012 patent, Mallinckrodt Hospital Products Inc. and Mallinckrodt IP filed suit in June 2017 in the U.S. District Court for the District of Delaware against B. Braun alleging that B. Braun infringed the '012 patent and the '265 patent. In both instances, a protective suit was filed in the U.S. District Court for the Eastern District of Pennsylvania to protect the 30-month stay against any venue challenge in Delaware. In July 2017, B. Braun filed motions to dismiss both actions in Delaware due to improper venue based on the recent U.S. Supreme Court TC Heartland decision on venue in patent cases, and also filed a separate motion to dismiss in the original action in Pennsylvania. Following receipt of a third Paragraph IV notice letter from B. Braun on July 13, 2017 that included a certification to the '265 patent, amended complaints were filed in July 2017 in the U.S. District Courts for the Districts of Delaware and Eastern District of Pennsylvania by Mallinckrodt Hospital Products Inc., Mallinckrodt IP and Pharmatop. Also in July 2017, Mallinckrodt Hospital Products Inc., Mallinckrodt IP and Pharmatop filed a motion to stay the action in the Eastern District of Pennsylvania. A hearing occurred August 24, 2017 in the U.S. District Court for the District of Delaware regarding B. Braun's motion to dismiss the Delaware actions for improper venue. A scheduling conference occurred October 4, 2017 in the U.S. District Court for the Eastern District of Pennsylvania and no decisions were rendered on any of the pending motions. The judge in the Delaware District Court denied B. Braun's motion to dismiss the amended complaint without prejudice and ordered venue-related discovery on December 14, 2017. Subsequently, B. Braun withdrew the challenge to venue in Delaware but proceeded to file new motions to dismiss the Delaware actions on December 28, 2017. The actions in the U.S. District Court for the Eastern District of Pennsylvania were dismissed by stipulation on December 28, 2017. The motions to dismiss in Delaware were denied on May 17, 2018. The Company intends to vigorously enforce its intellectual property rights relating to Ofirmev.

Ofirmev Patent Litigation: InnoPharma Licensing LLC and InnoPharma, Inc. In September 2014, Cadence Pharmaceuticals, Inc. ("Cadence") and Mallinckrodt IP, subsidiaries of the Company, and Pharmatop, the then owner of the two U.S. patents licensed exclusively by the Company, filed suit in the U.S. District Court for the District of Delaware against InnoPharma Licensing LLC and InnoPharma, Inc. (both are subsidiaries of Pfizer and collectively "InnoPharma") alleging that InnoPharma infringed U.S. Patent Nos. 6,028,222 ("the '222 patent") and 6,992,218 ("the '218 patent"). Separately, on December 1, 2016 Mallinckrodt IP Filed suit in the U.S. District Court for the District of Delaware against InnoPharma alleging that InnoPharma infringed the '012 patent. On May 4, 2017 the parties entered into settlement agreements on both suits under which InnoPharma was granted the non-exclusive right to market a competing intravenous acetaminophen product in the U.S. under its NDA on or after December 6, 2020, or earlier under certain circumstances.

Ofirmev Patent Litigation: Agila Specialties Private Limited, Inc. (now Mylan Laboratories Ltd.) and Agila Specialties Inc. (a Mylan Inc. Group), (collectively "Agila"). In December 2014, Cadence and Mallinckrodt IP, subsidiaries of the Company, and Pharmatop filed suit in the U.S. District Court for the District of Delaware against Agila alleging that Agila infringed the '222 and the '218 patents. Separately, on December 1, 2016 Mallinckrodt IP filed suit in the U.S. District Court for the District of Delaware against Agila alleging that Agila infringed the '012 patent. On December 31, 2016, the parties entered into settlement agreements on both suits under which Agila was granted the non-exclusive right to market a competing intravenous acetaminophen product in the U.S. under its NDA on or after December 6, 2020, or earlier under certain circumstances.

The Company has successfully asserted the '222 and '218 patents and maintained their validity in both litigation and proceedings at the USPTO. The Company will continue to vigorously enforce its intellectual property rights relating to Ofirmev to prevent the marketing of infringing generic or competing products prior to December 6, 2020, which, if unsuccessful, could adversely affect the Company's ability to successfully maximize the value of Ofirmev and have an adverse effect on its financial condition, results of operations and cash flows.

Tyco Healthcare Group LP, et al. v. Mutual Pharmaceutical Group, Inc. In March 2007, the Company filed a patent infringement suit in the U.S. District Court for the District of New Jersey against Mutual Pharmaceutical Co., Inc., et al. (collectively, "Mutual") after Mutual submitted an ANDA to the FDA seeking to sell a generic version of the Company's 7.5 mg RESTORIL™ sleep aid product. Mutual also filed antitrust and unfair competition counterclaims. The patents at issue have since expired or been found invalid. In March 2017, the parties entered into a settlement agreement regarding the antitrust and unfair competition counterclaims and the case was dismissed.

Jazz Pharmaceuticals, Inc. and Jazz Pharmaceuticals Ireland v. Mallinckrodt PLC, Mallinckrodt Inc. and Mallinckrodt LLC. In January 2018, Jazz Pharmaceuticals, Inc. and Jazz Pharmaceuticals Ireland (collectively, "Jazz") filed suit in the U.S. District Court for the District of New Jersey against the Company alleging that the Company infringed U.S. Patent Nos. 7,668,730, 7,765,106, 7,765,107, 7,895,059, 8,457,988, 8,589,182, 8,731,963, 8,772,306, 9,050,302, and 9,486,426 following receipt of a November 2017 notice from the Company concerning its submission of an ANDA, containing a Paragraph IV patent certification with the FDA for a competing version of Xyrem. On June 4, 2018 the parties entered into a settlement agreement under which Company was granted the non-exclusive right to market a competing sodium oxybate product in the U.S. under its ANDA on or after December 31, 2025, or earlier under certain circumstances.

Shire Development LLC, Shire LLC and Shire US, Inc. v. SpecGx LLC. In May 2018, Shire Development LLC, Shire LLC and Shire US, Inc. (collectively “Shire”) filed suit in the U.S. District Court for the District of Delaware against the Company alleging that the Company infringed U.S. Patent Nos. 6,913,768, 8,846,100, and 9,173,857 following receipt of an April 2018 notice from the Company concerning its submission of an ANDA, containing a Paragraph IV patent certification with the FDA for a competing version of Mydayis. The Company intends to vigorously defend its position.

Commercial and Securities Litigation

Grifols. On March 13, 2018, Grifols initiated arbitration against the Company, alleging breach of a Manufacturing and Supply Agreement entered into between the Company’s predecessor-in-interest, Cadence Pharmaceuticals Inc., and Grifols. Mallinckrodt intends to vigorously defend itself in this matter.

Putative Class Action Litigation (MSP). On October 30, 2017, a putative class action lawsuit was filed against the Company and United BioSource Corporation ("UBC") in the U.S. District Court for the Central District of California. The case is captioned MSP Recovery Claims, Series II LLC, et al. v. Mallinckrodt ARD, Inc., et al. The complaint purports to be brought on behalf of two classes: all Medicare Advantage Organizations and related entities in the U.S. who purchased or provided reimbursement for H.P. Acthar Gel pursuant to (i) Medicare Part C contracts (Class 1) and (ii) Medicare Part D contracts (Class 2) since January 1, 2011, with certain exclusions. The complaint alleges that the Company engaged in anticompetitive, unfair, and deceptive acts to artificially raise and maintain the price of H.P. Acthar Gel. To this end, the complaint alleges that the Company unlawfully maintained a monopoly in a purported ACTH product market by acquiring the U.S. rights to Synacthen Depot and reaching anti-competitive agreements with the other defendants by selling H.P. Acthar Gel through an exclusive distribution network. The complaint purports to allege claims under federal and state antitrust laws and state unfair competition and unfair trade practice laws. Pursuant to a motion filed by defendants, this case has been transferred to the U.S. District Court for the Northern District of Illinois. The Company intends to vigorously defend itself in this matter.

Putative Class Action Litigation. On April 6, 2017, a putative class action lawsuit was filed against the Company and UBC in the U.S. District Court for the Northern District of Illinois. The case is captioned City of Rockford v. Mallinckrodt ARD, Inc., et al. The complaint was subsequently amended, most recently on December 8, 2017, to include an additional named plaintiff and additional defendants. As amended, the complaint purports to be brought on behalf of all self-funded entities in the U.S. and its Territories, excluding any Medicare Advantage Organizations, related entities and certain others, that paid for H.P. Acthar Gel from August 2007 to the present. The lawsuit alleges that the Company engaged in anticompetitive, unfair, and deceptive acts to artificially raise and maintain the price of H.P. Acthar Gel. To this end, the suit alleges that the Company unlawfully maintained a monopoly in a purported ACTH product market by acquiring the U.S. rights to Synacthen Depot; conspired with UBC and violated anti-racketeering laws by selling H.P. Acthar Gel through an exclusive distributor; and committed a fraud on consumers by failing to correctly identify H.P. Acthar Gel's active ingredient on package inserts. The Company intends to vigorously defend itself in this matter.

Employee Stock Purchase Plan Securities Litigation. On July 20, 2017, a purported purchaser of Mallinckrodt stock through Mallinckrodt's Employee Stock Purchase Plans ("ESPPs"), filed a derivative lawsuit in the Federal District Court in the Eastern District of Missouri, captioned Solomon v. Mallinckrodt plc, et al., against the Company, its Chief Executive Officer Mark C. Trudeau ("CEO"), its Chief Financial Officer Matthew K. Harbaugh ("CFO"), its Controller Kathleen A. Schaefer, and current and former directors of the Company. On September 6, 2017, plaintiff voluntarily dismissed its complaint in the Federal District Court for the Eastern District of Missouri and refiled virtually the same complaint in the U.S. District Court for the District of Columbia. The complaint purports to be brought on behalf of all persons who purchased or otherwise acquired Mallinckrodt stock between November 25, 2014, and January 18, 2017, through the ESPPs. In the alternative, the plaintiff alleges a class action for those same purchasers/acquirers of stock in the ESPPs during the same period. The complaint asserts claims under Section 11 of the Securities Act, and for breach of fiduciary duty, misrepresentation, non-disclosure, mismanagement of the ESPPs' assets and breach of contract arising from substantially similar allegations as those contained in the putative class action securities litigation described in the following paragraph. Stipulated co-lead plaintiffs were approved by the court on March 1, 2018. On July 6, 2018, this matter was stayed by agreement of the parties pending resolution of the Shenk matter below.

Putative Class Action Securities Litigation. On January 23, 2017, a putative class action lawsuit was filed against the Company and its CEO in the U.S. District Court for the District of Columbia, captioned Patricia A. Shenk v. Mallinckrodt plc, et al. The complaint purports to be brought on behalf of all persons who purchased Mallinckrodt's publicly traded securities on a domestic exchange between November 25, 2014 and January 18, 2017. The lawsuit generally alleges that the Company made false or misleading statements related to H.P. Acthar Gel and Synacthen to artificially inflate the price of the Company's stock. In particular, the complaint alleges a failure by the Company to provide accurate disclosures concerning the long-term sustainability of H.P. Acthar Gel revenues, and the exposure of H.P. Acthar Gel to Medicare and Medicaid reimbursement rates. On January 26, 2017, a second putative class action lawsuit, captioned Jyotindra Patel v. Mallinckrodt plc, et al. was filed against the same defendants named in the Shenk lawsuit in the U.S. District Court for the District of Columbia. The Patel complaint purports to be brought on behalf of shareholders during the same period of time as that set forth in the Shenk lawsuit and asserts claims similar to those set forth in the Shenk lawsuit. On March 13, 2017, a third putative class action lawsuit, captioned Amy T. Schwartz, et al., v. Mallinckrodt plc, et al., was filed against the same defendants named in the Shenk lawsuit in the U.S. District Court for the District of Columbia. The Schwartz complaint purports to be brought on behalf of shareholders who purchased shares of the Company between July 14, 2014 and January 18, 2017 and asserts claims similar to those set forth in the Shenk lawsuit. On March 23, 2017, a fourth putative class action lawsuit, captioned Fulton County Employees' Retirement System v. Mallinckrodt plc, et al., was filed against the Company and its CEO and CFO in the U.S. District Court for the District of Columbia. The Fulton County complaint purports to be brought on behalf of shareholders during the same period of time as that set forth in the Schwartz lawsuit and asserts claims similar to those set forth in the Shenk lawsuit. On March 27, 2017, four separate plaintiff groups moved to consolidate the pending cases and to be appointed as lead plaintiffs in the consolidated case. Since that time, two of the plaintiff groups have withdrawn their motions. Lead plaintiff was designated by the court on March 9, 2018. The Company intends to vigorously defend itself in this matter.

Pricing Litigation

State of Utah v. Apotex Corp., et al. The Company, along with several other pharmaceutical companies, was a defendant in this matter which was filed in May 2008, in the Third Judicial Circuit of Salt Lake County, Utah. The State of Utah alleged, generally, that the defendants reported false pricing information in connection with certain drugs that were reimbursable under Utah Medicaid, resulting in overpayment by Utah Medicaid for those drugs, and sought monetary damages and attorneys' fees. The Company believes that it had meritorious defenses to these claims and vigorously defended against them. In December 2015, the parties entered into a binding settlement agreement, under the terms of which the State of Utah agreed to dismiss the litigation with prejudice and the Company agreed to make a one-time cash payment to the State of Utah within the reserve established for this matter.

Environmental Remediation and Litigation Proceedings

The Company is involved in various stages of investigation and cleanup related to environmental remediation matters at a number of sites, including those described below. The ultimate cost of site cleanup and timing of future cash outlays is difficult to predict, given the uncertainties regarding the extent of the required cleanup, the interpretation of applicable laws and regulations and alternative cleanup methods. The Company concluded that, as of June 29, 2018, it was probable that it would incur remedial costs in the range of $27.1 million to $96.1 million. The Company also concluded that, as of June 29, 2018, the best estimate within this range was $65.2 million, of which $3.0 million was included in accrued and other current liabilities and the remainder was included in environmental liabilities on the unaudited condensed consolidated balance sheet at June 29, 2018. While it is not possible at this time to determine with certainty the ultimate outcome of these matters, the Company believes, given the information currently available, that the final resolution of all known claims, after taking into account amounts already accrued, will not have a material adverse effect on its financial condition, results of operations and cash flows.

Coldwater Creek, Saint Louis County, Missouri. The Company is named as a defendant in numerous tort complaints with numerous plaintiffs pending in the U.S. District Court for the Eastern District of Missouri that were filed in or after February 2012. These cases allege personal injury for alleged exposure to radiological substances, including in Coldwater Creek in Missouri, and in the air. Plaintiffs allegedly lived and/or worked in various locations in Saint Louis County, Missouri, near Coldwater Creek. Radiological residues which may have been present in the creek have previously been remediated by the U.S. Army Corps of Engineers ("USACE"). The USACE continues to study and remediate the creek and surrounding areas. The Company believes that it had meritorious defenses to these complaints and vigorously defended against them. Groups of bellwether plaintiffs have been selected by the court and discovery is ongoing. Upon further evaluation of the Company's potential exposure, this matter is no longer considered material.

Lower Passaic River, New Jersey. The Company and approximately 70 other companies originally comprised the Lower Passaic Cooperating Parties Group ("the CPG") and are parties to a May 2007 Administrative Order on Consent ("AOC") with the Environmental Protection Agency ("EPA") to perform a remedial investigation and feasibility study ("RI/FS") of the 17-mile stretch known as the Lower Passaic River Study Area ("the River"). The Company's potential liability stems from former operations at Lodi and Belleville, New Jersey. In June 2007, the EPA issued a draft Focused Feasibility Study ("FFS") that considered interim remedial options for the lower 8-miles of the River, in addition to a "no action" option. As an interim step related to the 2007 AOC, on June 18, 2012 the CPG voluntarily entered into an AOC with the EPA for remediation actions focused solely at mile 10.9 of the River. The Company's estimated costs related to the RI/FS and focused remediation at mile 10.9, based on interim allocations, are immaterial and have been accrued.

In April 2014, the EPA issued its revised FFS, with remedial alternatives to address cleanup of the lower 8-mile stretch of the River. The EPA estimated the cost for the remediation alternatives ranged from $365.0 million to $3.2 billion. The EPA's preferred approach had an estimated cost of $1.7 billion. Based on the issuance of the EPA's revised FFS, the Company recorded a $23.1 million accrual in the second quarter of fiscal 2014 representing the Company's estimate of its allocable share of the joint and several remediation liability resulting from this matter.

In April 2015, the CPG presented a draft of the RI/FS of the River to the EPA. The CPG's RI/FS included alternative remedial actions for the entire 17-mile stretch of the River. The Company recorded an additional accrual of $13.3 million in the second quarter of fiscal 2015 based on the Company's estimate of its allocable share of the potential liability resulting from this matter.

On November 20, 2015, the Company withdrew from the CPG, but remains liable for its obligations under the two above-referenced AOCs, as well as potential future liabilities.

On March 4, 2016, the EPA issued the Record of Decision ("ROD") for the lower 8 miles of the River. The EPA's selected remedy for this stretch of the River was a slight modification of the preferred approach it identified in the revised FFS issued in April 2014. The new discounted, estimated cost was $1.38 billion. On October 5, 2016, the EPA announced that Occidental Chemicals Corporation ("OCC") had entered into an agreement to develop the remedial design.

By letter dated March 30, 2017, the EPA notified the Company, limited to its former Lodi facility, and nineteen other PRPs of their eligibility to enter into a cash out settlement for the lower 8 miles of the River. In exchange for the settlement, the Company would receive, inter alia, a covenant not to sue and contribution protection. The Company submitted the executed settlement agreement to the EPA on July 26, 2017. The settlement was announced in the Federal Register on January 12, 2018 commencing a 30-day public comment period, which has closed. The EPA will review the comments and will determine whether to proceed with the settlement.

Despite the issuance of the revised FFS and ROD by the EPA, and the RI/FS by the CPG, there are many uncertainties associated with the final agreed-upon remediation and the Company's allocable share of the remediation. Given those uncertainties, the amounts accrued may not be indicative of the amounts for which the Company may be ultimately responsible and will be refined as the remediation progresses.

Occidental Chemical Corp. v. 21st Century Fox America, Inc. The Company and approximately 120 other companies were named as defendants in a suit filed on June 30, 2018, by OCC. OCC seeks cost recovery and contribution for past and future costs in response to releases and threatened releases of hazardous substances into the River. The suit relates to the lower 8 miles of the River. The Company's alleged liability stems from former operations at Jersey City, New Jersey. The Company intends to vigorously defend itself in this matter.

Mallinckrodt Veterinary, Inc., Millsboro, Delaware. The Company previously operated a facility in Millsboro, Delaware ("the Millsboro Site") where various animal healthcare products were manufactured. In 2005, the Delaware Department of Natural Resources and Environmental Control found trichloroethylene ("TCE") in the Millsboro public water supply at levels that exceeded the federal drinking water standards. Further investigation to identify the TCE plume in the ground water indicated that the plume has extended to property owned by a third party near the Millsboro Site. The Company, and another former owner, have assumed responsibility for the Millsboro Site cleanup under the Alternative Superfund Program administered by the EPA and have entered into two AOCs with the EPA to perform investigations to abate, mitigate or eliminate the release or threat of release of hazardous substances at the Millsboro Site and to conduct an Engineering Evaluation/Cost Analysis ("EE/CA") to characterize the nature and extent of the contamination. The Company, along with the other party, continues to conduct the studies and prepare remediation plans in accordance with the AOCs. In January 2017, the EPA issued its Action Memorandum regarding the EE/CA. The parties have negotiated a third AOC to implement the removal action. The AOC has been fully executed, with an effective date of August 8, 2017. While it is not possible at this time to determine with certainty the ultimate outcome of this matter, the Company believes, given the information currently available, that the ultimate resolution of all known claims, after taking into account amounts already accrued, will not have a material adverse effect on its financial condition, results of operations and cash flows.

Crab Orchard National Wildlife Refuge Superfund Site, near Marion, Illinois. The Company is a successor in interest to International Minerals and Chemicals Corporation ("IMC"). Between 1967 and 1982, IMC leased portions of the Additional and Uncharacterized Sites ("AUS") Operable Unit at the Crab Orchard Superfund Site ("the Site") from the government and manufactured various explosives for use in mining and other operations. In March 2002, the Department of Justice, the U.S. Department of the Interior and the EPA (together, "the Government Agencies") issued a special notice letter to General Dynamics Ordnance and Tactical Systems, Inc. ("General Dynamics"), one of the other potentially responsible parties ("PRPs") at the Site, to compel General Dynamics to perform the RI/FS for the AUS Operable Unit. General Dynamics negotiated an AOC with the Government Agencies to conduct an extensive RI/FS at the Site under the direction of the U.S. Fish and Wildlife Service. General Dynamics asserted in August 2004 that the Company is jointly and severally liable, along with approximately eight other lessees and operators at the AUS Operable Unit, for alleged contamination of soils and groundwater resulting from historic operations, and has threatened to file a contribution claim against the Company and other parties for recovery of its costs incurred in connection with the RI/FS activities being conducted at the AUS Operable Unit. The Company and other PRPs who received demand letters from General Dynamics have explored settlement alternatives, but have not reached settlement to date. General Dynamics has completed the RI and initiated the FS, and the PRPs have reached an agreement to enter into a non-binding mediation process, which has begun. While it is not possible at this time to determine with certainty the ultimate outcome of this matter, the Company believes, given the information currently available, that the final resolution of all known claims, after taking into account amounts already accrued, will not have a material adverse effect on its financial condition, results of operations and cash flows.

Products Liability Litigation

Beginning with lawsuits brought in July 1976, the Company is named as a defendant in personal injury lawsuits based on alleged exposure to asbestos-containing materials. A majority of the cases involve product liability claims based principally on allegations of past distribution of products containing asbestos. A limited number of the cases allege premises liability based on claims that individuals were exposed to asbestos while on the Company's property. Each case typically names dozens of corporate defendants in addition to the Company. The complaints generally seek monetary damages for personal injury or bodily injury resulting from alleged exposure to products containing asbestos. The Company's involvement in asbestos cases has been limited because it did not mine or produce asbestos. Furthermore, in the Company's experience, a large percentage of these claims have never been substantiated and have been dismissed by the courts. The Company has not suffered an adverse verdict in a trial court proceeding related to asbestos claims and intends to continue to vigorously defend itself in these matters. When appropriate, the Company settles claims; however, amounts paid to settle and defend all asbestos claims have been immaterial. As of June 29, 2018, there were approximately 11,600 asbestos-related cases pending against the Company.

The Company estimates pending asbestos claims and claims that were incurred but not reported and related insurance recoveries, which are recorded on a gross basis in the unaudited condensed consolidated balance sheets. The Company's estimate of its liability for pending and future claims is based on claims experience over the past five years and covers claims either currently filed or expected to be filed over the next seven years. The Company believes that it has adequate amounts recorded related to these matters. While it is not possible at this time to determine with certainty the ultimate outcome of these asbestos-related proceedings, the Company believes, given the information currently available, that the ultimate resolutions of all known and anticipated future claims, after taking into account amounts already accrued, along with recoveries from insurance, will not have a material adverse effect on its financial condition, results of operations and cash flows.

Acquisition-Related Litigation

Several putative class actions were filed by purported holders of Questcor common stock in connection with the Company's acquisition of Questcor in 2014 (Hansen v. Thompson, et al., Heng v. Questcor Pharmaceuticals, Inc., et al., Buck v. Questcor Pharmaceuticals, Inc., et al., Ellerbeck v. Questcor Pharmaceuticals, Inc., et al., Yokem v. Questcor Pharmaceuticals, Inc., et al., Richter v. Questcor Pharmaceuticals, Inc., et al., Tramantano v. Questcor Pharmaceuticals, Inc., et al., Crippen v. Questcor Pharmaceuticals, Inc., et al., Patel v. Questcor Pharmaceuticals, Inc., et al., and Postow v. Questcor Pharmaceuticals, Inc., et al.). The actions were consolidated on June 3, 2014. The consolidated complaint named as defendants, and generally alleged that, the directors of Questcor breached their fiduciary duties in connection with the acquisition by, among other things, agreeing to sell Questcor for inadequate consideration and pursuant to an inadequate process. The consolidated complaint also alleged that the Questcor directors breached their fiduciary duties by failing to disclose purportedly material information to shareholders in connection with the merger. The consolidated complaint also alleged, among other things, that the Company aided and abetted the purported breaches of fiduciary duty. The lawsuits sought various forms of relief, including but not limited to, rescission of the transaction, damages and attorneys' fees and costs.

On July 29, 2014, the defendants reached an agreement in principle with the plaintiffs in the consolidated actions, and that agreement was reflected in a Memorandum of Understanding ("MOU"). In connection with the settlement contemplated by the MOU, Questcor agreed to make certain additional disclosures related to the proposed transaction with the Company, which are contained in the Company's Current Report on Form 8-K filed with the SEC on July 30, 2014. Additionally, as part of the settlement and pursuant to the MOU, the Company agreed to forbear from exercising certain rights under the merger agreement with Questcor, as follows: the four business day period referenced in Section 5.3(e) of the merger agreement with Questcor was reduced to three business days. Consistent with the terms of the MOU, the parties entered into a formal stipulation of settlement in February 2015 and re-executed the stipulation of settlement on May 7, 2015 (collectively the "Stipulation of Settlement").

The Stipulation of Settlement was subject to customary conditions, including court approval. On May 8, 2015, the California Court denied plaintiffs' Motion for Preliminary Approval of Settlement. On October 23, 2015, the parties submitted a proposed Stipulation and Order re Dismissal With Prejudice dismissing the action with prejudice as to each of the named plaintiffs and without prejudice as to the remainder of the class and, on October 30, 2015, the California Court entered that Order.

Interest-bearing Deferred Tax Obligation

As part of the integration of Questcor, the Company entered into an internal installment sale transaction related to certain H.P. Acthar Gel intangible assets during the three months ended December 26, 2014. The installment sale transaction resulted in a taxable gain. In accordance with Internal Revenue Code Section 453A ("Section 453A") the gain is considered taxable in the period in which installment payments are received. During the three months ended December 25, 2015, the Company entered into similar transactions with certain intangible assets acquired in the acquisitions of Ikaria, Inc. and Therakos, Inc.

During the three months ended March 31, 2017, the Company sold its Intrathecal Therapy business with a portion of the consideration from the sale being in the form of a note receivable subject to the installment sale provisions described above. During the three months ended March 30, 2018, the Company received payment on the note receivable and settled all installment sale provisions related to its sale of the Intrathecal Therapy business.

As of June 29, 2018, the Company had an aggregate $554.2 million of interest-bearing U.S. deferred tax liabilities associated with outstanding installment notes. The GAAP calculation of interest associated with these deferred tax liabilities is subject to variable interest rates. The Company recognized interest expense associated with these deferred tax liabilities of $6.1 million and $17.8 million for the three months ended June 29, 2018 and June 30, 2017, respectively, and $11.7 million and $36.2 million for the six months ended June 29, 2018 and June 30, 2017, respectively.

The Company has reported Section 453A interest on its tax returns on the basis of its interpretation of the U.S. Internal Revenue Code and Regulations. Alternative interpretations of these provisions could result in additional interest payable on the deferred tax liability. Due to the inherent uncertainty in these interpretations, the Company has deferred the recognition of the benefit associated with the Company's interpretation and maintains a corresponding liability of $52.9 million and $46.0 million as of June 29, 2018 and December 29, 2017, respectively. The balance of this liability is expected to increase over future periods until such uncertainty is resolved. Favorable resolution of this uncertainty would likely result in a material reversal of this liability and a benefit being recorded to interest expense within the unaudited condensed consolidated statements of income.

Other Matters

The Company is a defendant in a number of other pending legal proceedings relating to present and former operations, acquisitions and dispositions. The Company does not expect the outcome of these proceedings, either individually or in the aggregate, to have a material adverse effect on its financial condition, results of operations and cash flows.

Financial Instruments and Fair Value Measurements

6 Months Ended

Jun. 29, 2018

Fair Value Disclosures [Abstract]

Financial Instruments and Fair Value Measurements



18.	Financial Instruments and Fair Value Measurements

Fair value is defined as the exit price that would be received from the sale of an asset or paid to transfer a liability, using assumptions that market participants would use in pricing an asset or liability. The fair value guidance establishes a three-level fair value hierarchy, which maximizes the use of observable inputs and minimizes the use of unobservable inputs used in measuring fair value. The levels within the hierarchy are as follows:

Level 1— observable inputs such as quoted prices in active markets for identical assets or liabilities;

Level 2— significant other observable inputs that are observable either directly or indirectly; and

Level 3— significant unobservable inputs in which there is little or no market data, which requires the Company to develop its own assumptions.

The following tables provide a summary of the significant assets and liabilities that are measured at fair value on a recurring basis at the end of each period:



	June 29, 2018		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Debt and equity securities held in rabbi trusts	$	35.0	$	23.9	$	11.1	$	—
Equity securities	13.6		13.6		—		—
Foreign exchange forward and option contracts	0.6		0.6		—		—
	$	49.2	$	38.1	$	11.1	$	—

Liabilities:
Deferred compensation liabilities	$	39.8	$	—	$	39.8	$	—
Contingent consideration and acquired contingent liabilities	170.5		—		—		170.5
Foreign exchange forward and option contracts	0.4		0.4		—		—
	$	210.7	$	0.4	$	39.8	$	170.5



	December 29, 2017		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Debt and equity securities held in rabbi trusts	$	35.4	$	24.0	$	11.4	$	—
Equity securities	22.7		22.7		—		—
Foreign exchange forward and option contracts	0.1		0.1		—		—
	$	58.2	$	46.8	$	11.4	$	—

Liabilities:
Deferred compensation liabilities	$	42.7	$	—	$	42.7	$	—
Contingent consideration and acquired contingent liabilities	246.4		—		—		246.4
Foreign exchange forward and option contracts	0.1		0.1		—		—
	$	289.2	$	0.1	$	42.7	$	246.4

Debt and equity securities held in rabbi trusts. Debt securities held in rabbi trusts primarily consist of U.S. government and agency securities and corporate bonds. When quoted prices are available in an active market, the investments are classified as level 1. When quoted market prices for a security are not available in an active market, they are classified as level 2. Equity securities held in rabbi trusts primarily consist of U.S. common stocks, which are valued using quoted market prices reported on nationally recognized securities exchanges.

Equity securities. Equity securities consist of shares in Mesoblast Limited, for which quoted prices are available in an active market; therefore, the investment is classified as level 1 and is valued based on quoted market prices reported on a nationally recognized securities exchange. During the six months ended June 29, 2018, approximately $8.4 million of shares were sold for gross proceeds of $9.4 million resulting in a $1.1 million gain being recognized within other (expense) income, net within the unaudited condensed consolidated statement of income, offset by foreign currency losses of $0.1 million. Total unrealized loss in this investment was $0.1 million for the three months ended June 29, 2018 and a gain of $0.4 million for the six months ended June 29, 2018, which was recorded within other (expense) income, net, within the unaudited condensed consolidated statement of income.

Foreign exchange forward and option contracts. Foreign currency option and forward contracts are used to economically manage the foreign exchange exposures of operations outside the U.S. Quoted prices are available in an active market; as such, these derivatives are classified as level 1.

Deferred compensation liabilities. The Company maintains a non-qualified deferred compensation plan in the U.S., which permits eligible employees of the Company to defer a portion of their compensation. A recordkeeping account is set up for each participant and the participant chooses from a variety of funds for the deemed investment of their accounts. The recordkeeping accounts generally correspond to the funds offered in the Company's U.S. tax-qualified defined contribution retirement plan and the account balance fluctuates with the investment returns on those funds.

Contingent consideration and acquired contingent liabilities. The Company maintains various contingent consideration and acquired contingent liabilities associated with the acquisitions of Questcor, three commercial stage topical hemostasis drugs from The Medicines Company ("the Hemostasis Acquisition"), Stratatech Corporation ("Stratatech"), InfaCare Pharmaceutical Corporation ("InfaCare") and Ocera Therapeutics, Inc. ("Ocera").

The contingent liability associated with the acquisition of Questcor pertains to the Company's license agreement with Novartis AG and Novartis Pharma AG (collectively "Novartis") related to the development product MNK-1411. During the six months ended June 29, 2018, the Company paid the required annual payment of $25.0 million related to the license of development product MNK-1411 from Novartis. The fair value of the remaining contingent payments was measured based on the net present value of a probability-weighted assessment. As of June 29, 2018, the total remaining payments under the license agreement shall not exceed $115.0 million. The Company determined the fair value of the contingent consideration associated with the acquisition of Questcor to be $85.7 million and $111.8 million as of June 29, 2018 and December 29, 2017, respectively.

As part of the Hemostasis Acquisition in February 2016, the Company provided contingent consideration to The Medicines Company in the form of sales based milestones associated with Raplixa and PreveLeak, and acquired contingent liabilities associated with The Medicines Company's prior acquisitions of the aforementioned products. The Company determined the fair value of the contingent consideration and acquired contingent liabilities based on an option pricing model to be $7.0 million and $17.1 million at December 29, 2017, respectively. The Company paid $12.0 million related to the FDA approval of PreveLeak during the three months ended March 30, 2018. On March 16, 2018, the Company sold a portion of the Hemostasis business, inclusive of the Recothrom and PreveLeak products to Baxter and the remaining contingent consideration liability balance of $12.1 million was transferred upon sale.

As part of the acquisition of a development program from Stratatech in August 2016, the Company provided contingent consideration to the prior shareholders of Stratatech, primarily in the form of regulatory filing and approval milestones associated with the deep partial thickness and full thickness indications associated with StrataGraft^®. The Company assesses the likelihood of and timing of making such payments. The fair value of the contingent payments was measured based on the net present value of a probability-weighted assessment. The Company determined the fair value of the contingent consideration associated with the acquisition of Stratatech to be $55.3 million and $53.5 million as of June 29, 2018 and December 29, 2017, respectively.

As part of the acquisition of InfaCare in September 2017, the Company provided contingent consideration to the prior shareholders of InfaCare in the form of both regulatory approval milestones for full-term and pre-term neonates for stannsoporfin and sales-based milestones associated with stannsoporfin. Due to recent developments and discussions with the FDA, as discussed in further detail in Note 11, the timing of the development program is expected to shift outward. During the three months ended June 29, 2018, the Company recognized a $27.5 million fair value adjustment due to this shift in timing and its impact on the achievement of milestones per the purchase agreement. The fair value of the contingent consideration based on an option pricing model was determined to be $7.0 million and $35.0 million as of June 29, 2018 and December 29, 2017, respectively.

As part of the acquisition of Ocera in December 2017, the Company provided contingent consideration to the prior shareholders of Ocera in the form of both patient enrollment clinical study milestones for MNK-6105 and MNK-6106 (previously referred to collectively as OCR-002), which represent the IV and Oral formulations, respectively, and sales-based milestones associated with MNK-6105 and MNK-6106. The Company determined the fair value of the contingent consideration based on an option pricing model to be $22.5 million and $22.0 million as of June 29, 2018 and December 29, 2017, respectively.

Of the total fair value of the contingent consideration of $170.5 million, $52.1 million was classified as current and $118.4 million was classified as non-current in the unaudited condensed consolidated balance sheet as of June 29, 2018. The following table summarizes the fiscal 2018 activity for contingent consideration:



Balance at December 29, 2017	$	246.4
Disposal of business	(12.1		)
Payments	(37.0		)
Accretion expense	2.3
Fair value adjustments	(29.1		)
Balance at June 29, 2018	$	170.5

Financial Instruments Not Measured at Fair Value

The following methods and assumptions were used by the Company in estimating fair values for financial instruments not measured at fair value as of June 29, 2018 and December 29, 2017:

•

The carrying amounts of cash and cash equivalents, accounts receivable, notes receivable, accounts payable and the majority of other current assets and liabilities approximate fair value because of their short-term nature. The Company classifies cash on hand and deposits in banks, including commercial paper, money market accounts and other investments it may hold from time to time, with an original maturity of three months or less, as cash and cash equivalents (level 1). The fair value of restricted cash was equivalent to its carrying value of $18.4 million and $18.3 million as of June 29, 2018 and December 29, 2017, (level 1), respectively, which was included in prepaid expenses and other current assets and other assets on the unaudited condensed consolidated balance sheets.

•

The Company received a portion of consideration as part of contingent earn-out payments related to the sale of the Nuclear Imaging business in the form of preferred equity certificates during the three months ended June 29, 2018. These securities are classified as held-to-maturity and are carried at amortized cost, which approximates fair value, of $9.0 million at June 29, 2018 (level 3). These securities are included in other assets on the unaudited condensed consolidated balance sheets.

•

The Company's life insurance contracts are carried at cash surrender value, which is based on the present value of future cash flows under the terms of the contracts (level 3). Significant assumptions used in determining the cash surrender value include the amount and timing of future cash flows, interest rates and mortality charges. The fair value of these contracts approximates the carrying value of $65.5 million and $67.0 million at June 29, 2018 and December 29, 2017, respectively. These contracts are included in other assets on the unaudited condensed consolidated balance sheets.

•

The carrying value of the Company's revolving credit facility and variable-rate receivable securitization approximates fair value due to the short-term nature of these instruments. Since the quoted market prices for the Company's term loans and 9.50% and 8.00% debentures are not available in an active market, they are classified as level 2 for purposes of developing an estimate of fair value. The Company's 3.50%, 4.875%, 5.75%, 4.75%, 5.625%, 5.50% notes are classified as level 1, as quoted prices are available in an active market for these notes. The fair value of the ACOA loan is based on the present value of future cash flows under the terms of the agreement (level 3) with future cash flows and interest rates as significant assumptions. The following table presents the carrying values and estimated fair values of the Company's debt, excluding capital leases, as of the end of each period:



	June 29, 2018				December 29, 2017
	Carrying Value		Fair Value		Carrying Value		Fair Value
Level 1
3.50% notes due April 2018	$	—	$	—	$	300.0	$	299.1
4.875% notes due April 2020	700.0		689.2		700.0		675.2
Variable-rate receivable securitization due July 2020	240.0		240.0		200.0		200.0
5.75% notes due August 2022	884.0		796.1		884.0		804.8
4.75% notes due April 2023	500.2		407.1		526.5		412.4
5.625% notes due October 2023	731.4		609.1		738.0		628.8
5.50% notes due April 2025	692.1		563.0		692.1		564.5
Revolving credit facility	450.0		450.0		900.0		900.0
Level 2
9.50% debentures due May 2022	10.4		10.9		10.4		10.9
8.00% debentures due March 2023	4.4		4.4		4.4		4.4
Term loan due September 2024	1,617.9		1,586.5		1,851.2		1,848.7
Term loan due February 2025	598.5		589.5		—		—
Level 3
ACOA loan due December 2028	1.7		1.7		—		—
Total debt	$	6,430.6	$	5,947.5	$	6,806.6	$	6,348.8

Concentration of Credit and Other Risks

Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of accounts receivable. The Company does not typically require collateral from customers. A portion of the Company's accounts receivable outside the U.S. includes sales to government-owned or supported healthcare systems in several countries, which are subject to payment delays. Payment is dependent upon the financial stability and creditworthiness of those countries' national economies.

The following table shows net sales attributable to distributors that accounted for 10.0% or more of the Company's total net sales:



	Three Months Ended				Six Months Ended
	June 29, 2018		June 30, 2017		June 29, 2018		June 30, 2017
CuraScript, Inc.	46.5	%	57.0	%	46.8	%	55.9	%

The following table shows accounts receivable attributable to distributors that accounted for 10.0% or more of the Company's gross accounts receivable at the end of each period:



	June 29, 2018		December 29, 2017
CuraScript, Inc.	35.3	%	33.8	%

The following table shows net sales attributable to products that accounted for 10.0% or more of the Company's total net sales:



	Three Months Ended				Six Months Ended
	June 29, 2018		June 30, 2017		June 29, 2018		June 30, 2017
H.P. Acthar Gel	46.4	%	53.2	%	44.6	%	51.0	%
Inomax	20.8	%	20.9	%	22.5	%	21.9	%
Ofirmev	13.6	%	12.6	%	13.9	%	12.9	%

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Segment Data

6 Months Ended

Jun. 29, 2018

Segment Reporting [Abstract]

Segment Data



19.	Segment Data

The Company's continuing operations are limited to the results of operations from the Specialty Brands segment as the Specialty Generics Disposal Group is reported as a discontinued operation. See Note 4 for further details on the Specialty Generics Disposal Group. Selected information for the reportable segment is as follows:



	Three Months Ended						Six Months Ended
	June 29, 2018			June 30, 2017			June 29, 2018			June 30, 2017
Net sales:
Specialty Brands	$	631.7		$	600.1		$	1,204.3		$	1,160.1
Operating income:
Specialty Brands	$	265.9		$	270.0		$	506.2		$	537.0
Unallocated amounts:
Corporate and unallocated expenses ⁽¹⁾	(10.2		)	(49.6		)	(53.9		)	(49.2		)
Intangible asset amortization	(184.3		)	(169.3		)	(360.6		)	(339.1		)
Restructuring and related charges, net ⁽²⁾	(58.7		)	(1.0		)	(81.8		)	(12.3		)
Operating income	$	12.7		$	50.1		$	9.9		$	136.4


(1)	Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segment.


(2)	Includes restructuring-related accelerated depreciation.

Net sales by product family within the Company's reportable segment is as follows:



	Three Months Ended				Six Months Ended
	June 29, 2018		June 30, 2017		June 29, 2018		June 30, 2017
H.P. Acthar Gel	$	293.2	$	319.4	$	537.0	$	591.2
Inomax	131.0		125.5		270.8		253.9
Ofirmev	85.6		75.7		167.6		149.1
Therakos	56.8		51.2		114.2		102.4
Amitiza ⁽¹⁾	48.0		—		71.0		—
BioVectra	11.3		10.5		21.8		20.4
Other	5.8		17.8		21.9		43.1
Net sales	$	631.7	$	600.1	$	1,204.3	$	1,160.1

⁽¹⁾ Amitiza consists of both product net sales and royalties. Refer to Note 3 for further details on Amitiza's revenues.

Condensed Consolidating Financial Statements

6 Months Ended

Jun. 29, 2018

Condensed Consolidating Financial Statements [Abstract]

Condensed Consolidating Financial Statements



20.	Condensed Consolidating Financial Statements

MIFSA, an indirectly 100%-owned subsidiary of Mallinckrodt plc, is the borrower under the 3.50% notes due April 2018, which were paid in full in April 2018, and the 4.75% notes due April 2023 (collectively, "the Notes"), which are fully and unconditionally guaranteed by Mallinckrodt plc. The following information provides the composition of the Company's comprehensive income, assets, liabilities, equity and cash flows by relevant group within the Company: Mallinckrodt plc as guarantor of the Notes, MIFSA as issuer of the Notes and the other subsidiaries. There are no subsidiary guarantees related to the Notes.

Set forth on the following pages are the condensed consolidating financial statements for the three and six months ended June 29, 2018 and June 30, 2017, and as of June 29, 2018 and December 29, 2017. Eliminations represent adjustments to eliminate investments in subsidiaries and intercompany balances and transactions between or among Mallinckrodt plc, MIFSA and other subsidiaries. Condensed consolidating financial information for Mallinckrodt plc and MIFSA, on a standalone basis, has been presented using the equity method of accounting for subsidiaries.

MALLINCKRODT PLC

CONDENSED CONSOLIDATING BALANCE SHEET

As of June 29, 2018

(unaudited, in millions)



	Mallinckrodt plc		Mallinckrodt International Finance S.A.		Other Subsidiaries		Eliminations			Consolidated
Assets
Current Assets:
Cash and cash equivalents	$	0.6	$	21.3	$	213.8	$	—		$	235.7
Accounts receivable, net	—		—		337.6		—			337.6
Inventories	—		—		184.4		—			184.4
Prepaid expenses and other current assets	0.3		0.4		134.9		—			135.6
Notes receivable	—		—		—		—			—
Current assets held for sale	—		—		1,112.5		—			1,112.5
Intercompany receivables	123.0		26.4		277.8		(427.2		)	—
Total current assets	123.9		48.1		2,261.0		(427.2		)	2,005.8
Property, plant and equipment, net	—		—		430.1		—			430.1
Goodwill	—		—		3,676.7		—			3,676.7
Intangible assets, net	—		—		8,769.0		—			8,769.0
Investment in subsidiaries	6,063.6		23,666.7		11,739.3		(41,469.6		)	—
Intercompany loans receivable	505.4		—		5,286.5		(5,791.9		)	—
Other assets	—		—		168.2		—			168.2
Total Assets	$	6,692.9	$	23,714.8	$	32,330.8	$	(47,688.7	)	$	15,049.8

Liabilities and Shareholders' Equity
Current Liabilities:
Current maturities of long-term debt	$	—	$	22.0	$	0.2	$	—		$	22.2
Accounts payable	0.2		—		75.6		—			75.8
Accrued payroll and payroll-related costs	—		—		74.6		—			74.6
Accrued interest	—		54.7		5.7		—			60.4
Income taxes payable	—		—		39.9		—			39.9
Accrued and other current liabilities	0.8		0.4		439.8		—			441.0
Current liabilities held for sale	—		—		170.6		—			170.6
Intercompany payables	217.5		19.4		190.3		(427.2		)	—
Total current liabilities	218.5		96.5		996.7		(427.2		)	884.5
Long-term debt	—		6,079.3		255.8		—			6,335.1
Pension and postretirement benefits	—		—		65.3		—			65.3
Environmental liabilities	—		—		62.2		—			62.2
Deferred income taxes	—		—		809.7		—			809.7
Other income tax liabilities	—		—		129.2		—			129.2
Intercompany loans payable	—		5,791.9		—		(5,791.9		)	—
Other liabilities	—		7.8		281.6		—			289.4
Total Liabilities	218.5		11,975.5		2,600.5		(6,219.1		)	8,575.4
Shareholders' Equity	6,474.4		11,739.3		29,730.3		(41,469.6		)	6,474.4
Total Liabilities and Shareholders' Equity	$	6,692.9	$	23,714.8	$	32,330.8	$	(47,688.7	)	$	15,049.8

MALLINCKRODT PLC

CONDENSED CONSOLIDATING BALANCE SHEET

As of December 29, 2017

(unaudited, in millions)



	Mallinckrodt plc		Mallinckrodt International Finance S.A.		Other Subsidiaries		Eliminations			Consolidated
Assets
Current Assets:
Cash and cash equivalents	$	0.7	$	908.8	$	351.4	$	—		$	1,260.9
Accounts receivable, net	—		—		275.4		—			275.4
Inventories	—		—		128.7		—			128.7
Prepaid expenses and other current assets	1.0		0.2		73.5		—			74.7
Notes receivable	—		—		154.0		—			154.0
Current assets held for sale	—		—		391.5		—			391.5
Intercompany receivables	70.0		173.4		831.4		(1,074.8		)	—
Total current assets	71.7		1,082.4		2,205.9		(1,074.8		)	2,285.2
Property, plant and equipment, net	—		—		413.2		—			413.2
Goodwill	—		—		3,482.7		—			3,482.7
Intangible assets, net	—		—		8,261.0		—			8,261.0
Long-term assets held for sale	—		—		742.7		—			742.7
Investment in subsidiaries	6,551.6		23,217.8		12,356.2		(42,125.6		)	—
Intercompany loans receivable	593.1		—		4,664.8		(5,257.9		)	—
Other assets	—		—		156.2		—			156.2
Total Assets	$	7,216.4	$	24,300.2	$	32,282.7	$	(48,458.3	)	$	15,341.0

Liabilities and Shareholders' Equity
Current Liabilities:
Current maturities of long-term debt	$	—	$	313.5	$	0.2	$	—		$	313.7
Accounts payable	0.1		—		77.2		—			77.3
Accrued payroll and payroll-related costs	—		—		78.4		—			78.4
Accrued interest	—		53.0		4.0		—			57.0
Income taxes payable	—		—		15.5		—			15.5
Accrued and other current liabilities	0.8		0.4		367.3		—			368.5
Current liabilities held for sale	—		—		140.0		—			140.0
Intercompany payables	693.5		104.6		276.7		(1,074.8		)	—
Total current liabilities	694.4		471.5		959.3		(1,074.8		)	1,050.4
Long-term debt	—		6,206.8		214.1		—			6,420.9
Pension and postretirement benefits	—		—		67.1		—			67.1
Environmental liabilities	—		—		62.8		—			62.8
Deferred income taxes	—		—		749.1		—			749.1
Other income tax liabilities	—		—		94.1		—			94.1
Long-term liabilities held for sale	—		—		22.6		—			22.6
Intercompany loans payable	—		5,257.9		—		(5,257.9		)	—
Other liabilities	—		7.8		344.2		—			352.0
Total Liabilities	694.4		11,944.0		2,513.3		(6,332.7		)	8,819.0
Shareholders' Equity	6,522.0		12,356.2		29,769.4		(42,125.6		)	6,522.0
Total Liabilities and Shareholders' Equity	$	7,216.4	$	24,300.2	$	32,282.7	$	(48,458.3	)	$	15,341.0

MALLINCKRODT PLC

CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME

For the three months ended June 29, 2018

(unaudited, in millions)



	Mallinckrodt plc			Mallinckrodt International Finance S.A.			Other Subsidiaries			Eliminations			Consolidated
Net sales	$	—		$	—		$	631.7		$	—		$	631.7
Cost of sales	0.7			—			314.0			—			314.7
Gross (loss) profit	(0.7		)	—			317.7			—			317.0
Selling, general and administrative expenses	11.3			0.2			152.8			—			164.3
Research and development expenses	1.7			—			79.6			—			81.3
Restructuring charges, net	—			—			58.7			—			58.7
Losses on divestiture	—			—			—			—			—
Operating (loss) income	(13.7		)	(0.2		)	26.6			—			12.7

Interest expense	(1.6		)	(110.0		)	(7.7		)	24.2			(95.1		)
Interest income	2.2			0.3			23.1			(24.2		)	1.4
Other income (expense), net	0.6			—			(1.1		)	—			(0.5		)
Intercompany fees	(4.0		)	—			4.0			—			—
Equity in net income of subsidiaries	31.0			232.9			124.3			(388.2		)	—
Income (loss) from continuing operations before income taxes	14.5			123.0			169.2			(388.2		)	(81.5		)
Income tax benefit	(1.1		)	(1.2		)	(51.1		)	—			(53.4		)
Income (loss) from continuing operations	15.6			124.2			220.3			(388.2		)	(28.1		)
Income from discontinued operations, net of income taxes	—			0.1			43.6			—			43.7
Net income	15.6			124.3			263.9			(388.2		)	15.6
Other comprehensive loss, net of tax	(4.9		)	(4.9		)	(9.9		)	14.8			(4.9		)
Comprehensive income	$	10.7		$	119.4		$	254.0		$	(373.4	)	$	10.7

MALLINCKRODT PLC

CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME

For the three months ended June 30, 2017

(unaudited, in millions)



	Mallinckrodt plc			Mallinckrodt International Finance S.A.			Other Subsidiaries			Eliminations			Consolidated
Net sales	$	—		$	—		$	600.1		$	—		$	600.1
Cost of sales	0.9			—			279.5			—			280.4
Gross (loss) profit	(0.9		)	—			320.6			—			319.7
Selling, general and administrative expenses	15.1			0.2			199.3			—			214.6
Research and development expenses	1.8			—			50.5			—			52.3
Restructuring charges, net	—			—			0.6			—			0.6
Losses on divestiture	—			—			2.1			—			2.1
Operating (loss) income	(17.8		)	(0.2		)	68.1			—			50.1

Interest expense	(3.4		)	(88.7		)	(18.7		)	18.6			(92.2		)
Interest income	2.0			0.3			16.9			(18.6		)	0.6
Other income (expense), net	2.2			6.6			(2.5		)	—			6.3
Intercompany fees	(3.5		)	—			3.5			—			—
Equity in net income of subsidiaries	81.0			254.7			172.9			(508.6		)	—
Income (loss) from continuing operations before income taxes	60.5			172.7			240.2			(508.6		)	(35.2		)
Income tax benefit	(1.3		)	(0.2		)	(52.1		)	—			(53.6		)
Income from continuing operations	61.8			172.9			292.3			(508.6		)	18.4
Income from discontinued operations, net of income taxes	1.0			—			43.4			—			44.4
Net income	62.8			172.9			335.7			(508.6		)	62.8
Other comprehensive income, net of tax	1.9			1.9			3.4			(5.3		)	1.9
Comprehensive income	$	64.7		$	174.8		$	339.1		$	(513.9	)	$	64.7

MALLINCKRODT PLC

CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME

For the six months ended June 29, 2018

(unaudited, in millions)



	Mallinckrodt plc			Mallinckrodt International Finance S.A.			Other Subsidiaries			Eliminations			Consolidated
Net sales	$	—		$	—		$	1,204.3		$	—		$	1,204.3
Cost of sales	0.9			—			609.6			—			610.5
Gross (loss) profit	(0.9		)	—			594.7			—			593.8
Selling, general and administrative expenses	17.7			0.4			338.6			—			356.7
Research and development expenses	2.2			—			143.2			—			145.4
Restructuring charges, net	—			—			81.8			—			81.8
Gains on divestiture	—			—			—			—			—
Operating (loss) income	(20.8		)	(0.4		)	31.1			—			9.9

Interest expense	(4.6		)	(211.2		)	(14.8		)	44.1			(186.5		)
Interest income	4.4			2.0			42.3			(44.1		)	4.6
Other income (expense), net	6.7			2.8			(5.4		)	—			4.1
Intercompany fees	(8.5		)	—			8.5			—			—
Equity in net income of subsidiaries	18.1			408.3			203.5			(629.9		)	—
(Loss) income from continuing operations before income taxes	(4.7		)	201.5			265.2			(629.9		)	(167.9		)
Income tax benefit	(2.3		)	(2.0		)	(92.5		)	—			(96.8		)
(Loss) income from continuing operations	(2.4		)	203.5			357.7			(629.9		)	(71.1		)
Income from discontinued operations, net of income taxes	—			—			68.7			—			68.7
Net (loss) income	(2.4		)	203.5			426.4			(629.9		)	(2.4		)
Other comprehensive loss, net of tax	(7.3		)	(7.3		)	(15.1		)	22.4			(7.3		)
Comprehensive (loss) income	$	(9.7	)	$	196.2		$	411.3		$	(607.5	)	$	(9.7	)

MALLINCKRODT PLC

CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME

For the six months ended June 30, 2017

(unaudited, in millions)



	Mallinckrodt plc			Mallinckrodt International Finance S.A.			Other Subsidiaries			Eliminations			Consolidated
Net sales	$	—		$	—		$	1,160.1		$	—		$	1,160.1
Cost of sales	0.9			—			539.4			—			540.3
Gross (loss) profit	(0.9		)	—			620.7			—			619.8
Selling, general and administrative expenses	33.3			0.4			398.5			—			432.2
Research and development expenses	1.8			—			95.5			—			97.3
Restructuring charges, net	—			—			10.9			—			10.9
Gains on divestiture	—			—			(57.0		)	—			(57.0		)
Operating (loss) income	(36.0		)	(0.4		)	172.8			—			136.4

Interest expense	(6.7		)	(174.0		)	(38.9		)	33.2			(186.4		)
Interest income	3.1			0.6			31.0			(33.2		)	1.5
Other income (expense), net	17.6			(3.3		)	(87.9		)	—			(73.6		)
Intercompany fees	(9.0		)	—			9.0			—			—
Equity in net income of subsidiaries	489.7			851.7			673.4			(2,014.8		)	—
Income (loss) from continuing operations before income taxes	458.7			674.6			759.4			(2,014.8		)	(122.1		)
Income tax benefit	(3.3		)	(0.5		)	(91.8		)	—			(95.6		)
Income (loss) from continuing operations	462.0			675.1			851.2			(2,014.8		)	(26.5		)
(Loss) income from discontinued operations, net of income taxes	—			(1.7		)	490.2			—			488.5
Net income	462.0			673.4			1,341.4			(2,014.8		)	462.0
Other comprehensive income, net of tax	64.5			64.5			128.4			(192.9		)	64.5
Comprehensive income	$	526.5		$	737.9		$	1,469.8		$	(2,207.7	)	$	526.5

MALLINCKRODT PLC

CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS

For the six months ended June 29, 2018

(unaudited, in millions)



	Mallinckrodt plc			Mallinckrodt International Finance S.A.			Other Subsidiaries			Eliminations			Consolidated
Cash Flows From Operating Activities:
Net cash from operating activities	$	453.6		$	102.3		$	1,135.9		$	(1,430.0	)	$	261.8
Cash Flows From Investing Activities:
Capital expenditures	—			—			(67.1		)	—			(67.1		)
Acquisitions, net of cash acquired	—			—			(699.9		)	—			(699.9		)
Proceeds from divestitures, net of cash	—			—			298.3			—			298.3
Intercompany loan investment, net	(398.3		)	(85.2		)	(12.4		)	495.9			—
Investment in subsidiary	—			(163.1		)	41.3			121.8			—
Other	—			—			12.4			—			12.4
Net cash from investing activities	(398.3		)	(248.3		)	(427.4		)	617.7			(456.3		)
Cash Flows From Financing Activities:
Issuance of external debt	—			600.0			57.2			—			657.2
Repayment of external debt and capital lease obligation	—			(1,011.2		)	(381.6		)	—			(1,392.8		)
Debt financing costs	—			(12.0		)	—			—			(12.0		)
Proceeds from exercise of share options	—			—			—			—			—
Repurchase of shares	(56.8		)	—			—			—			(56.8		)
Intercompany loan borrowings, net	—			495.9			—			(495.9		)	—
Intercompany dividends	—			(814.2		)	(615.8		)	1,430.0			—
Capital contribution	—			—			121.8			(121.8		)	—
Other	1.4			—			(26.3		)	—			(24.9		)
Net cash from financing activities	(55.4		)	(741.5		)	(844.7		)	812.3			(829.3		)
Effect of currency rate changes on cash	—			—			(1.2		)	—			(1.2		)
Net change in cash, cash equivalents and restricted cash	(0.1		)	(887.5		)	(137.4		)	—			(1,025.0		)
Cash, cash equivalents and restricted cash at beginning of period	0.7			908.8			369.6			—			1,279.1
Cash, cash equivalents and restricted cash at end of period	$	0.6		$	21.3		$	232.2		$	—		$	254.1

Cash and cash equivalents at end of period	$	0.6		$	21.3		$	213.8		$	—		$	235.7
Restricted Cash, included in other assets at end of period	—			—			18.4			—			18.4
Cash, cash equivalents and restricted cash at end of period	$	0.6		$	21.3		$	232.2		$	—		$	254.1

MALLINCKRODT PLC

CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS

For the six months ended June 30, 2017

(unaudited, in millions)



	Mallinckrodt plc			Mallinckrodt International Finance S.A.			Other Subsidiaries			Eliminations			Consolidated
Cash Flows From Operating Activities:
Net cash from operating activities	$	1,177.0		$	175.8		$	1,487.0		$	(2,617.3	)	$	222.5
Cash Flows From Investing Activities:
Capital expenditures	—			—			(101.6		)	—			(101.6		)
Acquisitions, net of cash acquired	—			—			—			—			—
Proceeds from divestitures, net of cash	—			—			576.9			—			576.9
Intercompany loan investment, net	(801.7		)	—			(860.4		)	1,662.1			—
Investment in subsidiary	—			(307.9		)	—			307.9			—
Other	—			—			(9.9		)	—			(9.9		)
Net cash from investing activities	(801.7		)	(307.9		)	(395.0		)	1,970.0			465.4
Cash Flows From Financing Activities:
Issuance of external debt	—			—			40.0			—			40.0
Repayment of external debt and capital lease obligation	—			(242.1		)	(90.7		)	—			(332.8		)
Debt financing costs	—			(12.5		)	(0.5		)	—			(13.0		)
Proceeds from exercise of share options	3.9			—			—			—			3.9
Repurchase of shares	(380.8		)	—			—			—			(380.8		)
Intercompany loan borrowings, net	—			1,662.1			—			(1,662.1		)	—
Intercompany dividends	—			(1,170.0		)	(1,447.3		)	2,617.3			—
Capital contribution	—			—			307.9			(307.9		)	—
Other	2.0			—			(21.5		)	—			(19.5		)
Net cash from financing activities	(374.9		)	237.5			(1,212.1		)	647.3			(702.2		)
Effect of currency rate changes on cash	—			—			1.6			—			1.6
Net change in cash, cash equivalents and restricted cash	0.4			105.4			(118.5		)	—			(12.7		)
Cash, cash equivalents and restricted cash at beginning of period	0.5			44.5			316.1			—			361.1
Cash, cash equivalents and restricted cash at end of period	$	0.9		$	149.9		$	197.6		$	—		$	348.4

Cash and cash equivalents at end of period	$	0.9		$	149.9		$	179.4		$	—		$	330.2
Restricted Cash, included in other assets at end of period	—			—			18.2			—			18.2
Cash, cash equivalents and restricted cash at end of period	$	0.9		$	149.9		$	197.6		$	—		$	348.4

Subsequent Events

6 Months Ended

Jun. 29, 2018

Subsequent Events [Abstract]

Subsequent Events



21.	Subsequent Events

Cancer Prevention Pharmaceuticals (CPP) Licensing Agreement

On August 4, 2018, the Company entered into a license agreement for development and commercialization of CPP's CPP-1X/sulindac. The Company paid $5.0 million upfront with cash on hand and gained exclusive rights to develop and commercialize the product in North America, if approved. The agreement includes additional payments of up to $185.0 million dependent on developmental, regulatory and sales milestones, subject to reduction up to $15.0 million related to amounts provided by the Company in advance of entering into this agreement, and provides for both parties' reimbursement of R&D expenses from future profits. Following the commercialization of the product, CPP and the Company will share profits in accordance with the agreement. The Company will manage the development of the product in North America.

Concurrently with the execution of the license agreement, the Company and CPP entered into a services agreement under which CPP will assist the Company with completing the FAP Phase 3 pivotal trial and certain activities supporting the preparation, filing and review of the NDA in the U.S.

Financing Activities

On August 3, 2018, the Company made a $75.0 million payment on the revolving credit facility, bringing total outstanding borrowings to $375.0 million for this instrument as of the date of this report.

Commitments and Contingencies

Certain litigation matters occurred during the six months ended June 29, 2018 or prior, but had subsequent updates through the issuance of this report. See further discussion in Note 17.

Revenue from Contracts with Customers (Tables)

6 Months Ended

Jun. 29, 2018

Disaggregation of Revenue [Line Items]

Contract with Customer, Asset and Liability



	June 29, 2018		December 29, 2017
Accrued and other current liabilities	$	20.2	$	13.9
Other liabilities	5.2		6.3
Contract liabilities	$	25.4	$	20.2

Sales Reserves Rollforward

The following table reflects activity in the Company's sales reserve accounts, on a continuing operations basis:



	Rebates and Chargebacks			Product Returns			Other Sales Deductions			Total
Balance at December 29, 2017	$	60.3		$	4.1		$	1.1		$	65.5
Provisions	147.7			4.1			4.9			156.7
Payments or credits	(119.5		)	(4.6		)	(4.7		)	(128.8		)
Balance at June 29, 2018	$	88.5		$	3.6		$	1.3		$	93.4

Disaggregation of Revenue

Product sales transferred to customers at a point in time and over time are as follows:



	Three Months Ended		Six Months Ended
	June 29, 2018		June 29, 2018
Product sales transferred at a point in time	79.1	%	77.3	%
Product sales transferred over time	20.9	%	22.7	%

Contract with Customer, Timing of Satisfaction of Performance Obligation and Payment

Transaction price allocated to the remaining performance obligations



Remainder of Fiscal 2018	$	63.9
Fiscal 2019	119.4
Fiscal 2020	101.8
Fiscal 2021	14.2

Discontinued Operations and Divestitures (Tables)

6 Months Ended

Jun. 29, 2018

Jun. 30, 2017

Schedule of Income (Loss) from Discontinued Operations

The following table summarizes the financial results of the Nuclear Imaging business presented in the unaudited condensed consolidated statements of income:



	Three months ended			Six months ended
	June 30, 2017			June 30, 2017
Major line items constituting income from discontinued operations
Net sales	$	—		$	31.6
Cost of sales	—			15.6
Selling, general and administrative expenses	—			7.8
Other	—			(0.2		)
Income from discontinued operations	—			8.4
(Loss) gain on divestiture of discontinued operations	(5.9		)	363.4
(Loss) income from discontinued operations, before income taxes	(5.9		)	371.8
Income tax (benefit) expense	(0.1		)	5.3
(Loss) income from discontinued operations, net of income taxes	$	(5.8	)	$	366.5

Specialty Generics Disposal Group

Schedule of Income (Loss) from Discontinued Operations

The following table summarizes the financial results of the Specialty Generics Disposal Group presented in the unaudited condensed consolidated statements of income:



	Three Months Ended				Six Months Ended
	June 29, 2018		June 30, 2017		June 29, 2018		June 30, 2017
Major line items constituting income from discontinued operations
Net sales	$	193.8	$	224.4	$	376.5	$	475.3
Cost of sales	116.8		128.0		228.8		259.2
Selling, general and administrative expenses	25.6		16.2		44.4		37.3
Research and development expenses	11.3		16.9		29.2		33.7
Restructuring charges, net	0.1		—		5.2		6.9
Other income, net	0.3		2.4		0.3		3.8
Income from discontinued operations	40.3		65.7		69.2		142.0
Income tax expense	9.0		13.5		15.8		16.0
Income from discontinued operations, net of income taxes	$	31.3	$	52.2	$	53.4	$	126.0

Schedule of Major Classes of Assets and Liabiltiies Held For Sale

The following table summarizes the assets and liabilities of the Specialty Generics Disposal Group that are classified as held for sale on the unaudited condensed consolidated balance sheets:



	June 29, 2018		December 29, 2017
Carrying amounts of major classes of assets included as part of discontinued operations
Accounts receivable	$	164.7	$	170.4
Inventories	202.1		211.7
Property, plant and equipment, net	558.6		553.6
Intangible assets, net	112.3		114.0
Other current and non-current assets	74.8		84.5
Total assets classified as held for sale in the balance sheet	$	1,112.5	$	1,134.2

Carrying amounts of major classes of liabilities included as part of discontinued operations
Accounts payable	$	40.0	$	36.0
Other current and non-current liabilities	130.6		126.6
Total liabilities classified as held for sale in the balance sheet	$	170.6	$	162.6

Schedule of Significant Cash and Non-Cash Transactions



	Three Months Ended				Six Months Ended
	June 29, 2018		June 30, 2017		June 29, 2018		June 30, 2017
Depreciation, including accelerated depreciation	$	2.6	$	14.9	$	11.5	$	30.4
Amortization	—		5.4		1.7		10.7
Capital expenditures	7.1		14.3		15.8		30.6

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=65878427&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1474-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1361-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=84176398&loc=SL51724579-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721675-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721663-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84176398&loc=d3e2941-110230

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721673-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721659-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721671-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721677-107760

+ Details

Acquisitions, License Agreements and Other Investments Tables

6 Months Ended

Jun. 29, 2018

Business Combinations [Abstract]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed



Cash and cash equivalents	$	149.6
Accounts receivable	35.7
Inventory	153.2
Intangible assets	919.5
Goodwill	246.0
Other current and non-current assets	25.6
Total assets acquired	1,529.6
Current liabilities	108.2
Deferred tax liabilities, net (non-current)	170.8
Debt	366.3
Other noncurrent liabilities	36.7
Total liabilities assumed	682.0
Net assets acquired	$	847.6

Business Combination, Reconciliation of Total Consideration

The following is a reconciliation of the total consideration to net assets acquired:



Total consideration, net of cash	$	698.0
Plus: cash assumed in acquisition	149.6
Total consideration/net assets acquired	$	847.6

Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination

Intangible assets acquired consist of the following:



	Amount		Amortization Period	Discount Rate
Completed technology - Amitiza	$	634.0	9 years	14.0%
Completed technology - Rescula	11.0		8 years	14.0%
In-process research and development - VTS-270	274.5		Non-Amortizable	15.0%

Business Combination, Earnings by Acquiree Allocation

Financial results - The amount of net sales and loss included in the Company's results for the periods presented were as follows:



	Three Months Ended					Six Months Ended
	June 29, 2018			June 30, 2017		June 29, 2018			June 30, 2017
Net sales	$	49.6		$	—	$	73.8		$	—
Operating loss	(37.0		)	—		(67.7		)	—

Restructuring and Related Charges (Tables)

6 Months Ended

Jun. 29, 2018

Restructuring and Related Activities [Abstract]

Schedule of Restructuring and Related Charges by Segment

Net restructuring and related charges reflected in continuing operations by segment are as follows:



	Three Months Ended					Six Months Ended
	June 29, 2018		June 30, 2017			June 29, 2018		June 30, 2017
Specialty Brands	$	53.4	$	0.3		$	70.5	$	9.5
Corporate	5.3		0.7			11.3		2.8
Restructuring and related charges, net	58.7		1.0			81.8		12.3
Less: accelerated depreciation	—		(0.4		)	—		(1.4		)
Restructuring charges, net	$	58.7	$	0.6		$	81.8	$	10.9

Schedule of Net Restructuring and Related Charges

Net restructuring and related charges reflected in continuing operations by program are comprised of the following:



	Three Months Ended					Six Months Ended
	June 29, 2018		June 30, 2017			June 29, 2018		June 30, 2017
2016 Mallinckrodt Program	$	52.3	$	1.0		$	55.4	$	12.3
Acquisition programs	6.4		—			26.4		—
Total	58.7		1.0			81.8		12.3
Less: accelerated depreciation	—		(0.4		)	—		(1.4		)
Total charges expected to be settled in cash	$	58.7	$	0.6		$	81.8	$	10.9

Schedule of Restructuring Reserves by Type of Cost



	2016 Mallinckrodt Program			Acquisition Programs			Total
Balance at December 29, 2017	$	14.1		$	0.8		$	14.9
Charges	56.8			26.8			83.6
Changes in estimate	(1.4		)	(0.4		)	(1.8		)
Cash payments	(8.1		)	(17.8		)	(25.9		)
Balance at June 29, 2018	$	61.4		$	9.4		$	70.8

Schedule of Restructuring Charges Incurred Cumulative to Date

et restructuring and related charges, including associated asset impairments, incurred cumulative-to-date related to the 2016 Mallinckrodt Program was as follows:



	2016 Mallinckrodt Program
Specialty Brands	$	80.0
Corporate	16.9
Specialty Generics Disposal Group	14.3
	$	111.2

Earnings per Share (Tables)

6 Months Ended

Jun. 29, 2018

Earnings Per Share [Abstract]

Schedule of Earnings per Share

The weighted-average number of shares outstanding used in the computations of basic and diluted earnings per share were as follows (in millions):



	Three Months Ended		Six Months Ended
	June 29, 2018	June 30, 2017	June 29, 2018	June 30, 2017
Basic	83.2	98.5	84.7	100.9
Dilutive impact of restricted share units and share options	—	0.2	—	—
Diluted	83.2	98.7	84.7	100.9

Inventories (Tables)

6 Months Ended

Jun. 29, 2018

Inventory, Net [Abstract]

Schedule of Inventories

Inventories were comprised of the following at the end of each period:



	June 29, 2018		December 29, 2017
Raw materials and supplies	$	26.1	$	23.7
Work in process	118.1		61.1
Finished goods	40.2		43.9
	$	184.4	$	128.7

Property, Plant and Equipment (Tables)

6 Months Ended

Jun. 29, 2018

Property, Plant and Equipment

Property, Plant and Equipment

The gross carrying amount and accumulated depreciation of property, plant and equipment at the end of each period was as follows:



	June 29, 2018			December 29, 2017
Property, plant and equipment, gross	$	599.6		$	569.7
Less: accumulated depreciation	(169.5		)	(156.5		)
Property, plant and equipment, net	$	430.1		$	413.2

Depreciation of Fixed Assets

Depreciation expense for property, plant and equipment was as follows:



	Three Months Ended				Six Months Ended
	June 29, 2018		June 30, 2017		June 29, 2018		June 30, 2017
Depreciation expense	$	11.6	$	12.5	$	23.3	$	25.8

Goodwill and Intangible Assets (Tables)

6 Months Ended

Jun. 29, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill

The gross carrying amount and accumulated impairment of goodwill at the end of each period were as follows:



	June 29, 2018				December 29, 2017
	Gross Carrying Amount		Accumulated Impairment		Gross Carrying Amount		Accumulated Impairment
Specialty Brands	$	3,676.7	$	—	$	3,482.7	$	—

Schedule of Intangible Assets

The gross carrying amount and accumulated amortization of intangible assets at the end of each period were as follows:



	June 29, 2018				December 29, 2017
	Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization
Amortizable:
Completed technology	$	10,278.4	$	2,473.7	$	9,693.0	$	2,126.1
Customer relationships	28.0		13.0		29.5		12.2
Trademarks	75.2		12.5		75.5		10.8
Other	8.6		8.6		8.6		8.6
Total	$	10,390.2	$	2,507.8	$	9,806.6	$	2,157.7
Non-Amortizable:
Trademarks	$	35.0			$	35.0
In-process research and development	851.6				577.1
Total	$	886.6			$	612.1

Intangible Asset Amortization Expense

Intangible asset amortization expense was as follows:



	Three Months Ended				Six Months Ended
	June 29, 2018		June 30, 2017		June 29, 2018		June 30, 2017
Amortization expense	$	184.3	$	169.3	$	360.6	$	339.1

Schedule of Future Amortization Expense, Intangible Assets

The estimated aggregate amortization expense on intangible assets owned by the Company is expected to be as follows:



Remainder of Fiscal 2018	$	368.4
Fiscal 2019	737.1
Fiscal 2020	736.8
Fiscal 2021	736.5
Fiscal 2022	609.6

Debt (Tables)

6 Months Ended

Jun. 29, 2018

Debt Disclosure [Abstract]

Schedule of Applicable Interest Rate on Variable-rate Debt

As of June 29, 2018, the applicable interest rate and outstanding borrowings on the Company's variable-rate debt instruments were as follows:



	Applicable interest rate		Outstanding borrowings
Term loan due September 2024	5.20	%	$	1,617.9
Term loan due February 2025	5.52	%	598.5
Variable-rate receivable securitization	2.99	%	240.0
Revolving credit facility	4.58	%	450.0

Schedule of Debt including Capital Lease Obligation

Debt was comprised of the following at the end of each period:



	June 29, 2018				December 29, 2017
	Principal		Unamortized Discount and Debt Issuance Costs		Principal		Unamortized Discount and Debt Issuance Costs
Current maturities of long-term debt:
3.50% notes due April 2018	$	—	$	—	$	300.0	$	0.2
Term loan due September 2024	16.4		0.2		14.0		0.3
Term loan due February 2025	6.0		0.1		—		—
ACOA loan due December 2028	0.1		—		—		—
Capital lease obligation and vendor financing agreements	—		—		0.2		—
Total current debt	22.5		0.3		314.2		0.5
Long-term debt:
4.875% notes due April 2020	700.0		4.5		700.0		5.7
Variable-rate receivable securitization due July 2020	240.0		0.5		200.0		0.7
9.50% debentures due May 2022	10.4		—		10.4		—
5.75% notes due August 2022	884.0		8.5		884.0		9.5
8.00% debentures due March 2023	4.4		—		4.4		—
4.75% notes due April 2023	500.2		3.9		526.5		4.5
5.625% notes due October 2023	731.4		8.8		738.0		9.7
Term loan due September 2024	1,601.5		21.6		1,837.2		26.7
Term loan due February 2025	592.5		11.6		—		—
5.50% notes due April 2025	692.1		8.4		692.1		9.0
ACOA loan due December 2028	1.6		—		—		—
Revolving credit facility	450.0		5.2		900.0		5.9
Total long-term debt	6,408.1		73.0		6,492.6		71.7
Total debt	$	6,430.6	$	73.3	$	6,806.8	$	72.2

Retirement Plans (Tables)

6 Months Ended

Jun. 29, 2018

Pension Plan [Member]

Defined Benefit Plan Disclosure [Line Items]

Schedule of Net Periodic Benefit Cost

The net periodic benefit cost for the Company's defined benefit pension plans was as follows:



	Three Months Ended				Six Months Ended
	June 29, 2018		June 30, 2017		June 29, 2018		June 30, 2017
Service cost	$	—	$	0.2	$	0.1	$	1.3
Interest cost	0.1		0.4		0.3		1.6
Expected return on plan assets	—		—		—		(0.8		)
Amortization of net actuarial loss	0.2		0.3		0.3		1.8
Amortization of prior service cost	0.1		0.1		0.1		0.2
Plan settlements	—		0.5		—		69.7
Net periodic benefit cost	$	0.4	$	1.5	$	0.8	$	73.8

Accumulated Other Comprehensive Income (Tables)

6 Months Ended

Jun. 29, 2018

Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]

Schedule of Accumulated Other Comprehensive Income

The following summarizes the change in accumulated other comprehensive loss for the six months ended June 29, 2018 and June 30, 2017:



	Currency Translation			Unrecognized Loss on Derivatives			Unrecognized Loss on Benefit Plans			Unrecognized Gain on Investment ⁽¹⁾		Accumulated Other Comprehensive Loss ⁽¹⁾
Balance at December 29, 2017	$	(8.2	)	$	(4.7	)	$	(1.5	)	$	—	$	(14.4	)
Other comprehensive (loss) income before reclassifications	(7.3		)	—			0.9			—		(6.4		)
Amounts reclassified from accumulated other comprehensive loss	—			0.5			(1.4		)	—		(0.9		)
Net current period other comprehensive (loss) income	(7.3		)	0.5			(0.5		)	—		(7.3		)
Balance at June 29, 2018	$	(15.5	)	$	(4.2	)	$	(2.0	)	$	—	$	(21.7	)


(1)	Upon adoption of ASU 2016-01, a reclassification of $1.5 million relating to the unrealized gain on investment resulted in an increase to beginning retained earnings with an offsetting decrease to accumulated other comprehensive loss. See Note 2 for additional details.



	Currency Translation			Unrecognized Loss on Derivatives			Unrecognized Loss on Benefit Plans			Unrecognized Gain on Investment		Accumulated Other Comprehensive Loss
Balance at December 30, 2016	$	(19.5	)	$	(5.7	)	$	(47.3	)	$	—	$	(72.5	)
Other comprehensive income before reclassifications	12.1			—			5.9			10.6		28.6
Amounts reclassified from accumulated other comprehensive loss	(4.7		)	0.6			40.0			—		35.9
Net current period other comprehensive income	7.4			0.6			45.9			10.6		64.5
Balance at June 30, 2017	$	(12.1	)	$	(5.1	)	$	(1.4	)	$	10.6	$	(8.0	)

Schedule of Reclassifications out of Accumulated Other Comprehensive Income

The following summarizes reclassifications from accumulated other comprehensive loss for the six months ended June 29, 2018 and June 30, 2017:



	Amount Reclassified from Accumulated Other Comprehensive Loss
	Six Months Ended
	June 29, 2018			June 30, 2017			Line Item in the Unaudited Condensed Consolidated Statement of Income
Currency translation	$	—		$	(4.7	)	Income from discontinued operations, net of income taxes

Amortization and other of unrealized loss on derivatives	0.5			0.8			Interest expense
Income tax provision	—			(0.2		)	Income tax benefit
Net of income taxes	0.5			0.6

Amortization of pension and post-retirement benefit plans:
Net actuarial loss	0.3			1.8			⁽¹⁾
Prior service credit	(1.0		)	(1.0		)	⁽¹⁾
Divestiture of discontinued operations	—			(3.1		)	Income from discontinued operations, net of income taxes
Plan settlements	(0.7		)	69.7			⁽¹⁾
Total before tax	(1.4		)	67.4
Income tax provision	—			(27.4		)	Income tax benefit
Net of income taxes	(1.4		)	40.0

Total reclassifications for the period	$	(0.9	)	$	35.9


(1)	These accumulated other comprehensive loss components are included in the computation of net periodic benefit cost. See Note 13 for additional details.

Equity (Tables)

6 Months Ended

Jun. 29, 2018

Schedule of Share Repurchases under the Repurchase Plan

Schedule of Share Repurchases under the Repurchase Plan



	March 2017 Repurchase Program			March 2016 Repurchase Program
	Number of Shares	Amount		Number of Shares	Amount
Authorized repurchase amount		$	1,000.0		$	350.0
Repurchases:
Transition Period 2016 ⁽¹⁾	—	—		1,501,676	84.0
Fiscal 2017	13,490,448	380.6		5,366,741	266.0
Fiscal 2018	3,610,968	55.2		—	—
Remaining amount available		$	564.2		$	—

Financial Instruments and Fair Value Measurements (Tables)

6 Months Ended

Jun. 29, 2018

Fair Value Disclosures [Abstract]

Schedule of Fair Value of Assets and Liabilities Measured on a Recurring Basis

The following tables provide a summary of the significant assets and liabilities that are measured at fair value on a recurring basis at the end of each period:



	June 29, 2018		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Debt and equity securities held in rabbi trusts	$	35.0	$	23.9	$	11.1	$	—
Equity securities	13.6		13.6		—		—
Foreign exchange forward and option contracts	0.6		0.6		—		—
	$	49.2	$	38.1	$	11.1	$	—

Liabilities:
Deferred compensation liabilities	$	39.8	$	—	$	39.8	$	—
Contingent consideration and acquired contingent liabilities	170.5		—		—		170.5
Foreign exchange forward and option contracts	0.4		0.4		—		—
	$	210.7	$	0.4	$	39.8	$	170.5



	December 29, 2017		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Debt and equity securities held in rabbi trusts	$	35.4	$	24.0	$	11.4	$	—
Equity securities	22.7		22.7		—		—
Foreign exchange forward and option contracts	0.1		0.1		—		—
	$	58.2	$	46.8	$	11.4	$	—

Liabilities:
Deferred compensation liabilities	$	42.7	$	—	$	42.7	$	—
Contingent consideration and acquired contingent liabilities	246.4		—		—		246.4
Foreign exchange forward and option contracts	0.1		0.1		—		—
	$	289.2	$	0.1	$	42.7	$	246.4

Schedule of Reconciliation of Changes in Fair Value of Contingent Liabilities



Balance at December 29, 2017	$	246.4
Disposal of business	(12.1		)
Payments	(37.0		)
Accretion expense	2.3
Fair value adjustments	(29.1		)
Balance at June 29, 2018	$	170.5

Schedule of Carrying Amount and Fair Value of Long-term Debt

The following table presents the carrying values and estimated fair values of the Company's debt, excluding capital leases, as of the end of each period:



	June 29, 2018				December 29, 2017
	Carrying Value		Fair Value		Carrying Value		Fair Value
Level 1
3.50% notes due April 2018	$	—	$	—	$	300.0	$	299.1
4.875% notes due April 2020	700.0		689.2		700.0		675.2
Variable-rate receivable securitization due July 2020	240.0		240.0		200.0		200.0
5.75% notes due August 2022	884.0		796.1		884.0		804.8
4.75% notes due April 2023	500.2		407.1		526.5		412.4
5.625% notes due October 2023	731.4		609.1		738.0		628.8
5.50% notes due April 2025	692.1		563.0		692.1		564.5
Revolving credit facility	450.0		450.0		900.0		900.0
Level 2
9.50% debentures due May 2022	10.4		10.9		10.4		10.9
8.00% debentures due March 2023	4.4		4.4		4.4		4.4
Term loan due September 2024	1,617.9		1,586.5		1,851.2		1,848.7
Term loan due February 2025	598.5		589.5		—		—
Level 3
ACOA loan due December 2028	1.7		1.7		—		—
Total debt	$	6,430.6	$	5,947.5	$	6,806.6	$	6,348.8

Schedules of Concentration of Risk

The following table shows net sales attributable to distributors that accounted for 10.0% or more of the Company's total net sales:



	Three Months Ended				Six Months Ended
	June 29, 2018		June 30, 2017		June 29, 2018		June 30, 2017
CuraScript, Inc.	46.5	%	57.0	%	46.8	%	55.9	%

The following table shows accounts receivable attributable to distributors that accounted for 10.0% or more of the Company's gross accounts receivable at the end of each period:



	June 29, 2018		December 29, 2017
CuraScript, Inc.	35.3	%	33.8	%

The following table shows net sales attributable to products that accounted for 10.0% or more of the Company's total net sales:



	Three Months Ended				Six Months Ended
	June 29, 2018		June 30, 2017		June 29, 2018		June 30, 2017
H.P. Acthar Gel	46.4	%	53.2	%	44.6	%	51.0	%
Inomax	20.8	%	20.9	%	22.5	%	21.9	%
Ofirmev	13.6	%	12.6	%	13.9	%	12.9	%

Segment Data (Tables)

6 Months Ended

Jun. 29, 2018

Segment Reporting [Abstract]

Schedule of Segment Reporting Information by Reportable Segment

Selected information for the reportable segment is as follows:



	Three Months Ended						Six Months Ended
	June 29, 2018			June 30, 2017			June 29, 2018			June 30, 2017
Net sales:
Specialty Brands	$	631.7		$	600.1		$	1,204.3		$	1,160.1
Operating income:
Specialty Brands	$	265.9		$	270.0		$	506.2		$	537.0
Unallocated amounts:
Corporate and unallocated expenses ⁽¹⁾	(10.2		)	(49.6		)	(53.9		)	(49.2		)
Intangible asset amortization	(184.3		)	(169.3		)	(360.6		)	(339.1		)
Restructuring and related charges, net ⁽²⁾	(58.7		)	(1.0		)	(81.8		)	(12.3		)
Operating income	$	12.7		$	50.1		$	9.9		$	136.4


(1)	Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segment.


(2)	Includes restructuring-related accelerated depreciation.

Schedule of Net Sales from External Customers by Products

Net sales by product family within the Company's reportable segment is as follows:



	Three Months Ended				Six Months Ended
	June 29, 2018		June 30, 2017		June 29, 2018		June 30, 2017
H.P. Acthar Gel	$	293.2	$	319.4	$	537.0	$	591.2
Inomax	131.0		125.5		270.8		253.9
Ofirmev	85.6		75.7		167.6		149.1
Therakos	56.8		51.2		114.2		102.4
Amitiza ⁽¹⁾	48.0		—		71.0		—
BioVectra	11.3		10.5		21.8		20.4
Other	5.8		17.8		21.9		43.1
Net sales	$	631.7	$	600.1	$	1,204.3	$	1,160.1

⁽¹⁾ Amitiza consists of both product net sales and royalties. Refer to Note 3 for further details on Amitiza's revenues.

Condensed Consolidating Financial Statements (Tables)

6 Months Ended

Jun. 29, 2018

Condensed Consolidating Financial Statements [Abstract]

Schedule of Condensed Consolidating Balance Sheets

MALLINCKRODT PLC

CONDENSED CONSOLIDATING BALANCE SHEET

As of June 29, 2018

(unaudited, in millions)



	Mallinckrodt plc		Mallinckrodt International Finance S.A.		Other Subsidiaries		Eliminations			Consolidated
Assets
Current Assets:
Cash and cash equivalents	$	0.6	$	21.3	$	213.8	$	—		$	235.7
Accounts receivable, net	—		—		337.6		—			337.6
Inventories	—		—		184.4		—			184.4
Prepaid expenses and other current assets	0.3		0.4		134.9		—			135.6
Notes receivable	—		—		—		—			—
Current assets held for sale	—		—		1,112.5		—			1,112.5
Intercompany receivables	123.0		26.4		277.8		(427.2		)	—
Total current assets	123.9		48.1		2,261.0		(427.2		)	2,005.8
Property, plant and equipment, net	—		—		430.1		—			430.1
Goodwill	—		—		3,676.7		—			3,676.7
Intangible assets, net	—		—		8,769.0		—			8,769.0
Investment in subsidiaries	6,063.6		23,666.7		11,739.3		(41,469.6		)	—
Intercompany loans receivable	505.4		—		5,286.5		(5,791.9		)	—
Other assets	—		—		168.2		—			168.2
Total Assets	$	6,692.9	$	23,714.8	$	32,330.8	$	(47,688.7	)	$	15,049.8

Liabilities and Shareholders' Equity
Current Liabilities:
Current maturities of long-term debt	$	—	$	22.0	$	0.2	$	—		$	22.2
Accounts payable	0.2		—		75.6		—			75.8
Accrued payroll and payroll-related costs	—		—		74.6		—			74.6
Accrued interest	—		54.7		5.7		—			60.4
Income taxes payable	—		—		39.9		—			39.9
Accrued and other current liabilities	0.8		0.4		439.8		—			441.0
Current liabilities held for sale	—		—		170.6		—			170.6
Intercompany payables	217.5		19.4		190.3		(427.2		)	—
Total current liabilities	218.5		96.5		996.7		(427.2		)	884.5
Long-term debt	—		6,079.3		255.8		—			6,335.1
Pension and postretirement benefits	—		—		65.3		—			65.3
Environmental liabilities	—		—		62.2		—			62.2
Deferred income taxes	—		—		809.7		—			809.7
Other income tax liabilities	—		—		129.2		—			129.2
Intercompany loans payable	—		5,791.9		—		(5,791.9		)	—
Other liabilities	—		7.8		281.6		—			289.4
Total Liabilities	218.5		11,975.5		2,600.5		(6,219.1		)	8,575.4
Shareholders' Equity	6,474.4		11,739.3		29,730.3		(41,469.6		)	6,474.4
Total Liabilities and Shareholders' Equity	$	6,692.9	$	23,714.8	$	32,330.8	$	(47,688.7	)	$	15,049.8

MALLINCKRODT PLC

CONDENSED CONSOLIDATING BALANCE SHEET

As of December 29, 2017

(unaudited, in millions)



	Mallinckrodt plc		Mallinckrodt International Finance S.A.		Other Subsidiaries		Eliminations			Consolidated
Assets
Current Assets:
Cash and cash equivalents	$	0.7	$	908.8	$	351.4	$	—		$	1,260.9
Accounts receivable, net	—		—		275.4		—			275.4
Inventories	—		—		128.7		—			128.7
Prepaid expenses and other current assets	1.0		0.2		73.5		—			74.7
Notes receivable	—		—		154.0		—			154.0
Current assets held for sale	—		—		391.5		—			391.5
Intercompany receivables	70.0		173.4		831.4		(1,074.8		)	—
Total current assets	71.7		1,082.4		2,205.9		(1,074.8		)	2,285.2
Property, plant and equipment, net	—		—		413.2		—			413.2
Goodwill	—		—		3,482.7		—			3,482.7
Intangible assets, net	—		—		8,261.0		—			8,261.0
Long-term assets held for sale	—		—		742.7		—			742.7
Investment in subsidiaries	6,551.6		23,217.8		12,356.2		(42,125.6		)	—
Intercompany loans receivable	593.1		—		4,664.8		(5,257.9		)	—
Other assets	—		—		156.2		—			156.2
Total Assets	$	7,216.4	$	24,300.2	$	32,282.7	$	(48,458.3	)	$	15,341.0

Liabilities and Shareholders' Equity
Current Liabilities:
Current maturities of long-term debt	$	—	$	313.5	$	0.2	$	—		$	313.7
Accounts payable	0.1		—		77.2		—			77.3
Accrued payroll and payroll-related costs	—		—		78.4		—			78.4
Accrued interest	—		53.0		4.0		—			57.0
Income taxes payable	—		—		15.5		—			15.5
Accrued and other current liabilities	0.8		0.4		367.3		—			368.5
Current liabilities held for sale	—		—		140.0		—			140.0
Intercompany payables	693.5		104.6		276.7		(1,074.8		)	—
Total current liabilities	694.4		471.5		959.3		(1,074.8		)	1,050.4
Long-term debt	—		6,206.8		214.1		—			6,420.9
Pension and postretirement benefits	—		—		67.1		—			67.1
Environmental liabilities	—		—		62.8		—			62.8
Deferred income taxes	—		—		749.1		—			749.1
Other income tax liabilities	—		—		94.1		—			94.1
Long-term liabilities held for sale	—		—		22.6		—			22.6
Intercompany loans payable	—		5,257.9		—		(5,257.9		)	—
Other liabilities	—		7.8		344.2		—			352.0
Total Liabilities	694.4		11,944.0		2,513.3		(6,332.7		)	8,819.0
Shareholders' Equity	6,522.0		12,356.2		29,769.4		(42,125.6		)	6,522.0
Total Liabilities and Shareholders' Equity	$	7,216.4	$	24,300.2	$	32,282.7	$	(48,458.3	)	$	15,341.0

Schedule of Condensed Consolidating Statements of Comprehensive Income

MALLINCKRODT PLC

CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME

For the three months ended June 29, 2018

(unaudited, in millions)



	Mallinckrodt plc			Mallinckrodt International Finance S.A.			Other Subsidiaries			Eliminations			Consolidated
Net sales	$	—		$	—		$	631.7		$	—		$	631.7
Cost of sales	0.7			—			314.0			—			314.7
Gross (loss) profit	(0.7		)	—			317.7			—			317.0
Selling, general and administrative expenses	11.3			0.2			152.8			—			164.3
Research and development expenses	1.7			—			79.6			—			81.3
Restructuring charges, net	—			—			58.7			—			58.7
Losses on divestiture	—			—			—			—			—
Operating (loss) income	(13.7		)	(0.2		)	26.6			—			12.7

Interest expense	(1.6		)	(110.0		)	(7.7		)	24.2			(95.1		)
Interest income	2.2			0.3			23.1			(24.2		)	1.4
Other income (expense), net	0.6			—			(1.1		)	—			(0.5		)
Intercompany fees	(4.0		)	—			4.0			—			—
Equity in net income of subsidiaries	31.0			232.9			124.3			(388.2		)	—
Income (loss) from continuing operations before income taxes	14.5			123.0			169.2			(388.2		)	(81.5		)
Income tax benefit	(1.1		)	(1.2		)	(51.1		)	—			(53.4		)
Income (loss) from continuing operations	15.6			124.2			220.3			(388.2		)	(28.1		)
Income from discontinued operations, net of income taxes	—			0.1			43.6			—			43.7
Net income	15.6			124.3			263.9			(388.2		)	15.6
Other comprehensive loss, net of tax	(4.9		)	(4.9		)	(9.9		)	14.8			(4.9		)
Comprehensive income	$	10.7		$	119.4		$	254.0		$	(373.4	)	$	10.7

MALLINCKRODT PLC

CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME

For the three months ended June 30, 2017

(unaudited, in millions)



	Mallinckrodt plc			Mallinckrodt International Finance S.A.			Other Subsidiaries			Eliminations			Consolidated
Net sales	$	—		$	—		$	600.1		$	—		$	600.1
Cost of sales	0.9			—			279.5			—			280.4
Gross (loss) profit	(0.9		)	—			320.6			—			319.7
Selling, general and administrative expenses	15.1			0.2			199.3			—			214.6
Research and development expenses	1.8			—			50.5			—			52.3
Restructuring charges, net	—			—			0.6			—			0.6
Losses on divestiture	—			—			2.1			—			2.1
Operating (loss) income	(17.8		)	(0.2		)	68.1			—			50.1

Interest expense	(3.4		)	(88.7		)	(18.7		)	18.6			(92.2		)
Interest income	2.0			0.3			16.9			(18.6		)	0.6
Other income (expense), net	2.2			6.6			(2.5		)	—			6.3
Intercompany fees	(3.5		)	—			3.5			—			—
Equity in net income of subsidiaries	81.0			254.7			172.9			(508.6		)	—
Income (loss) from continuing operations before income taxes	60.5			172.7			240.2			(508.6		)	(35.2		)
Income tax benefit	(1.3		)	(0.2		)	(52.1		)	—			(53.6		)
Income from continuing operations	61.8			172.9			292.3			(508.6		)	18.4
Income from discontinued operations, net of income taxes	1.0			—			43.4			—			44.4
Net income	62.8			172.9			335.7			(508.6		)	62.8
Other comprehensive income, net of tax	1.9			1.9			3.4			(5.3		)	1.9
Comprehensive income	$	64.7		$	174.8		$	339.1		$	(513.9	)	$	64.7

MALLINCKRODT PLC

CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME

For the six months ended June 29, 2018

(unaudited, in millions)



	Mallinckrodt plc			Mallinckrodt International Finance S.A.			Other Subsidiaries			Eliminations			Consolidated
Net sales	$	—		$	—		$	1,204.3		$	—		$	1,204.3
Cost of sales	0.9			—			609.6			—			610.5
Gross (loss) profit	(0.9		)	—			594.7			—			593.8
Selling, general and administrative expenses	17.7			0.4			338.6			—			356.7
Research and development expenses	2.2			—			143.2			—			145.4
Restructuring charges, net	—			—			81.8			—			81.8
Gains on divestiture	—			—			—			—			—
Operating (loss) income	(20.8		)	(0.4		)	31.1			—			9.9

Interest expense	(4.6		)	(211.2		)	(14.8		)	44.1			(186.5		)
Interest income	4.4			2.0			42.3			(44.1		)	4.6
Other income (expense), net	6.7			2.8			(5.4		)	—			4.1
Intercompany fees	(8.5		)	—			8.5			—			—
Equity in net income of subsidiaries	18.1			408.3			203.5			(629.9		)	—
(Loss) income from continuing operations before income taxes	(4.7		)	201.5			265.2			(629.9		)	(167.9		)
Income tax benefit	(2.3		)	(2.0		)	(92.5		)	—			(96.8		)
(Loss) income from continuing operations	(2.4		)	203.5			357.7			(629.9		)	(71.1		)
Income from discontinued operations, net of income taxes	—			—			68.7			—			68.7
Net (loss) income	(2.4		)	203.5			426.4			(629.9		)	(2.4		)
Other comprehensive loss, net of tax	(7.3		)	(7.3		)	(15.1		)	22.4			(7.3		)
Comprehensive (loss) income	$	(9.7	)	$	196.2		$	411.3		$	(607.5	)	$	(9.7	)

MALLINCKRODT PLC

CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME

For the six months ended June 30, 2017

(unaudited, in millions)



	Mallinckrodt plc			Mallinckrodt International Finance S.A.			Other Subsidiaries			Eliminations			Consolidated
Net sales	$	—		$	—		$	1,160.1		$	—		$	1,160.1
Cost of sales	0.9			—			539.4			—			540.3
Gross (loss) profit	(0.9		)	—			620.7			—			619.8
Selling, general and administrative expenses	33.3			0.4			398.5			—			432.2
Research and development expenses	1.8			—			95.5			—			97.3
Restructuring charges, net	—			—			10.9			—			10.9
Gains on divestiture	—			—			(57.0		)	—			(57.0		)
Operating (loss) income	(36.0		)	(0.4		)	172.8			—			136.4

Interest expense	(6.7		)	(174.0		)	(38.9		)	33.2			(186.4		)
Interest income	3.1			0.6			31.0			(33.2		)	1.5
Other income (expense), net	17.6			(3.3		)	(87.9		)	—			(73.6		)
Intercompany fees	(9.0		)	—			9.0			—			—
Equity in net income of subsidiaries	489.7			851.7			673.4			(2,014.8		)	—
Income (loss) from continuing operations before income taxes	458.7			674.6			759.4			(2,014.8		)	(122.1		)
Income tax benefit	(3.3		)	(0.5		)	(91.8		)	—			(95.6		)
Income (loss) from continuing operations	462.0			675.1			851.2			(2,014.8		)	(26.5		)
(Loss) income from discontinued operations, net of income taxes	—			(1.7		)	490.2			—			488.5
Net income	462.0			673.4			1,341.4			(2,014.8		)	462.0
Other comprehensive income, net of tax	64.5			64.5			128.4			(192.9		)	64.5
Comprehensive income	$	526.5		$	737.9		$	1,469.8		$	(2,207.7	)	$	526.5

Schedule of Condensed Consolidating Statements of Cash Flows

MALLINCKRODT PLC

CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS

For the six months ended June 29, 2018

(unaudited, in millions)



	Mallinckrodt plc			Mallinckrodt International Finance S.A.			Other Subsidiaries			Eliminations			Consolidated
Cash Flows From Operating Activities:
Net cash from operating activities	$	453.6		$	102.3		$	1,135.9		$	(1,430.0	)	$	261.8
Cash Flows From Investing Activities:
Capital expenditures	—			—			(67.1		)	—			(67.1		)
Acquisitions, net of cash acquired	—			—			(699.9		)	—			(699.9		)
Proceeds from divestitures, net of cash	—			—			298.3			—			298.3
Intercompany loan investment, net	(398.3		)	(85.2		)	(12.4		)	495.9			—
Investment in subsidiary	—			(163.1		)	41.3			121.8			—
Other	—			—			12.4			—			12.4
Net cash from investing activities	(398.3		)	(248.3		)	(427.4		)	617.7			(456.3		)
Cash Flows From Financing Activities:
Issuance of external debt	—			600.0			57.2			—			657.2
Repayment of external debt and capital lease obligation	—			(1,011.2		)	(381.6		)	—			(1,392.8		)
Debt financing costs	—			(12.0		)	—			—			(12.0		)
Proceeds from exercise of share options	—			—			—			—			—
Repurchase of shares	(56.8		)	—			—			—			(56.8		)
Intercompany loan borrowings, net	—			495.9			—			(495.9		)	—
Intercompany dividends	—			(814.2		)	(615.8		)	1,430.0			—
Capital contribution	—			—			121.8			(121.8		)	—
Other	1.4			—			(26.3		)	—			(24.9		)
Net cash from financing activities	(55.4		)	(741.5		)	(844.7		)	812.3			(829.3		)
Effect of currency rate changes on cash	—			—			(1.2		)	—			(1.2		)
Net change in cash, cash equivalents and restricted cash	(0.1		)	(887.5		)	(137.4		)	—			(1,025.0		)
Cash, cash equivalents and restricted cash at beginning of period	0.7			908.8			369.6			—			1,279.1
Cash, cash equivalents and restricted cash at end of period	$	0.6		$	21.3		$	232.2		$	—		$	254.1

Cash and cash equivalents at end of period	$	0.6		$	21.3		$	213.8		$	—		$	235.7
Restricted Cash, included in other assets at end of period	—			—			18.4			—			18.4
Cash, cash equivalents and restricted cash at end of period	$	0.6		$	21.3		$	232.2		$	—		$	254.1

MALLINCKRODT PLC

CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS

For the six months ended June 30, 2017

(unaudited, in millions)



	Mallinckrodt plc			Mallinckrodt International Finance S.A.			Other Subsidiaries			Eliminations			Consolidated
Cash Flows From Operating Activities:
Net cash from operating activities	$	1,177.0		$	175.8		$	1,487.0		$	(2,617.3	)	$	222.5
Cash Flows From Investing Activities:
Capital expenditures	—			—			(101.6		)	—			(101.6		)
Acquisitions, net of cash acquired	—			—			—			—			—
Proceeds from divestitures, net of cash	—			—			576.9			—			576.9
Intercompany loan investment, net	(801.7		)	—			(860.4		)	1,662.1			—
Investment in subsidiary	—			(307.9		)	—			307.9			—
Other	—			—			(9.9		)	—			(9.9		)
Net cash from investing activities	(801.7		)	(307.9		)	(395.0		)	1,970.0			465.4
Cash Flows From Financing Activities:
Issuance of external debt	—			—			40.0			—			40.0
Repayment of external debt and capital lease obligation	—			(242.1		)	(90.7		)	—			(332.8		)
Debt financing costs	—			(12.5		)	(0.5		)	—			(13.0		)
Proceeds from exercise of share options	3.9			—			—			—			3.9
Repurchase of shares	(380.8		)	—			—			—			(380.8		)
Intercompany loan borrowings, net	—			1,662.1			—			(1,662.1		)	—
Intercompany dividends	—			(1,170.0		)	(1,447.3		)	2,617.3			—
Capital contribution	—			—			307.9			(307.9		)	—
Other	2.0			—			(21.5		)	—			(19.5		)
Net cash from financing activities	(374.9		)	237.5			(1,212.1		)	647.3			(702.2		)
Effect of currency rate changes on cash	—			—			1.6			—			1.6
Net change in cash, cash equivalents and restricted cash	0.4			105.4			(118.5		)	—			(12.7		)
Cash, cash equivalents and restricted cash at beginning of period	0.5			44.5			316.1			—			361.1
Cash, cash equivalents and restricted cash at end of period	$	0.9		$	149.9		$	197.6		$	—		$	348.4

Cash and cash equivalents at end of period	$	0.9		$	149.9		$	179.4		$	—		$	330.2
Restricted Cash, included in other assets at end of period	—			—			18.2			—			18.2
Cash, cash equivalents and restricted cash at end of period	$	0.9		$	149.9		$	197.6		$	—		$	348.4

Recently Issued Accounting Standards (Details)	6 Months Ended
Recently Issued Accounting Standards (Details)	Jun. 29, 2018	Jun. 30, 2017
Accounting Standards Update 2016-01 [Member] \| Retained Earnings
New Accounting Pronouncement or Change in Accounting Principle, Description of Prior-period Information Retrospectively Adjusted	1.5
Accounting Standards Update 2014-09 [Member] \| Retained Earnings
New Accounting Pronouncement or Change in Accounting Principle, Description of Prior-period Information Retrospectively Adjusted	1.1
Other Nonoperating Income (Expense) [Member] \| ASU 2017-07 [Member]
New Accounting Pronouncement or Change in Accounting Principle, Description of Prior-period Information Retrospectively Adjusted		72.3
Selling, General and Administrative Expenses [Member] \| ASU 2017-07 [Member]
New Accounting Pronouncement or Change in Accounting Principle, Description of Prior-period Information Retrospectively Adjusted		70.7
Cost of Sales \| ASU 2017-07 [Member]
New Accounting Pronouncement or Change in Accounting Principle, Description of Prior-period Information Retrospectively Adjusted		1.2
Research and Development Expense [Member] \| ASU 2017-07 [Member]
New Accounting Pronouncement or Change in Accounting Principle, Description of Prior-period Information Retrospectively Adjusted		.4

Revenue from Contracts with Customers Future Performance Obligations (Details) $ in Millions	Jun. 29, 2018 USD ($)
Current Fiscal Year [Member]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, Remaining Performance Obligation	$ 63.9
Year Two [Member]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, Remaining Performance Obligation	119.4
Year Three [Member]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, Remaining Performance Obligation	101.8
Year Four [Member]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, Remaining Performance Obligation	$ 14.2

Revenue from Contracts with Customers (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 29, 2018	Jun. 29, 2018	Dec. 29, 2017
Disaggregation of Revenue [Line Items]
Revenue Reserves	$ 93.4	$ 93.4	$ 65.5
Revenue Reserve Provision		156.7
Revenue Reserve Payments or Credits		(128.8)
Deferred Revenue, Revenue Recognized		14.6
Contract with Customer, Liability	25.4	25.4	20.2
Contract with Customer, Liability, Current	20.2	20.2	13.9
Capitalized Contract Cost, Gross	27.9	27.9
Capitalized Contract Cost, Amortization		6.8
Contract with Customer, Liability, Noncurrent	$ 5.2	$ 5.2	6.3
Transferred at Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue	79.10%	77.30%
Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue	20.90%	22.70%
Amitiza [Member]
Disaggregation of Revenue [Line Items]
Royalty Revenue	$ 21.6	$ 29.6
Rebates and Chargebacks [Member]
Disaggregation of Revenue [Line Items]
Revenue Reserves	88.5	88.5	60.3
Revenue Reserve Provision		147.7
Revenue Reserve Payments or Credits		(119.5)
Allowance for Sales Returns [Member]
Disaggregation of Revenue [Line Items]
Revenue Reserves	3.6	3.6	4.1
Revenue Reserve Provision		4.1
Revenue Reserve Payments or Credits		(4.6)
Other Sales Deductions [Member]
Disaggregation of Revenue [Line Items]
Revenue Reserves	$ 1.3	1.3	$ 1.1
Revenue Reserve Provision		4.9
Revenue Reserve Payments or Credits		$ (4.7)

Discontinued Operations and Divestitures Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 29, 2018	Jun. 30, 2017	Jun. 29, 2018	Jun. 30, 2017	Mar. 16, 2018	Mar. 17, 2017	Jan. 27, 2017
Nuclear Imaging
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Capital Expenditure, Discontinued Operations				$ 0.3
Disposal Group, Including Discontinued Operation, Consideration							$ 690.0
Disposal Group, Including Discontinued Operation, Upfront Consideration							574.0
Disposal group, Including Discontinued Operation, Contingent Consideration Maximum Amount							$ 77.0
Gain (loss) on divestiture of discontinued operations		$ (5.9)		363.4
Discontinued operation, income tax (benefit) expense		(0.1)		5.3
Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation				4.3
Income from discontinued operations	$ 15.0	0.0		8.4
Other Tax Expense (Benefit)				1.0
Income from discontinued operations, before income taxes		(5.9)		371.8
Contingent Consideration Received, Cash, Discontinued Operation	6.0
Contingent consideration received, equity certificates	9.0
Income tax expense on contingent consideration received, discontinued operations	1.5
Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax	13.5
Hemostasis Products
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Upfront Consideration					$ 153.0
Disposal Group, Not Discontinued Operation, Consideration					185.0
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal			$ (0.1)
Goodwill, Period Increase (Decrease)			51.5
Disposal Group, Not Discontinued Operations, Account Receivable Consideration					14.3
Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent	49.9		49.9
Disposal Group, Not Discontinued Operation, Contingent Consideration					$ (12.1)
Intrathecal Therapy
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Not Discontinued Operation, Consideration						$ 203.0
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal		(2.1)		57.0
Proceeds from Collection of Notes Receivable			154.0
Disposal Group, Not Discontinued Operation, Upfront Consideration						17.0
Disposal Group, Not Discontinued Operation, Note Receivable Consideration						154.0
Disposal Group, Not Discontinued Operation, Contingent Consideration						32.0
Disposal Group, Not Discontinued Operation, Fixed Consideration						171.0
Disposal Group, Not Discontinued Operations, Other Commitment	3.2		3.2			$ 7.3
Specialty Generics Disposal Group
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Capital Expenditure, Discontinued Operations	7.1	14.3	15.8	30.6
Discontinued operation, income tax (benefit) expense	9.0	13.5	15.8	16.0
Income from discontinued operations, before income taxes	$ 40.3	$ 65.7	$ 69.2	142.0
Other Intangible Assets \| Intrathecal Therapy
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal				48.7
Goodwill \| Intrathecal Therapy
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal				$ 49.8

Discontinued Operations and Divestitures Discontinued Operations (Income) Loss from Discontinued Operations (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 29, 2018	Jun. 30, 2017	Jun. 29, 2018	Jun. 30, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income from discontinued operations, net of income taxes	$ 43.7	$ 44.4	$ 68.7	$ 488.5
Nuclear Imaging
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operations, Net Sales		0.0		31.6
Discontinued operation, costs of goods sold		0.0		15.6
Discontinued operation, selling general and administrative expense		0.0		7.8
Discontinued operation, other income		0.0		0.2
Gain on divestiture of discontinued operations		(5.9)		363.4
Income from discontinued operations, before income taxes		(5.9)		371.8
Income tax expense		(0.1)		5.3
Income from discontinued operations, net of income taxes		(5.8)		366.5
Specialty Generics Disposal Group
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operations, Net Sales	193.8	224.4	376.5	475.3
Discontinued operation, costs of goods sold	116.8	128.0	228.8	259.2
Discontinued operation, selling general and administrative expense	25.6	16.2	44.4	37.3
Disposal Group, Including Discontinued Operations, Research and Development Expense	11.3	16.9	29.2	33.7
Disposal Group, Including Discontinued Operations, Restructuring Charges	0.1	0.0	5.2	6.9
Discontinued operation, other income	0.3	2.4	0.3	3.8
Income from discontinued operations, before income taxes	40.3	65.7	69.2	142.0
Income tax expense	9.0	13.5	15.8	16.0
Income from discontinued operations, net of income taxes	$ 31.3	$ 52.2	$ 53.4	$ 126.0

Discontinued Operations and Divestitures Discontinued Operations (Assets and Liabilities Held-for-sale) (Details) - Specialty Generics Disposal Group - USD ($) $ in Millions	Jun. 29, 2018	Dec. 29, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Accounts receivable, held for sale	$ 164.7	$ 170.4
Inventory, held for sale	202.1	211.7
Property, Plant and Equipment, held for sale	558.6	553.6
Intangible Assets, held for sale	112.3	114.0
Other current assets and non-current assets, held for sale	74.8	84.5
Total assets classified as held for sale in the balance sheet	1,112.5	1,134.2
Accounts payable, held for sale	40.0	36.0
Other current and non-current liabilities, held for sale	130.6	126.6
Total liabilities classified as held for sale in the balance sheet	$ 170.6	$ 162.6

Discontinued Operations and Divestitures Discontinued Operations (Significant Cash and Non-Cash Transactions) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 29, 2018	Jun. 30, 2017	Jun. 29, 2018	Jun. 30, 2017
Specialty Generics Disposal Group
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Depreciation, Discontinued Operations	$ 2.6	$ 14.9	$ 11.5	$ 30.4
Capital Expenditure, Discontinued Operations	7.1	14.3	15.8	30.6
Amortization, Discontinued Operations	$ 0.0	$ 5.4	$ 1.7	10.7
Nuclear Imaging
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Capital Expenditure, Discontinued Operations				$ 0.3

Acquisitions, License Agreements and Other Investments (Narrative) (Details) - USD ($)		3 Months Ended		6 Months Ended
	Feb. 13, 2018	Jun. 29, 2018	Jun. 30, 2017	Jun. 29, 2018	Jun. 30, 2017	Apr. 05, 2018	Dec. 29, 2017
Business Acquisition [Line Items]
Amortization of Intangible Assets		$ 184,300,000	$ 169,300,000	$ 360,600,000	$ 339,100,000
Long-term Debt		6,408,100,000		6,408,100,000			$ 6,492,600,000
Sucampo [Member]
Business Acquisition [Line Items]
Business Combination, Consideration Transferred	$ 1,200,000,000
Amortization of Intangible Assets		17,900,000	0	27,000,000	0
Business Combination Consideration Transferred, Net Of Cash	698,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents	149,600,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities	36,700,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities	682,000,000
Business Combination, Acquisition Related Costs				2,700,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	847,600,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other	170,800,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt	366,300,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables	35,700,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory	153,200,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	919,500,000
Goodwill, Acquired During Period				246,000,000
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets Other	25,600,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets	1,529,600,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities	108,200,000
CPP [Member]
Business Acquisition [Line Items]
Payment for License Option Exercised						$ 10,000,000
Research and Development Expense [Member] \| CPP [Member]
Business Acquisition [Line Items]
Payment for License Option Exercised, Expensed		6,300,000
Cost of Sales \| Sucampo [Member]
Business Acquisition [Line Items]
Amortization Of Inventory Step-Up To Cost Of Sales		31,500,000	$ 0	46,500,000	$ 0
Convertible Debt Securities [Member] \| Sucampo 2021 Notes [Member]
Business Acquisition [Line Items]
Debt Conversion, Converted Instrument, Amount	1,221
Long-term Debt	$ 300,000,000
Stated interest rate	3.25%
Debt Instrument, Face Amount	$ 1,000
Secured Debt \| Term Loan due 2025
Business Acquisition [Line Items]
Loans Payable		598,500,000		598,500,000			0
Long-term Debt		592,500,000		$ 592,500,000			$ 0
Secured Debt \| Term Loan due 2025 \| Sucampo [Member]
Business Acquisition [Line Items]
Loans Payable	600,000,000
Unsecured Debt \| 2015 Revolving Credit Facility
Business Acquisition [Line Items]
Long-term Debt	$ 900,000,000
Prepaid Expenses and Other Current Assets [Member] \| CPP [Member]
Business Acquisition [Line Items]
Payment for License Option Exercised, Capitalized		$ 3,700,000

Acquisitions, License Agreements and Other Investments Schedule of Fair Value of Assets and Liabilities Acquired (Details) - USD ($) $ in Millions	Jun. 29, 2018	Dec. 29, 2017
Business Acquisition [Line Items]
Goodwill	$ 3,676.7	$ 3,482.7

Acquisitions, License Agreements and Other Investments Schedule of Intangible Assets Acquired (Details) - Sucampo [Member] $ in Millions	Feb. 13, 2018 USD ($)
Amitiza [Member]
Acquired Indefinite-lived Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	$ 634.0
Business Combination, Cash Flow Discount Rate	14.00%
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	9 years
Rescula [Member]
Acquired Indefinite-lived Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	$ 11.0
Business Combination, Cash Flow Discount Rate	14.00%
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	8 years
VTS-270 [Member]
Acquired Indefinite-lived Intangible Assets [Line Items]
Business Combination, Cash Flow Discount Rate	15.00%
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets	$ 274.5

Acquisitions, License Agreements and Other Investments Schedule of Financial Results of Acquirees (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 29, 2018	Jun. 30, 2017	Jun. 29, 2018	Jun. 30, 2017
Business Acquisition [Line Items]
Amortization of Intangible Assets	$ 184.3	$ 169.3	$ 360.6	$ 339.1
Net sales	631.7	600.1	1,204.3	1,160.1
Operating Income (Loss)	12.7	50.1	9.9	136.4
Sucampo [Member]
Business Acquisition [Line Items]
Amortization of Intangible Assets	17.9	0.0	27.0	0.0
Net sales	49.6	0.0	73.8	0.0
Operating Income (Loss)	(37.0)	0.0	(67.7)	0.0
Sucampo [Member] \| Cost of Sales
Business Acquisition [Line Items]
Amortization Of Inventory Step-Up To Cost Of Sales	$ 31.5	$ 0.0	$ 46.5	$ 0.0

Restructuring and Related Charges (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 29, 2018	Jun. 30, 2017	Jun. 29, 2018	Jun. 30, 2017
Restructuring Cost and Reserve
Restructuring charges, net	$ 58.7	$ 0.6	$ 81.8	$ 10.9
Restructuring Fiscal 2016 Plan \| Minimum
Restructuring Cost and Reserve
Restructuring and Related Cost, Expected Cost	100.0		100.0
Restructuring Fiscal 2016 Plan \| Maximum
Restructuring Cost and Reserve
Restructuring and Related Cost, Expected Cost	125.0		125.0
Restructuring Fiscal 2018 Plan \| Minimum
Restructuring Cost and Reserve
Restructuring and Related Cost, Expected Cost	100.0		100.0
Restructuring Fiscal 2018 Plan \| Maximum
Restructuring Cost and Reserve
Restructuring and Related Cost, Expected Cost	125.0		$ 125.0
Raplixa \| Contract Termination [Member]
Restructuring Cost and Reserve
Restructuring charges, net	$ 48.1

Restructuring and Related Charges (Schedule of Restructuring and Related Charges by Segment) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 29, 2018	Jun. 30, 2017	Jun. 29, 2018	Jun. 30, 2017
Restructuring Cost and Reserve
Restructuring and related charges, net	$ 58.7	$ 1.0	$ 81.8	$ 12.3
Less: accelerated depreciation	0.0	(0.4)	0.0	(1.4)
Restructuring charges, net	58.7	0.6	81.8	10.9
Specialty Brands
Restructuring Cost and Reserve
Restructuring and related charges, net	53.4	0.3	70.5	9.5
Corporate
Restructuring Cost and Reserve
Restructuring and related charges, net	$ 5.3	$ 0.7	$ 11.3	$ 2.8

Restructuring and Related Charges (Schedule of Net Restructuring and Related Charges) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 29, 2018	Jun. 30, 2017	Jun. 29, 2018	Jun. 30, 2017
Restructuring Cost and Reserve
Restructuring and related charges, net	$ 58.7	$ 1.0	$ 81.8	$ 12.3
Less: accelerated depreciation	0.0	(0.4)	0.0	(1.4)
Total charges expected to be settled in cash	58.7	0.6	81.8	10.9
Restructuring Fiscal 2016 Plan
Restructuring Cost and Reserve
Restructuring and related charges, net	52.3	1.0	55.4	12.3
Acquisitions
Restructuring Cost and Reserve
Restructuring and related charges, net	$ 6.4	$ 0.0	$ 26.4	$ 0.0

Restructuring and Related Charges (Schedule of Restructuring Reserves by Type of Cost) (Details) $ in Millions	6 Months Ended
	Jun. 29, 2018 USD ($)
Restructuring Reserve [Roll Forward]
Beginning Balance	$ 14.9
Charges	83.6
Changes in estimate	(1.8)
Cash payments	(25.9)
Ending Balance	70.8
Restructuring Fiscal 2016 Plan
Restructuring Reserve [Roll Forward]
Beginning Balance	14.1
Charges	56.8
Changes in estimate	(1.4)
Cash payments	(8.1)
Ending Balance	61.4
Acquisitions
Restructuring Reserve [Roll Forward]
Beginning Balance	0.8
Charges	26.8
Changes in estimate	(0.4)
Cash payments	(17.8)
Ending Balance	$ 9.4

Restructuring and Related Charges (Schedule of Restructuring Charges Incurred Cumulative to Date) (Details) - Restructuring Fiscal 2016 Plan $ in Millions	Jun. 29, 2018 USD ($)
Restructuring Cost and Reserve
Restructuring costs incurred cumulative to date	$ 111.2
Specialty Brands
Restructuring Cost and Reserve
Restructuring costs incurred cumulative to date	80.0
Specialty Generics Disposal Group
Restructuring Cost and Reserve
Restructuring costs incurred cumulative to date	14.3
Corporate
Restructuring Cost and Reserve
Restructuring costs incurred cumulative to date	$ 16.9

Income Taxes (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
Income Taxes (Details) - USD ($)	Jun. 29, 2018	Jun. 30, 2017	Jun. 29, 2018	Jun. 30, 2017	Dec. 29, 2017	Mar. 16, 2018	Feb. 13, 2018
Income Taxes [Line Items]
Deferred tax benefit, intangible assets				$ (190,600,000)
Deferred tax expense, Utilization of Tax Attributes				27,200,000
Income tax benefit	$ 53,400,000	$ 53,600,000	$ 96,800,000	95,600,000
Increase (decrease) tax benefit	200,000		1,200,000
Increase (Decrease) Tax Expense (Benefit) Due to Pension Settlement			17,500,000
Increase (Decrease) Deferred Tax Liability Resulting From Tax Reform, TCJA					$ 444,800,000
Loss (income) from continuing operations before income taxes	$ 81,500,000	$ 35,200,000	$ 167,900,000	$ 122,100,000
Effective tax rate	65.50%	152.30%	57.70%	78.30%
Current Income Tax Expense (Benefit)	$ 9,500,000	$ 33,900,000.0	$ 13,100,000	$ 67,800,000
Deferred Income Tax Expense (Benefit)	(62,900,000)	(87,500,000)	(109,900,000)	(163,400,000)
Income Taxes Paid, Net			13,700,000		73,400,000
Income from discontinued operations, net of income taxes	43,700,000	44,400,000	68,700,000	488,500,000
Unrecognized tax benefits	202,900,000		202,900,000		182,500,000
Unrecognized tax benefits, net increase			20,400,000
Unrecognized tax benefits, net increase related to prior period tax positions			19,900,000
Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities			400,000
Unrecognized tax benefits, additions related to current year tax positions			900,000
Unrecognized tax benefits, which if favorably settled would benefit the effective tax rate	190,200,000		190,200,000
Interest accrued on unrecognized tax benefits	17,800,000		17,800,000		$ 7,100,000
Unrecognized tax benefits that would impact effective tax rate, upper bound of change	39,800,000		39,800,000
Income tax penalties and interest accrued that would impact effective tax rate, upper bound of change	6,600,000		6,600,000
Increase (Decrease) Tax Expense (Benefit) Due to U.S. Tax Reform	(9,800,000)		(33,400,000)
Increase (Decrease) Foreign Tax Expense (Benefit) Due To Acquisitions	3,600,000		8,100,000
Increase (Decrease) Tax Expense (Benefit) Due to Divestiture			31,200,000
Increase (Decrease) Tax Expense (Benefit), Change in Operating Income	6,000,000		12,800,000
Sucampo [Member]
Income Taxes [Line Items]
Increase (Decrease) Deferred Tax Asset, Net Operating Losses			(28,000,000)
Increase (Decrease) Deferred Tax Assets, Tax Credits			2,700,000
Deferred tax benefit, intangible assets			(180,500,000)
Increase (Decrease) Deferred Tax Liability, Inventory Step-Up			(24,100,000)
Increase (Decrease) Deferred Tax Asset, Net			3,100,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other							$ 170,800,000
Specialty Generics Disposal Group
Income Taxes [Line Items]
Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax	(40,300,000)	(65,700,000)	(69,200,000)	(142,000,000)
Income tax expense	9,000,000	13,500,000	15,800,000	16,000,000
Income from discontinued operations, net of income taxes	31,300,000	52,200,000	53,400,000	126,000,000
Nuclear Imaging
Income Taxes [Line Items]
Other Tax Expense (Benefit)				1,000,000
Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax		5,900,000		(371,800,000)
Contingent Consideration Received, Cash, Discontinued Operation	6,000,000
Contingent consideration received, equity certificates	9,000,000
Income tax expense on contingent consideration received, discontinued operations	1,500,000
Income tax expense		(100,000)		5,300,000
Income from discontinued operations, net of income taxes		$ (5,800,000)		$ 366,500,000
Hemostasis Products
Income Taxes [Line Items]
Increase (Decrease) in Deferred Tax Liability, Future Consideration			(1,500,000)
Increase (Decrease) Deferred Tax Asset, Net Operating Losses			(2,400,000)
Deferred tax benefit, intangible assets			4,200,000
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount			8,100,000
Increase (Decrease) Deferred Tax Liability, Inventory Step-Up			3,000,000
Increase (Decrease), Deferred Tax Liability, Net						$ 3,000,000
Discontinued Operations [Member]
Income Taxes [Line Items]
Unrecognized tax benefits, which if favorably settled would benefit the effective tax rate	$ 20,000,000		$ 20,000,000

Earnings per Share (Details) - shares shares in Millions	3 Months Ended		6 Months Ended
Earnings per Share (Details) - shares shares in Millions	Jun. 29, 2018	Jun. 30, 2017	Jun. 29, 2018	Jun. 30, 2017
Earnings Per Share
Weighted-average shares outstanding - basic (in shares)	83.2	98.5	84.7	100.9
Dilutive impact of restricted share units and share options (in shares)	0.0	0.2	0.0	0.0
Weighted-average shares outstanding - diluted (in shares)	83.2	98.7	84.7	100.9

Earnings per Share Anti-Dilutive Shares (Details) - shares shares in Millions	3 Months Ended		6 Months Ended
	Jun. 29, 2018	Jun. 30, 2017	Jun. 29, 2018	Jun. 30, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3.6	4.0	3.6	3.6

Inventories (Details) - USD ($) $ in Millions	Jun. 29, 2018	Dec. 29, 2017
Raw materials and supplies	$ 26.1	$ 23.7
Work in process	118.1	61.1
Finished goods	40.2	43.9
Inventories	$ 184.4	$ 128.7

Property, Plant and Equipment (Schedule of Property, Plant and Equipment) (Details) - USD ($) $ in Millions	Jun. 29, 2018	Dec. 29, 2017
Property, Plant and Equipment
Property, plant and equipment, gross	$ 599.6	$ 569.7
Less: accumulated depreciation	(169.5)	(156.5)
Property, plant and equipment, net	$ 430.1	$ 413.2

Property, Plant and Equipment Depreciation (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 29, 2018	Jun. 30, 2017	Jun. 29, 2018	Jun. 30, 2017
Property, Plant and Equipment
Depreciation	$ 11.6	$ 12.5	$ 23.3	$ 25.8

Goodwill and Intangible Assets (Schedule Of Goodwill) (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 29, 2018	Dec. 29, 2017
Goodwill
Goodwill	$ 3,676.7	$ 3,482.7
Indefinite-Lived Intangible Assets (Excluding Goodwill)	886.6	612.1
Specialty Brands
Goodwill
Goodwill	3,676.7
Goodwill, Period Increase (Decrease)	194.0
Accumulated Impairment	0.0	0.0
Goodwill, Gross		$ 3,482.7
Sucampo [Member]
Goodwill
Goodwill, Acquired During Period	246.0
Hemostasis Products
Goodwill
Goodwill, Period Increase (Decrease)	51.5
Stannsoporfin [Member] \| InfaCare Acquisition
Goodwill
Indefinite-Lived Intangible Assets (Excluding Goodwill)	$ 113.5

Goodwill and Intangible Assets (Schedule Of Intangible Assets) (Details) - USD ($) $ in Millions	Jun. 29, 2018	Dec. 29, 2017
Schedule of Intangible Asset by Major Class [Line Items]
Amortizable intangible assets, gross	$ 10,390.2	$ 9,806.6
Accumulated amortization	2,507.8	2,157.7
Non-Amortizable intangible assets, gross	886.6	612.1
Trademarks
Schedule of Intangible Asset by Major Class [Line Items]
Non-Amortizable intangible assets, gross	35.0	35.0
In-process Research and Development
Schedule of Intangible Asset by Major Class [Line Items]
Non-Amortizable intangible assets, gross	851.6	577.1
Completed Technology
Schedule of Intangible Asset by Major Class [Line Items]
Amortizable intangible assets, gross	10,278.4	9,693.0
Accumulated amortization	2,473.7	2,126.1
Customer Relationships
Schedule of Intangible Asset by Major Class [Line Items]
Amortizable intangible assets, gross	28.0	29.5
Accumulated amortization	13.0	12.2
Trademarks
Schedule of Intangible Asset by Major Class [Line Items]
Amortizable intangible assets, gross	75.2	75.5
Accumulated amortization	12.5	10.8
Other
Schedule of Intangible Asset by Major Class [Line Items]
Amortizable intangible assets, gross	8.6	8.6
Accumulated amortization	$ 8.6	$ 8.6

Goodwill and Intangible Assets (Narrative) (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 29, 2018	Dec. 29, 2017
Goodwill
Goodwill	$ 3,676.7	$ 3,482.7
Indefinite-Lived Intangible Assets (Excluding Goodwill)	886.6	$ 612.1
Specialty Brands
Goodwill
Goodwill, Period Increase (Decrease)	194.0
Goodwill	$ 3,676.7

Goodwill and Intangible Assets (Schedule of Intangible Asset Amortization Expense) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 29, 2018	Jun. 30, 2017	Jun. 29, 2018	Jun. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of Intangible Assets	$ 184.3	$ 169.3	$ 360.6	$ 339.1

Goodwill and Intangible Assets (Schedule of Future Amortization Expense, Intangible Assets) (Details) $ in Millions	Jun. 29, 2018 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of Fiscal 2018	$ 368.4
Fiscal 2019	737.1
Fiscal 2020	736.8
Fiscal 2021	736.5
Fiscal 2022	$ 609.6

Debt (Details) - USD ($) $ in Millions		3 Months Ended
Debt (Details) - USD ($) $ in Millions	Jan. 16, 2018	Jun. 29, 2018	Mar. 15, 2018	Dec. 29, 2017	Apr. 30, 2013
Current maturities of long-term debt
Debt Issuance Costs, Current, Net		$ 0.3		$ 0.5
Long-term Debt, Current Maturities		22.5		314.2
Long-term debt
Long-term Debt		6,408.1		6,492.6
Total Debt		6,430.6		6,806.6
Total Debt Issuance Costs		73.3		72.2
Debt and Capital Lease Obligations				6,806.8
Long-term Debt
Long-term debt
Debt Issuance Costs		$ 73.0		71.7
Term Loan due 2025 \| Secured Debt
Schedule of Long-term Debt including Capital Lease Obligation [Line Items]
Long-term Debt, Weighted Average Interest Rate, at Point in Time		5.52%
Current maturities of long-term debt
Debt Issuance Costs, Current, Net		$ 0.1		0.0
Long-term Debt, Current Maturities		6.0		0.0
Long-term debt
Long-term Debt		592.5		0.0
Debt Issuance Costs		11.6		0.0
Loans Payable		598.5		0.0
ACOA Loan due 2028 \| Unsecured Debt
Schedule of Long-term Debt including Capital Lease Obligation [Line Items]
Debt Instrument, Face Amount			$ 5.0
Current maturities of long-term debt
Debt Issuance Costs, Current, Net		0.0		0.0
Long-term Debt, Current Maturities		0.1		0.0
Long-term debt
Long-term Debt		1.6		0.0
Debt Issuance Costs		0.0		0.0
Loans Payable		1.7
Capital Lease Obligations and Vendor Financing
Current maturities of long-term debt
Debt Issuance Costs, Current, Net		0.0		0.0
Capital Lease Obligations, Current		0.0		0.2
3.50% Senior Notes \| Unsecured Debt
Schedule of Long-term Debt including Capital Lease Obligation [Line Items]
Repayments of Debt		300.0
Current maturities of long-term debt
Debt Issuance Costs, Current, Net		0.0		0.2
Long-term Debt, Current Maturities		$ 0.0		300.0
3.50% Senior Notes \| Senior Notes
Schedule of Long-term Debt including Capital Lease Obligation [Line Items]
Stated interest rate					3.50%
Term Loan due 2024 \| Secured Debt
Schedule of Long-term Debt including Capital Lease Obligation [Line Items]
Repayments of Debt	$ 225.0
Long-term Debt, Weighted Average Interest Rate, at Point in Time		5.20%
Current maturities of long-term debt
Debt Issuance Costs, Current, Net		$ 0.2		0.3
Long-term Debt, Current Maturities		16.4		14.0
Long-term debt
Long-term Debt		1,601.5		1,837.2
Debt Issuance Costs		21.6		26.7
Loans Payable		1,617.9		1,851.2
4.88% Senior Notes \| Unsecured Debt
Long-term debt
Long-term Debt		700.0		700.0
Debt Issuance Costs		4.5		5.7
Receivable securitization, Maturity Date of July 2020
Long-term debt
Long-term Debt		240.0		200.0
Debt Issuance Costs		0.5		0.7
9.50% Debenture \| Debentures
Long-term debt
Long-term Debt		10.4		10.4
Debt Issuance Costs		0.0		0.0
5.75% Senior Notes \| Unsecured Debt
Long-term debt
Long-term Debt		884.0		884.0
Debt Issuance Costs		8.5		9.5
8.00% Debenture \| Debentures
Long-term debt
Long-term Debt		4.4		4.4
Debt Issuance Costs		0.0		0.0
4.75% Senior Notes \| Unsecured Debt
Long-term debt
Long-term Debt		500.2		526.5
Debt Issuance Costs		3.9		4.5
4.75% Senior Notes \| Senior Notes
Schedule of Long-term Debt including Capital Lease Obligation [Line Items]
Stated interest rate					4.75%
5.625% Senior Notes \| Unsecured Debt
Long-term debt
Long-term Debt		731.4		738.0
Debt Issuance Costs		8.8		9.7
5.50% Senior Notes \| Unsecured Debt
Long-term debt
Long-term Debt		692.1		692.1
Debt Issuance Costs		8.4		9.0
2017 Revolving Credit Facility \| Secured Debt
Long-term debt
Long-term Debt		450.0		900.0
Debt Issuance Costs		$ 5.2		$ 5.9

Debt (Narrative) (Details) - USD ($) $ in Millions	Feb. 13, 2018	Jan. 16, 2018	Jun. 29, 2018	Dec. 29, 2017
Debt Instrument
Long-term Debt			$ 6,408.1	$ 6,492.6
Total Debt			6,430.6	6,806.6
Receivable securitization, Maturity Date of July 2020
Debt Instrument
Long-term Debt			240.0	200.0
Secured Debt \| Term Loan due 2025
Debt Instrument
Long-term Debt			$ 592.5	0.0
Long-term Debt, Weighted Average Interest Rate, at Point in Time			5.52%
Loans Payable			$ 598.5	0.0
Secured Debt \| Receivable securitization, Maturity Date of July 2020
Debt Instrument
Interest rate			2.99%
Long-term Line of Credit			$ 240.0
Secured Debt \| Term Loan due 2024
Debt Instrument
Long-term Debt			$ 1,601.5	1,837.2
Repayments of Debt		$ 225.0
Long-term Debt, Weighted Average Interest Rate, at Point in Time			5.20%
Loans Payable			$ 1,617.9	1,851.2
Secured Debt \| 2017 Revolving Credit Facility
Debt Instrument
Long-term Debt			$ 450.0	$ 900.0
Revolving Credit Facility
Debt Instrument
Interest rate			4.58%
Long-term Line of Credit			$ 450.0
Sucampo [Member] \| Secured Debt \| Term Loan due 2025
Debt Instrument
Debt Instrument, Basis Spread on Variable Rate	300.00%
Debt Instrument, Discount Percentage	25.00%
Loans Payable	$ 600.0

Debt (Schedule of Applicable Interest Rates on Variable-rate Debt) (Details) - USD ($) $ in Millions	Jun. 29, 2018	Dec. 29, 2017
Revolving Credit Facility
Schedule of Applicable Interest Rate on Variable-rate Debt [Line Items]
Interest rate	4.58%
Long-term Line of Credit	$ 450.0
Term Loan due 2025 \| Secured Debt
Schedule of Applicable Interest Rate on Variable-rate Debt [Line Items]
Long-term Debt, Weighted Average Interest Rate, at Point in Time	5.52%
Loans Payable	$ 598.5	$ 0.0
Receivable securitization, Maturity Date of July 2020 \| Secured Debt
Schedule of Applicable Interest Rate on Variable-rate Debt [Line Items]
Interest rate	2.99%
Long-term Line of Credit	$ 240.0
Term Loan due 2024 \| Secured Debt
Schedule of Applicable Interest Rate on Variable-rate Debt [Line Items]
Long-term Debt, Weighted Average Interest Rate, at Point in Time	5.20%
Loans Payable	$ 1,617.9	$ 1,851.2

Retirement Plans (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 29, 2018	Jun. 30, 2017	Jun. 29, 2018	Jun. 30, 2017
Postretirement Benefits
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Net periodic benefit credit	$ 0.7	$ 0.0	$ 1.0	$ 0.0
Pension Plan [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Net periodic benefit credit	0.4	1.5	0.8	73.8
Defined Benefit Plan, Plan Assets, Contributions by Employer				61.3
Plan settlements	$ 0.0	$ 0.5	$ 0.0	$ 69.7

Retirement Plans (Schedule of Net Periodic Benefit Cost) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 29, 2018	Jun. 30, 2017	Jun. 29, 2018	Jun. 30, 2017
Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 0.0	$ 0.2	$ 0.1	$ 1.3
Interest cost	0.1	0.4	0.3	1.6
Expected return on plan assets	0.0	0.0	0.0	(0.8)
Amortization of net actuarial loss	0.2	0.3	0.3	1.8
Amortization of prior service cost	0.1	0.1	0.1	0.2
Plan settlements	0.0	0.5	0.0	69.7
Net periodic benefit cost	0.4	1.5	0.8	73.8
Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Net periodic benefit cost	$ 0.7	$ 0.0	$ 1.0	$ 0.0

Accumulated Other Comprehensive Income (Schedule of Accumulated Other Comprehensive Income) (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 29, 2018	Jun. 30, 2017	Dec. 29, 2017
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income (Loss), Net of Tax, Adjusted for ASU			$ (14.4)
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning Balance	$ (12.9)	$ (72.5)
Other Comprehensive Income (Loss), before Reclassifications	(6.4)	28.6
Reclassification from Accumulated Other Comprehensive Income	(0.9)	35.9
Other Comprehensive Income (Loss)	(7.3)	64.5
Ending Balance	(21.7)	(8.0)
Accumulated Currency Translation Adjustment
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning Balance	(8.2)	(19.5)
Other Comprehensive Income (Loss), before Reclassifications	(7.3)	12.1
Reclassification from Accumulated Other Comprehensive Income	0.0	(4.7)
Other Comprehensive Income (Loss)	(7.3)	7.4
Ending Balance	(15.5)	(12.1)
Accumulated Unrecognized Gain (Loss) on Derivatives
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning Balance	(4.7)	(5.7)
Other Comprehensive Income (Loss), before Reclassifications	0.0	0.0
Reclassification from Accumulated Other Comprehensive Income	0.5	0.6
Other Comprehensive Income (Loss)	0.5	0.6
Ending Balance	(4.2)	(5.1)
Accumulated Unrecognized Gain (Loss) on Benefit Plans
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning Balance	(1.5)	(47.3)
Other Comprehensive Income (Loss), before Reclassifications	0.9	5.9
Reclassification from Accumulated Other Comprehensive Income	(1.4)	40.0
Other Comprehensive Income (Loss)	(0.5)	45.9
Ending Balance	(2.0)	(1.4)
Accumulated Unrecognized Gain on Equity Securities
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning Balance	0.0	0.0
Other Comprehensive Income (Loss), before Reclassifications	0.0	10.6
Reclassification from Accumulated Other Comprehensive Income	0.0	0.0
Other Comprehensive Income (Loss)	0.0	10.6
Ending Balance	$ 0.0	$ 10.6
Retained Earnings \| Accounting Standards Update 2016-01 [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
New Accounting Pronouncement or Change in Accounting Principle, Description of Prior-period Information Retrospectively Adjusted	1.5

Accumulated Other Comprehensive Income (Schedule of Reclassifications out of Accumulated Other Comprehensive Income) (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 29, 2018	Jun. 30, 2017
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total reclassifications for the period	$ (0.9)	$ 35.9
Reclassification out of Accumulated Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Amortization of unrealized loss on derivatives, before tax	0.5	0.8
Amortization of unrealized loss on derivatives, tax	0.0	(0.2)
Amortization of unrealized loss on derivatives, net of tax	0.5	0.6
Amortization of pension and post-retirement plans, net actuarial loss	0.3	1.8
Amortization of pension and post-retirement plans, prior service credit	(1.0)	(1.0)
Divestiture of discontinued operations	0.0	(3.1)
Plan settlements	(0.7)	69.7
Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, before Tax	(1.4)	67.4
Amortization of pension and post-retirement plans, tax	0.0	(27.4)
Amortization of pension and post-retirement plans, net of tax	(1.4)	40.0
Currency translation	$ 0.0	$ (4.7)

Equity (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended	6 Months Ended	12 Months Ended
	Dec. 30, 2016	Jun. 29, 2018	Dec. 29, 2017	Mar. 01, 2017	Mar. 16, 2016
March 2016 Repurchase Program
Equity, Class of Treasury Stock
Stock Repurchase Program, Authorized Amount					$ 350.0
Stock Repurchased During Period, Number of Shares	1,501,676	0	5,366,741
Stock Repurchased During Period, Amount	$ 84.0	$ 0.0	$ 266.0
Stock Repurchase Program, Remaining Amount Available		$ 0.0
March 2017 Repurchase Program
Equity, Class of Treasury Stock
Stock Repurchase Program, Authorized Amount				$ 1,000.0
Stock Repurchased During Period, Number of Shares	0	3,610,968	13,490,448
Stock Repurchased During Period, Amount	$ 0.0	$ 55.2	$ 380.6
Stock Repurchase Program, Remaining Amount Available		$ 564.2

Guarantees (Details) - USD ($) $ in Millions	6 Months Ended
Guarantees (Details) - USD ($) $ in Millions	Jun. 29, 2018	Dec. 29, 2017
Others
Guarantor Obligations [Line Items]
Maximum future payments	$ 23.5
Mallinckrodt Baker \| Indemnification Agreement
Guarantor Obligations [Line Items]
Guarantor obligations, obligation term	17 years
Maximum future payments	$ 70.2
Escrow Deposit	30.0
Mallinckrodt Baker \| Indemnification Agreement \| Other Liabilities
Guarantor Obligations [Line Items]
Guarantors obligation	14.5	$ 14.9
Mallinckrodt Baker \| Indemnification Agreement \| Other Assets
Guarantor Obligations [Line Items]
Escrow Deposit	18.4	18.3
Mallinckrodt Baker \| Environmental, Health and Safety Matters \| Indemnification Agreement \| Other Liabilities
Guarantor Obligations [Line Items]
Guarantors obligation	$ 11.7	$ 12.1

Commitments and Contingencies (Narrative) (Details) $ in Millions		3 Months Ended		6 Months Ended		12 Months Ended
	Apr. 01, 2014 USD ($) Defendent	Jun. 29, 2018 USD ($) Case	Jun. 30, 2017 USD ($)	Jun. 29, 2018 USD ($) lawsuit Case	Jun. 30, 2017 USD ($)	Dec. 29, 2017 USD ($)	Sep. 25, 2015 order	Mar. 25, 2016 USD ($)	Mar. 27, 2015 USD ($)	Mar. 28, 2014 USD ($)
Loss Contingencies [Line Items]
Litigation Settlement, Expense						$ 102.0
Payments for Legal Settlements						35.0
Environmental liabilities		$ 65.2		$ 65.2
Deferred tax liabilities related to installment sales		554.2		554.2
Section 453(a) interest		6.1	$ 17.8	11.7	$ 36.2
Interest Payable, Installment Sales		$ 52.9		$ 52.9		$ 46.0
Lower Passaic River, New Jersey
Loss Contingencies [Line Items]
Number of defendants \| Defendent	70
Environmental liabilities									$ 13.3	$ 23.1
Remedial cost, estimate	$ 1,700.0							$ 1,380.0
Asbestos Matters
Loss Contingencies [Line Items]
Pending claims \| Case		11,600		11,600
Estimation of liability, historical term				5 years
Estimation of liability, expected future term of claims				7 years
Accrued and other current liabilities
Loss Contingencies [Line Items]
Environmental liabilities, current		$ 3.0		$ 3.0
Opioid Crisis [Member]
Loss Contingencies [Line Items]
Loss Contingency, Number of Plaintiffs \| lawsuit				1,019
Mallinckrodt Veterinary, Inc., Millsboro, Delaware [Member]
Loss Contingencies [Line Items]
Number of Administrative Orders of Consent Entered Into \| order							2
Minimum \| Environmental Remediation
Loss Contingencies [Line Items]
Remedial cost, estimate		27.1		$ 27.1
Minimum \| Lower Passaic River, New Jersey
Loss Contingencies [Line Items]
Remedial cost, estimate	365.0
Maximum \| Environmental Remediation
Loss Contingencies [Line Items]
Remedial cost, estimate		$ 96.1		$ 96.1
Maximum \| Lower Passaic River, New Jersey
Loss Contingencies [Line Items]
Remedial cost, estimate	$ 3,200.0

Financial Instruments and Fair Value Measurements (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 29, 2018	Mar. 30, 2018	Jun. 29, 2018	Mar. 16, 2018	Dec. 29, 2017	Apr. 30, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Business Combination, Contingent Consideration, Liability, Current	$ 52.1		$ 52.1
Business Combination, Contingent Consideration, Liability, Noncurrent	118.4		118.4
Mesoblast [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Available-for-sale Securities, Sold at Par			8.4
Proceeds from Sale of Available-for-sale Securities, Equity			9.4
Available-for-sale Securities, Gross Realized Gains (Losses), Sale Proceeds			1.1
Foreign Currency Transaction Loss, before Tax			0.1
Available-for-sale Securities, Gross Unrealized Gain (Loss)	(0.1)		0.4
Senior Notes \| 3.50% Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Stated interest rate						3.50%
Senior Notes \| 4.75% Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Stated interest rate						4.75%
Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Investments, Fair Value Disclosure	35.0		35.0		$ 35.4
PreveLeak \| Hemostasis Products
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Business Combination, Contingent Consideration, Payment		$ 12.0
Level 3 \| Other Assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Cash surrender value of life insurance	65.5		65.5		67.0
Level 3 \| Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Investments, Fair Value Disclosure	0.0		0.0		0.0
Level 3 \| Recurring \| Questcor Pharmaceuticals, Inc.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Fair value of contingent liability	85.7		85.7		111.8
Level 3 \| Recurring \| Stratatech
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Fair value of contingent liability	55.3		55.3		53.5
Level 3 \| Raplixa \| Recurring \| Hemostasis Products
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Fair value of contingent consideration					7.0
Level 3 \| PreveLeak \| Recurring \| Hemostasis Products
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Fair value of contingent liability					17.1
Level 3 \| Stannsoporfin [Member] \| Recurring \| InfaCare Acquisition
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Fair value of contingent consideration	7.0		7.0		35.0
Fair value adjustment	27.5
Level 3 \| MNK-6105 [Member] \| Recurring \| Ocera [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Fair value of contingent consideration	$ 22.5		$ 22.5		22.0
Level 2 \| Debentures \| 8.00% Debenture
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Stated interest rate	8.00%		8.00%
Level 2 \| Debentures \| 9.50% Debenture
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Stated interest rate	9.50%		9.50%
Level 2 \| Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Investments, Fair Value Disclosure	$ 11.1		$ 11.1		11.4
Level 1 \| Senior Notes \| 3.50% Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Stated interest rate	3.50%		3.50%
Level 1 \| Senior Notes \| 4.75% Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Stated interest rate	4.75%		4.75%
Level 1 \| Senior Notes \| 5.75% Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Stated interest rate	5.75%		5.75%
Level 1 \| Senior Notes \| 4.88% Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Stated interest rate	4.875%		4.875%
Level 1 \| Senior Notes \| 5.50% Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Stated interest rate	5.50%		5.50%
Level 1 \| Unsecured Debt \| 5.625% Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Stated interest rate	5.625%		5.625%
Level 1 \| Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Investments, Fair Value Disclosure	$ 23.9		$ 23.9		24.0
Maximum \| Synacthen \| Questcor Pharmaceuticals, Inc.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Milestone Payment			115.0
Hemostasis Products
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Disposal Group, Not Discontinued Operation, Contingent Consideration				$ 12.1
Nuclear Imaging
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Contingent consideration received, equity certificates	9.0
Nuclear Imaging \| Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Contingent consideration received, equity certificates	9.0
Indemnification Agreement \| Mallinckrodt Baker \| Level 1 \| Other Assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Restricted Cash and Cash Equivalents	$ 18.4		18.4		$ 18.3
Novartis 2015 and 2016 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Business Combination, Contingent Consideration, Annual Payments			$ 25.0

Financial Instruments and Fair Value Measurements (Schedule of Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details) - Recurring - USD ($) $ in Millions	6 Months Ended
	Jun. 29, 2018	Dec. 29, 2017
Assets:
Rabbi Trust Investments, Fair Value Disclosure	$ 35.0	$ 35.4
Equity Securities, Fair Value Disclosure	13.6	22.7
Foreign exchange forward and option contracts	0.6	0.1
Total assets at fair value	49.2	58.2
Liabilities:
Deferred Compensation Liability, Fair Value	39.8	42.7
Contingent consideration and acquired contingent liabilities	170.5	246.4
Foreign exchange forward and option contracts	0.4	0.1
Total liabilities at fair value	210.7	289.2
Level 1
Assets:
Rabbi Trust Investments, Fair Value Disclosure	23.9	24.0
Equity Securities, Fair Value Disclosure	13.6	22.7
Foreign exchange forward and option contracts	0.6	0.1
Total assets at fair value	38.1	46.8
Liabilities:
Deferred Compensation Liability, Fair Value	0.0	0.0
Contingent consideration and acquired contingent liabilities	0.0	0.0
Foreign exchange forward and option contracts	0.4	0.1
Total liabilities at fair value	0.4	0.1
Level 2
Assets:
Rabbi Trust Investments, Fair Value Disclosure	11.1	11.4
Equity Securities, Fair Value Disclosure	0.0	0.0
Foreign exchange forward and option contracts	0.0	0.0
Total assets at fair value	11.1	11.4
Liabilities:
Deferred Compensation Liability, Fair Value	39.8	42.7
Contingent consideration and acquired contingent liabilities	0.0	0.0
Foreign exchange forward and option contracts	0.0	0.0
Total liabilities at fair value	39.8	42.7
Level 3
Assets:
Rabbi Trust Investments, Fair Value Disclosure	0.0	0.0
Equity Securities, Fair Value Disclosure	0.0	0.0
Foreign exchange forward and option contracts	0.0	0.0
Total assets at fair value	0.0	0.0
Liabilities:
Deferred Compensation Liability, Fair Value	0.0	0.0
Contingent consideration and acquired contingent liabilities	170.5	246.4
Foreign exchange forward and option contracts	0.0	0.0
Total liabilities at fair value	170.5	$ 246.4
Contingent Liabilities \| Level 3
Liabilities:
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements	$ (37.0)

Financial Instruments and Fair Value Measurements (Schedule of Reconciliation of Changes in Fair Value of Contingent Liabilities) (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 29, 2018	Jun. 29, 2018	Mar. 16, 2018
Level 3 \| Recurring \| Contingent Liabilities
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance		$ 246.4
Payments		(37.0)
Accretion expense		2.3
Fair value adjustment		(29.1)
Ending balance	$ 170.5	$ 170.5
Stannsoporfin [Member] \| InfaCare Acquisition \| Level 3 \| Recurring
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value adjustment	$ (27.5)
Hemostasis Products
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Disposal of business			$ (12.1)

Financial Instruments and Fair Value Measurements (Schedule of Carrying Amount and Fair Value of Long-term Debt) (Details) - USD ($) $ in Millions	Jun. 29, 2018	Dec. 29, 2017
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Long-term Debt, Current Maturities	$ 22.5	$ 314.2
Long term debt, fair value	5,947.5	6,348.8
Long-term Debt	6,408.1	6,492.6
Total Debt	6,430.6	6,806.6
Receivable securitization, Maturity Date of July 2020
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Long term debt, fair value	240.0	200.0
Long-term Debt	240.0	200.0
Secured Debt \| Term Loan due 2024
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Long-term Debt, Current Maturities	16.4	14.0
Loans Payable	1,617.9	1,851.2
Long-term Debt	1,601.5	1,837.2
Loans Payable, Fair Value Disclosure	1,586.5	1,848.7
Secured Debt \| 2017 Revolving Credit Facility
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Long term debt, fair value	450.0	900.0
Long-term Debt	450.0	900.0
Secured Debt \| Term Loan due 2025
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Long-term Debt, Current Maturities	6.0	0.0
Loans Payable	598.5	0.0
Long-term Debt	592.5	0.0
Loans Payable, Fair Value Disclosure	589.5	0.0
Unsecured Debt \| 3.50% Senior Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Long-term Debt, Current Maturities	0.0	300.0
Long term debt, fair value	0.0	299.1
Unsecured Debt \| 4.88% Senior Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Long term debt, fair value	689.2	675.2
Long-term Debt	700.0	700.0
Unsecured Debt \| 5.75% Senior Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Long term debt, fair value	796.1	804.8
Long-term Debt	884.0	884.0
Unsecured Debt \| 4.75% Senior Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Long term debt, fair value	407.1	412.4
Long-term Debt	500.2	526.5
Unsecured Debt \| 5.625% Senior Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Long term debt, fair value	609.1	628.8
Long-term Debt	731.4	738.0
Unsecured Debt \| 5.50% Senior Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Long term debt, fair value	563.0	564.5
Long-term Debt	692.1	692.1
Unsecured Debt \| ACOA Loan due 2028
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Long-term Debt, Current Maturities	0.1	0.0
Loans Payable	1.7
Long-term Debt	1.6	0.0
Loans Payable, Fair Value Disclosure	1.7	0.0
Debentures \| 9.50% Debenture
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Long term debt, fair value	10.9	10.9
Long-term Debt	10.4	10.4
Debentures \| 8.00% Debenture
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Long term debt, fair value	4.4	4.4
Long-term Debt	$ 4.4	$ 4.4

Financial Instruments and Fair Value Measurements (Schedules of Concentration of Risk) (Details)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 29, 2018	Jun. 30, 2017	Jun. 29, 2018	Jun. 30, 2017	Dec. 29, 2017
Distributor Concentration Risk \| Net Sales Attributable to Distributors \| CuraScript, Inc
Concentration Risk
Concentration Risk, Percentage	46.50%	57.00%	46.80%	55.90%
Distributor Concentration Risk \| Accounts Receivable Attributable to Distributors \| CuraScript, Inc
Concentration Risk
Concentration Risk, Percentage			35.30%		33.80%
Product Concentration Risk \| Net Sales Attributable to Products \| Acthar
Concentration Risk
Concentration Risk, Percentage	46.40%	53.20%	44.60%	51.00%
Product Concentration Risk \| Net Sales Attributable to Products \| Inomax
Concentration Risk
Concentration Risk, Percentage	20.80%	20.90%	22.50%	21.90%
Product Concentration Risk \| Net Sales Attributable to Products \| Ofirmev
Concentration Risk
Concentration Risk, Percentage	13.60%	12.60%	13.90%	12.90%

Segment Data (Schedule of Segment Reporting Information by Business Segment) (Details) - USD ($)
$ in Millions

3 Months Ended

6 Months Ended

Jun. 29, 2018

Jun. 30, 2017

Jun. 29, 2018

Jun. 30, 2017

Net sales

$ 631.7

$ 600.1

$ 1,204.3

$ 1,160.1

Operating Income (Loss)

12.7

50.1

9.9

136.4

Intangible asset amortization

(184.3)

(169.3)

(360.6)

(339.1)

Restructuring and related charges, net

(58.7)

(1.0)

(81.8)

(12.3)

Specialty Brands

Restructuring and related charges, net

(53.4)

(0.3)

(70.5)

(9.5)

Operating Segments | Specialty Brands

Net sales

631.7

600.1

1,204.3

1,160.1

Operating Income (Loss)

265.9

270.0

506.2

537.0

Corporate, Non-Segment

Corporate and unallocated expenses

^[1]

(10.2)

(49.6)

(53.9)

(49.2)

Intangible asset amortization

(184.3)

(169.3)

(360.6)

(339.1)

Restructuring and related charges, net

^[2]

$ (58.7)

$ (1.0)

$ (81.8)

$ (12.3)

[1]	Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segment.
[2]	Includes restructuring-related accelerated depreciation.

Segment Data (Schedule of Net Sales from External Customers by Products) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 29, 2018	Jun. 30, 2017	Jun. 29, 2018	Jun. 30, 2017
Segment Reporting Information
Net sales	$ 631.7	$ 600.1	$ 1,204.3	$ 1,160.1
Operating Segments \| Specialty Brands
Segment Reporting Information
Net sales	631.7	600.1	1,204.3	1,160.1
Acthar \| Operating Segments \| Specialty Brands
Segment Reporting Information
Net sales	293.2	319.4	537.0	591.2
Inomax \| Operating Segments \| Specialty Brands
Segment Reporting Information
Net sales	131.0	125.5	270.8	253.9
Ofirmev \| Operating Segments \| Specialty Brands
Segment Reporting Information
Net sales	85.6	75.7	167.6	149.1
Therakos immunotherapy \| Operating Segments \| Specialty Brands
Segment Reporting Information
Net sales	56.8	51.2	114.2	102.4
Amitiza [Member] \| Operating Segments \| Specialty Brands
Segment Reporting Information
Net sales	48.0	0.0	71.0	0.0
BioVectra Inc [Member] \| Operating Segments \| Specialty Brands
Segment Reporting Information
Net sales	11.3	10.5	21.8	20.4
Other \| Operating Segments \| Specialty Brands
Segment Reporting Information
Net sales	$ 5.8	$ 17.8	$ 21.9	$ 43.1

Condensed Consolidating Financial Statements (Narrative) (Details)	Jun. 29, 2018	Apr. 30, 2013
Condensed Consolidating Financial Statements
Percentage of ownership in MIFSA	100.00%
Senior Notes \| 3.50% Senior Notes
Condensed Consolidating Financial Statements
Stated interest rate		3.50%
Senior Notes \| 4.75% Senior Notes
Condensed Consolidating Financial Statements
Stated interest rate		4.75%

Condensed Consolidating Financial Statements (Schedule of Condensed Consolidating Balance Sheets) (Details) - USD ($) $ in Millions	Jun. 29, 2018	Dec. 29, 2017	Jun. 30, 2017
Current Assets:
Cash and cash equivalents	$ 235.7	$ 1,260.9	$ 330.2
Accounts receivable, net	337.6	275.4
Inventories	184.4	128.7
Prepaid expenses and other current assets	135.6	74.7
Notes receivable	0.0	154.0
Current assets held for sale	1,112.5	391.5
Intercompany receivables	0.0	0.0
Total current assets	2,005.8	2,285.2
Property, plant and equipment, net	430.1	413.2
Goodwill	3,676.7	3,482.7
Intangible assets, net	8,769.0	8,261.0
Disposal Group, Including Discontinued Operation, Assets, Noncurrent	0.0	742.7
Investment in subsidiaries	0.0	0.0
Intercompany loans receivable	0.0	0.0
Other assets	168.2	156.2
Total Assets	15,049.8	15,341.0
Current Liabilities:
Current maturities of long-term debt	22.2	313.7
Accounts payable	75.8	77.3
Accrued payroll and payroll-related costs	74.6	78.4
Accrued interest	60.4	57.0
Income taxes payable	39.9	15.5
Accrued and other current liabilities	441.0	368.5
Current liabilities held for sale	170.6	140.0
Intercompany payables	0.0	0.0
Total current liabilities	884.5	1,050.4
Long-term debt	6,335.1	6,420.9
Pension and postretirement benefits	65.3	67.1
Environmental liabilities	62.2	62.8
Deferred income taxes	809.7	749.1
Other income tax liabilities	129.2	94.1
Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent	0.0	22.6
Intercompany loans payable	0.0	0.0
Other liabilities	289.4	352.0
Total Liabilities	8,575.4	8,819.0
Shareholders' Equity	6,474.4	6,522.0
Total Liabilities and Shareholders' Equity	15,049.8	15,341.0
Mallinckrodt plc
Current Assets:
Cash and cash equivalents	0.6	0.7	0.9
Accounts receivable, net	0.0	0.0
Inventories	0.0	0.0
Prepaid expenses and other current assets	0.3	1.0
Notes receivable	0.0	0.0
Current assets held for sale	0.0	0.0
Intercompany receivables	123.0	70.0
Total current assets	123.9	71.7
Property, plant and equipment, net	0.0	0.0
Goodwill	0.0	0.0
Intangible assets, net	0.0	0.0
Disposal Group, Including Discontinued Operation, Assets, Noncurrent		0.0
Investment in subsidiaries	6,063.6	6,551.6
Intercompany loans receivable	505.4	593.1
Other assets	0.0	0.0
Total Assets	6,692.9	7,216.4
Current Liabilities:
Current maturities of long-term debt	0.0	0.0
Accounts payable	0.2	0.1
Accrued payroll and payroll-related costs	0.0	0.0
Accrued interest	0.0	0.0
Income taxes payable	0.0	0.0
Accrued and other current liabilities	0.8	0.8
Current liabilities held for sale	0.0	0.0
Intercompany payables	217.5	693.5
Total current liabilities	218.5	694.4
Long-term debt	0.0	0.0
Pension and postretirement benefits	0.0	0.0
Environmental liabilities	0.0	0.0
Deferred income taxes	0.0	0.0
Other income tax liabilities	0.0	0.0
Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent		0.0
Intercompany loans payable	0.0	0.0
Other liabilities	0.0	0.0
Total Liabilities	218.5	694.4
Shareholders' Equity	6,474.4	6,522.0
Total Liabilities and Shareholders' Equity	6,692.9	7,216.4
Mallinckrodt International Finance S.A.
Current Assets:
Cash and cash equivalents	21.3	908.8	149.9
Accounts receivable, net	0.0	0.0
Inventories	0.0	0.0
Prepaid expenses and other current assets	0.4	0.2
Notes receivable	0.0	0.0
Current assets held for sale	0.0	0.0
Intercompany receivables	26.4	173.4
Total current assets	48.1	1,082.4
Property, plant and equipment, net	0.0	0.0
Goodwill	0.0	0.0
Intangible assets, net	0.0	0.0
Disposal Group, Including Discontinued Operation, Assets, Noncurrent		0.0
Investment in subsidiaries	23,666.7	23,217.8
Intercompany loans receivable	0.0	0.0
Other assets	0.0	0.0
Total Assets	23,714.8	24,300.2
Current Liabilities:
Current maturities of long-term debt	22.0	313.5
Accounts payable	0.0	0.0
Accrued payroll and payroll-related costs	0.0	0.0
Accrued interest	54.7	53.0
Income taxes payable	0.0	0.0
Accrued and other current liabilities	0.4	0.4
Current liabilities held for sale	0.0	0.0
Intercompany payables	19.4	104.6
Total current liabilities	96.5	471.5
Long-term debt	6,079.3	6,206.8
Pension and postretirement benefits	0.0	0.0
Environmental liabilities	0.0	0.0
Deferred income taxes	0.0	0.0
Other income tax liabilities	0.0	0.0
Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent		0.0
Intercompany loans payable	5,791.9	5,257.9
Other liabilities	7.8	7.8
Total Liabilities	11,975.5	11,944.0
Shareholders' Equity	11,739.3	12,356.2
Total Liabilities and Shareholders' Equity	23,714.8	24,300.2
Other Subsidiaries
Current Assets:
Cash and cash equivalents	213.8	351.4	179.4
Accounts receivable, net	337.6	275.4
Inventories	184.4	128.7
Prepaid expenses and other current assets	134.9	73.5
Notes receivable	0.0	154.0
Current assets held for sale	1,112.5	391.5
Intercompany receivables	277.8	831.4
Total current assets	2,261.0	2,205.9
Property, plant and equipment, net	430.1	413.2
Goodwill	3,676.7	3,482.7
Intangible assets, net	8,769.0	8,261.0
Disposal Group, Including Discontinued Operation, Assets, Noncurrent		742.7
Investment in subsidiaries	11,739.3	12,356.2
Intercompany loans receivable	5,286.5	4,664.8
Other assets	168.2	156.2
Total Assets	32,330.8	32,282.7
Current Liabilities:
Current maturities of long-term debt	0.2	0.2
Accounts payable	75.6	77.2
Accrued payroll and payroll-related costs	74.6	78.4
Accrued interest	5.7	4.0
Income taxes payable	39.9	15.5
Accrued and other current liabilities	439.8	367.3
Current liabilities held for sale	170.6	140.0
Intercompany payables	190.3	276.7
Total current liabilities	996.7	959.3
Long-term debt	255.8	214.1
Pension and postretirement benefits	65.3	67.1
Environmental liabilities	62.2	62.8
Deferred income taxes	809.7	749.1
Other income tax liabilities	129.2	94.1
Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent		22.6
Intercompany loans payable	0.0	0.0
Other liabilities	281.6	344.2
Total Liabilities	2,600.5	2,513.3
Shareholders' Equity	29,730.3	29,769.4
Total Liabilities and Shareholders' Equity	32,330.8	32,282.7
Eliminations
Current Assets:
Cash and cash equivalents	0.0	0.0	$ 0.0
Accounts receivable, net	0.0	0.0
Inventories	0.0	0.0
Prepaid expenses and other current assets	0.0	0.0
Notes receivable	0.0	0.0
Current assets held for sale	0.0	0.0
Intercompany receivables	(427.2)	(1,074.8)
Total current assets	(427.2)	(1,074.8)
Property, plant and equipment, net	0.0	0.0
Goodwill	0.0	0.0
Intangible assets, net	0.0	0.0
Disposal Group, Including Discontinued Operation, Assets, Noncurrent		0.0
Investment in subsidiaries	(41,469.6)	(42,125.6)
Intercompany loans receivable	(5,791.9)	(5,257.9)
Other assets	0.0	0.0
Total Assets	(47,688.7)	(48,458.3)
Current Liabilities:
Current maturities of long-term debt	0.0	0.0
Accounts payable	0.0	0.0
Accrued payroll and payroll-related costs	0.0	0.0
Accrued interest	0.0	0.0
Income taxes payable	0.0	0.0
Accrued and other current liabilities	0.0	0.0
Current liabilities held for sale	0.0	0.0
Intercompany payables	(427.2)	(1,074.8)
Total current liabilities	(427.2)	(1,074.8)
Long-term debt	0.0	0.0
Pension and postretirement benefits	0.0	0.0
Environmental liabilities	0.0	0.0
Deferred income taxes	0.0	0.0
Other income tax liabilities	0.0	0.0
Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent		0.0
Intercompany loans payable	(5,791.9)	(5,257.9)
Other liabilities	0.0	0.0
Total Liabilities	(6,219.1)	(6,332.7)
Shareholders' Equity	(41,469.6)	(42,125.6)
Total Liabilities and Shareholders' Equity	(47,688.7)	(48,458.3)
Ordinary A
Condensed Consolidating Financial Statements
Ordinary A shares	$ 0.0	$ 0.0

Condensed Consolidating Financial Statements (Schedule of Condensed Consolidating Statements of Comprehensive Income) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 29, 2018	Jun. 30, 2017	Jun. 29, 2018	Jun. 30, 2017
Condensed Consolidating Financial Statements
Net sales	$ 631.7	$ 600.1	$ 1,204.3	$ 1,160.1
Cost of sales	314.7	280.4	610.5	540.3
Gross profit	317.0	319.7	593.8	619.8
Selling, general and administrative expenses	164.3	214.6	356.7	432.2
Research and development expenses	81.3	52.3	145.4	97.3
Restructuring charges, net	58.7	0.6	81.8	10.9
Losses (gains) on divestiture and license	0.0	2.1	0.0	(57.0)
Operating income	12.7	50.1	9.9	136.4
Interest expense	(95.1)	(92.2)	(186.5)	(186.4)
Interest income	1.4	0.6	4.6	1.5
Other (expense) income, net	(0.5)	6.3	4.1	(73.6)
Intercompany Interest And Fees	0.0	0.0	0.0	0.0
Income (Loss) from Equity Method Investments	0.0	0.0	0.0	0.0
Loss from continuing operations before income taxes	(81.5)	(35.2)	(167.9)	(122.1)
Income tax benefit	(53.4)	(53.6)	(96.8)	(95.6)
Income (Loss) from Continuing Operations	(28.1)	18.4	(71.1)	(26.5)
Income from discontinued operations, net of income taxes	43.7	44.4	68.7	488.5
Net Income (Loss)	15.6	62.8	(2.4)	462.0
Other Comprehensive Income (Loss), Net of Tax	(4.9)	1.9	(7.3)	64.5
Comprehensive Income (Loss)	10.7	64.7	(9.7)	526.5
Mallinckrodt plc
Condensed Consolidating Financial Statements
Net sales	0.0	0.0	0.0	0.0
Cost of sales	0.7	0.9	0.9	0.9
Gross profit	(0.7)	(0.9)	(0.9)	(0.9)
Selling, general and administrative expenses	11.3	15.1	17.7	33.3
Research and development expenses	1.7	1.8	2.2	1.8
Restructuring charges, net	0.0	0.0	0.0	0.0
Losses (gains) on divestiture and license	0.0	0.0	0.0	0.0
Operating income	(13.7)	(17.8)	(20.8)	(36.0)
Interest expense	(1.6)	(3.4)	(4.6)	(6.7)
Interest income	2.2	2.0	4.4	3.1
Other (expense) income, net	0.6	2.2	6.7	17.6
Intercompany Interest And Fees	(4.0)	(3.5)	(8.5)	(9.0)
Income (Loss) from Equity Method Investments	31.0	81.0	18.1	489.7
Loss from continuing operations before income taxes	14.5	60.5	(4.7)	458.7
Income tax benefit	(1.1)	(1.3)	(2.3)	(3.3)
Income (Loss) from Continuing Operations	15.6	61.8	(2.4)	462.0
Income from discontinued operations, net of income taxes	0.0	1.0	0.0	0.0
Net Income (Loss)	15.6	62.8	(2.4)	462.0
Other Comprehensive Income (Loss), Net of Tax	(4.9)	1.9	(7.3)	64.5
Comprehensive Income (Loss)	10.7	64.7	(9.7)	526.5
Mallinckrodt International Finance S.A.
Condensed Consolidating Financial Statements
Net sales	0.0	0.0	0.0	0.0
Cost of sales	0.0	0.0	0.0	0.0
Gross profit	0.0	0.0	0.0	0.0
Selling, general and administrative expenses	0.2	0.2	0.4	0.4
Research and development expenses	0.0	0.0	0.0	0.0
Restructuring charges, net	0.0	0.0	0.0	0.0
Losses (gains) on divestiture and license	0.0	0.0	0.0	0.0
Operating income	(0.2)	(0.2)	(0.4)	(0.4)
Interest expense	(110.0)	(88.7)	(211.2)	(174.0)
Interest income	0.3	0.3	2.0	0.6
Other (expense) income, net	0.0	6.6	2.8	(3.3)
Intercompany Interest And Fees	0.0	0.0	0.0	0.0
Income (Loss) from Equity Method Investments	232.9	254.7	408.3	851.7
Loss from continuing operations before income taxes	123.0	172.7	201.5	674.6
Income tax benefit	(1.2)	(0.2)	(2.0)	(0.5)
Income (Loss) from Continuing Operations	124.2	172.9	203.5	675.1
Income from discontinued operations, net of income taxes	0.1	0.0	0.0	(1.7)
Net Income (Loss)	124.3	172.9	203.5	673.4
Other Comprehensive Income (Loss), Net of Tax	(4.9)	1.9	(7.3)	64.5
Comprehensive Income (Loss)	119.4	174.8	196.2	737.9
Other Subsidiaries
Condensed Consolidating Financial Statements
Net sales	631.7	600.1	1,204.3	1,160.1
Cost of sales	314.0	279.5	609.6	539.4
Gross profit	317.7	320.6	594.7	620.7
Selling, general and administrative expenses	152.8	199.3	338.6	398.5
Research and development expenses	79.6	50.5	143.2	95.5
Restructuring charges, net	58.7	0.6	81.8	10.9
Losses (gains) on divestiture and license	0.0	2.1	0.0	(57.0)
Operating income	26.6	68.1	31.1	172.8
Interest expense	(7.7)	(18.7)	(14.8)	(38.9)
Interest income	23.1	16.9	42.3	31.0
Other (expense) income, net	(1.1)	(2.5)	(5.4)	(87.9)
Intercompany Interest And Fees	4.0	3.5	8.5	9.0
Income (Loss) from Equity Method Investments	124.3	172.9	203.5	673.4
Loss from continuing operations before income taxes	169.2	240.2	265.2	759.4
Income tax benefit	(51.1)	(52.1)	(92.5)	(91.8)
Income (Loss) from Continuing Operations	220.3	292.3	357.7	851.2
Income from discontinued operations, net of income taxes	43.6	43.4	68.7	490.2
Net Income (Loss)	263.9	335.7	426.4	1,341.4
Other Comprehensive Income (Loss), Net of Tax	(9.9)	3.4	(15.1)	128.4
Comprehensive Income (Loss)	254.0	339.1	411.3	1,469.8
Eliminations
Condensed Consolidating Financial Statements
Net sales	0.0	0.0	0.0	0.0
Cost of sales	0.0	0.0	0.0	0.0
Gross profit	0.0	0.0	0.0	0.0
Selling, general and administrative expenses	0.0	0.0	0.0	0.0
Research and development expenses	0.0	0.0	0.0	0.0
Restructuring charges, net	0.0	0.0	0.0	0.0
Losses (gains) on divestiture and license	0.0	0.0	0.0	0.0
Operating income	0.0	0.0	0.0	0.0
Interest expense	24.2	18.6	44.1	33.2
Interest income	(24.2)	(18.6)	(44.1)	(33.2)
Other (expense) income, net	0.0	0.0	0.0	0.0
Intercompany Interest And Fees	0.0	0.0	0.0	0.0
Income (Loss) from Equity Method Investments	(388.2)	(508.6)	(629.9)	(2,014.8)
Loss from continuing operations before income taxes	(388.2)	(508.6)	(629.9)	(2,014.8)
Income tax benefit	0.0	0.0	0.0	0.0
Income (Loss) from Continuing Operations	(388.2)	(508.6)	(629.9)	(2,014.8)
Income from discontinued operations, net of income taxes	0.0	0.0	0.0	0.0
Net Income (Loss)	(388.2)	(508.6)	(629.9)	(2,014.8)
Other Comprehensive Income (Loss), Net of Tax	14.8	(5.3)	22.4	(192.9)
Comprehensive Income (Loss)	$ (373.4)	$ (513.9)	$ (607.5)	$ (2,207.7)

Condensed Consolidating Financial Statements (Schedule of Condensed Consolidating Statements of Cash Flows) (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 29, 2018	Jun. 30, 2017
Cash Flows From Operating Activities:
Net cash from operating activities	$ 261.8	$ 222.5
Cash Flows From Investing Activities:
Capital expenditures	(67.1)	(101.6)
Acquisitions, net of cash acquired	(699.9)	0.0
Proceeds from divestitures, net of cash	298.3	576.9
Intercompany loan investment, net	0.0	0.0
Investment in subsidiary	0.0	0.0
Other	12.4	(9.9)
Net cash from investing activities	(456.3)	465.4
Cash Flows From Financing Activities:
Issuance of external debt	657.2	40.0
Repayment of external debt and capital lease obligation	(1,392.8)	(332.8)
Debt financing costs	(12.0)	(13.0)
Proceeds from exercise of share options	0.0	3.9
Repurchase of shares	(56.8)	(380.8)
Intercompany loan borrowings, net	0.0	0.0
Payment of Subsidiary Dividend	0.0	0.0
Capital contribution	0.0	0.0
Other	(24.9)	(19.5)
Net cash from financing activities	(829.3)	(702.2)
Effect of currency rate changes on cash	(1.2)	1.6
Net change in cash, cash equivalents and restricted cash	(1,025.0)	(12.7)
Cash and cash equivalents, end of period	235.7	330.2
Restricted Cash and Investments, Noncurrent	18.4	18.2
Cash and Cash Equivalents and Restricted Cash	1,279.1	361.1
Cash and Cash Equivalents, Including Restricted Cash, Period End	254.1	348.4
Mallinckrodt plc
Cash Flows From Operating Activities:
Net cash from operating activities	453.6	1,177.0
Cash Flows From Investing Activities:
Capital expenditures	0.0	0.0
Acquisitions, net of cash acquired	0.0	0.0
Proceeds from divestitures, net of cash	0.0	0.0
Intercompany loan investment, net	(398.3)	(801.7)
Investment in subsidiary	0.0	0.0
Other	0.0	0.0
Net cash from investing activities	(398.3)	(801.7)
Cash Flows From Financing Activities:
Issuance of external debt	0.0	0.0
Repayment of external debt and capital lease obligation	0.0	0.0
Debt financing costs	0.0	0.0
Proceeds from exercise of share options	0.0	3.9
Repurchase of shares	(56.8)	(380.8)
Intercompany loan borrowings, net	0.0	0.0
Payment of Subsidiary Dividend	0.0	0.0
Capital contribution	0.0	0.0
Other	1.4	2.0
Net cash from financing activities	(55.4)	(374.9)
Effect of currency rate changes on cash	0.0	0.0
Net change in cash, cash equivalents and restricted cash	(0.1)	0.4
Cash and cash equivalents, end of period	0.6	0.9
Restricted Cash and Investments, Noncurrent	0.0	0.0
Cash and Cash Equivalents and Restricted Cash	0.7	0.5
Cash and Cash Equivalents, Including Restricted Cash, Period End	0.6	0.9
Mallinckrodt International Finance S.A.
Cash Flows From Operating Activities:
Net cash from operating activities	102.3	175.8
Cash Flows From Investing Activities:
Capital expenditures	0.0	0.0
Acquisitions, net of cash acquired	0.0	0.0
Proceeds from divestitures, net of cash	0.0	0.0
Intercompany loan investment, net	(85.2)	0.0
Investment in subsidiary	(163.1)	(307.9)
Other	0.0	0.0
Net cash from investing activities	(248.3)	(307.9)
Cash Flows From Financing Activities:
Issuance of external debt	600.0	0.0
Repayment of external debt and capital lease obligation	(1,011.2)	(242.1)
Debt financing costs	(12.0)	(12.5)
Proceeds from exercise of share options	0.0	0.0
Repurchase of shares	0.0	0.0
Intercompany loan borrowings, net	495.9	1,662.1
Payment of Subsidiary Dividend	(814.2)	(1,170.0)
Capital contribution	0.0	0.0
Other	0.0	0.0
Net cash from financing activities	(741.5)	237.5
Effect of currency rate changes on cash	0.0	0.0
Net change in cash, cash equivalents and restricted cash	(887.5)	105.4
Cash and cash equivalents, end of period	21.3	149.9
Restricted Cash and Investments, Noncurrent	0.0	0.0
Cash and Cash Equivalents and Restricted Cash	908.8	44.5
Cash and Cash Equivalents, Including Restricted Cash, Period End	21.3	149.9
Other Subsidiaries
Cash Flows From Operating Activities:
Net cash from operating activities	1,135.9	1,487.0
Cash Flows From Investing Activities:
Capital expenditures	(67.1)	(101.6)
Acquisitions, net of cash acquired	(699.9)	0.0
Proceeds from divestitures, net of cash	298.3	576.9
Intercompany loan investment, net	(12.4)	(860.4)
Investment in subsidiary	41.3	0.0
Other	12.4	(9.9)
Net cash from investing activities	(427.4)	(395.0)
Cash Flows From Financing Activities:
Issuance of external debt	57.2	40.0
Repayment of external debt and capital lease obligation	(381.6)	(90.7)
Debt financing costs	0.0	(0.5)
Proceeds from exercise of share options	0.0	0.0
Repurchase of shares	0.0	0.0
Intercompany loan borrowings, net	0.0	0.0
Payment of Subsidiary Dividend	(615.8)	(1,447.3)
Capital contribution	121.8	307.9
Other	(26.3)	(21.5)
Net cash from financing activities	(844.7)	(1,212.1)
Effect of currency rate changes on cash	(1.2)	1.6
Net change in cash, cash equivalents and restricted cash	(137.4)	(118.5)
Cash and cash equivalents, end of period	213.8	179.4
Restricted Cash and Investments, Noncurrent	18.4	18.2
Cash and Cash Equivalents and Restricted Cash	369.6	316.1
Cash and Cash Equivalents, Including Restricted Cash, Period End	232.2	197.6
Eliminations
Cash Flows From Operating Activities:
Net cash from operating activities	(1,430.0)	(2,617.3)
Cash Flows From Investing Activities:
Capital expenditures	0.0	0.0
Acquisitions, net of cash acquired	0.0	0.0
Proceeds from divestitures, net of cash	0.0	0.0
Intercompany loan investment, net	495.9	1,662.1
Investment in subsidiary	121.8	307.9
Other	0.0	0.0
Net cash from investing activities	617.7	1,970.0
Cash Flows From Financing Activities:
Issuance of external debt	0.0	0.0
Repayment of external debt and capital lease obligation	0.0	0.0
Debt financing costs	0.0	0.0
Proceeds from exercise of share options	0.0	0.0
Repurchase of shares	0.0	0.0
Intercompany loan borrowings, net	(495.9)	(1,662.1)
Payment of Subsidiary Dividend	1,430.0	2,617.3
Capital contribution	(121.8)	(307.9)
Other	0.0	0.0
Net cash from financing activities	812.3	647.3
Effect of currency rate changes on cash	0.0	0.0
Net change in cash, cash equivalents and restricted cash	0.0	0.0
Cash and cash equivalents, end of period	0.0	0.0
Restricted Cash and Investments, Noncurrent	0.0	0.0
Cash and Cash Equivalents and Restricted Cash	0.0	0.0
Cash and Cash Equivalents, Including Restricted Cash, Period End	$ 0.0	$ 0.0

Subsequent Events Subsequent Events (Details) - USD ($) $ in Millions	Aug. 06, 2018	Aug. 03, 2018	Aug. 04, 2018	Jun. 29, 2018	Dec. 29, 2017
Subsequent Event [Line Items]
Long-term Debt				$ 6,408.1	$ 6,492.6
2017 Revolving Credit Facility [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Repayments of Debt		$ 75.0
Long-term Debt		$ 375.0
CPP [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
License Agreement, Upfront Payment	$ 5.0
License Agreement, Potential Payment, Range of Outcomes, Value, High			$ 185.0
Potential reduction of future payment			$ 15.0